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1. INTRODUCTION 
A. Statement of Problem 
One third of North Americans will die of an atherosclerotic dis-
ease. In comparison, this disease will cause the death of three 
quarters of America•s diabetic population. Diabetes occurs in ten 
percent of the U.S. Armed Forces veteran population with more than 90 
percent of these veterans having type II (non-insulin dependent or 
maturity-onset) diabetes (1). Atherosclerotic occlusive vascular 
disease is the most common complication in diabetes (2-4). Epidemio-
logical studies have indicated that other risk factors involved in 
atherosclerosis include age, sex, race, family history, smoking, 
hypertension, dyslipoproteinemi_~ and obesity (5). 
While it may be useful to consider atherosclerosis in the dia-
betic as a severe form of the disease found in non-diabetics, many 
investigators believe this approach to be simplistic. Many differences 
occur between groups of patients in the progression of the disease 
manifestations. Which risk factors make diabetics especially suscept-
ible to atherosclerosis or whether the disease produces its own factors 
to increase atheroslcerotic susceptibility are open to debate. 
Hypertriglyceridemia and hypercholesterolemia are common problems 
of the diabetic. While drug therapy is, in many cases, ineffective for 
lowering and managing triglyceride and cholesterol concentrations, an 
effective and safe dietary approach would be advantageous. The major 
concern in treating diabetic, hypertriglyceridemic patients is the 
type of dietary therapy to be administered. Since increased hyper-
1 
lipemia occurs with increased fat consumption, there has been a grow-
ing tendency to limit fat intake in diabetic patients. This results 
in diets that are composed of higher amounts of carbohydrate and 
protein relative to fat. This trend in diabetic care has received 
official sanction from the American Diabetes Association•s Committee 
on Food and Nutrition (6}. It is now recommended that most diabetics 
should consume a diet containing up to 50 or 60% carbohydrate. In a 
recent editorial in Diabetologia, Reaven (102) is skeptical about the 
effects of high carbohydrate diets. He observes that the beneficial 
effects of high carbohydrate diets on diabetic patients are modest at 
best. 
2 
The effects of a high carbohydrate diet on the diabetic popula-
tion were first studied by Himsworth (7}. One advantage claimed for 
the use of a high carbohydrate diet was the enhancement of insulin 
sensitivity. In a series of studies in normal patients, he demon-
strated that the plasma glucose response to the oral glucose load 
improved when dietary carbohydrate was increased. In similar studies 
with both insulin-dependent and non-dependent diabetics, Himsworth (8) 
was able to show a sensitive and insensitive population to high 
carbohydrate intake. Insensitive patients showed no increase in 
insulin sensitivity and a significant deterioration in glucose toler-
ance. Brunzell and Anderson (9-10) performed similar experiments and 
found an improvement of 8-11% in blood glucose levels when carbohy-
drate was increased from 45 percent to 78-85 percent of total caloric 
intake. 
In recent years, sources of carbohydrate have changed. The 
current level of simple sugars supplied by the diet is about 200 
g/person/day; of this, 62 percent is composed of the refined sugar 
sucrose (11). Many industrialized food preparations and processed 
beverages contain sucrose, accounting for more than two-thirds of the 
refined sugar consumed (11). Beverage products now comprise the 
3 
single largest industrialized usage of refined sugar while the next 
largest use is in cereal and bakery products. These three food sources 
now account for about one-sixth the per capita consumption of refined 
sugar. Much of this sucrose is hidden sugar, either used in the baking 
process or in enhancing the sweetness of foods. Therefore, consumers 
(including diabetics) are unaware of their total sucrose consumption. 
As early as 1950, worker~ with the Kemper Rice Diet reported that 
although high carbohydrate diets increase glucose tolerance and lowered 
serum cholesterol levels, there was also a sizeable increase in neutral 
fats (triglycerides) (12). Waddell and Fallon (13) examined the pos-
sibility that diets of high sugar content accelerate hepatic trigly-
ceride synthesis by increasing the capacity for fatty acid esterifica-
tion in rats. Rats fed diets containing 75 percent glucose or fructose 
increased their capacity for triglyceride formation from [13c] glycerol 
(14). An initial increase occurred when both sugars were administered, 
but a sustained increase in serum triglyceride could only be accomp-
lished with a high fructose intake. When serum triglyceride removal-
was inhibited by administration of Triton WR-1339, both diets increas-
ed labelled glycerol incorporation and increased triglyceride levels. 
They concluded that the difference in triglyceride levels between 
fructose and glucose diets may be attributed to a smaller increase in 
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hepatic production of triglyceride when rats were given glucose. 
These investigators speculated that another factor involved was the 
rate of serum triglyceride removal. Bierman and Hamlin (14) studied 
the effects of low-fat, high carbohydrate diets in diabetic patients. 
The liquid diets were administered with rice supplements and contained 
15 percent protein, 85 percent carbohydrate and virtually no fat. 
Their results demonstrated that insulin-treated diabetics exhibited a 
hyperlipemic response to isocaloric substitution of carbohydrate for 
fat. Several studies, however, tend to refute these observations. 
Kiem and Anderson (15) studied the effects of a high-carbohydrate, 
high-fiber diet on hyperglycemic diabetic men. Their finding showed 
that solid diets containing 75 percent of calories as carbohydrate re-
sulted in a significant improvement in glucose tolerance and lowered 
the average fasting serum triglyceride levels. 
The use of carbohydrate induction as a viable theory for hyper-
triglyceridemia was questioned from its inception. Antonis and Bersohn 
(16) reported that subjects, given an isocaloric high-carbohydrate diet, 
showed a rise in fasting triglycerides in the first few weeks, but the 
abnormally increased levels tended to recede to the prediet level after 
3 weeks. If carbohydrate-induced lipemia was a physiological fact, 
then populations which consume high-carbohydrate diets would tend to 
have chronically elevated triglyceride levels. Several investigators 
have demonstrated that this is not the case (17-21). 
In contrast, MacDonald and Braithwaite (22) in 1964, and Kuo and 
Bassett (23) in 1965, studied the effects of the disaccharide sucrose 
on hyperlipemia. Both groups found the consumption of low fat diets, 
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containing 500 g of sucrose as compared to corn starch, resulted in 
increased serum lipids. Fatty-acid patterns in adipose tissue were 
also affected by the high carbohydrate intake. Mann and co-workers 
were able to reduce fasting serum triglyceride levels by an average of 
22 percent through voluntary sucrose restriction (24,25). The inter-
pretation of the results was clouded by the effect of weight loss in 
most hypertriglyceridemic individuals. Thus, the effect of sucrose 
might be calorie-induced rather than sugar-induced lipemia. 
Evidence continued to mount that increased sucrose consumption 
produced virtually all the clinical symptoms of diabetes. Cohen, et al. 
demonstrated that feeding high sucrose diets to human volunteers result-
ed in impaired glucose toleranc,e, hyperlipemia, and impaired insulin 
activity (26). In his experiments, he also found the feeding of sucrose 
to rats produced diabetes, renal arteriosclerosis and diabetic retinal 
angiopathy. Studies in which sucrose-restricted diets were administer-
ed, tended to confirm the effect of sucrose on hyperlipemia with no 
significant correlation made between changes in triglyceride levels 
and weight (27-28). Since sucrose is a disaccharide, studies were 
undertaken to determine if sucrose or its monosaccharide components, 
glucose and fructose, could be responsible for the hyperlipemic effect. 
MacDonald (29) gave patients fat-free liquid diets of sucrose, starch, 
or glucose-maltose. He found a decrease in serum lipids on the glucose-
maltose regime, whereas with the sucrose-starch diet, the lipid level 
remained constant. Since previous fat-free diets had been shown to 
lower lipid levels, these findings suggested that the absence of fat in 
the diet was compensated for by the formation of lipids from carbohy-
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drate when the starch-sucrose diet was consumed. Further evidence to 
support this possibility was the altered fatty acid pattern observed in 
patients on the starch-sucrose diet. The increased oleic acid content 
observed was consistent with the conversion of carbohydrate to fat. 
MacDonald (30) investigated the effects of glucose and fructose diets on 
blood lipid levels concluding that the fructose component of the diet 
gives rise to responses of lipid metabolism that are different from 
those found after consuming glucose. Triglyceride responses to dietary 
glucose appeared to be unaffected by the many factors that affect serum 
triglyceride responses to fructose. However, Akgun and Ertel (31) 
demonstrated that fructose and sorbitol meals resulted in lower plasma 
glucose and immunoreactive insu)in levels than corresponding amounts of 
sucrose in a meal. This observation was directly in contrast to the 
ones made by MacDonald (30). 
A direct relationship has been observed between the estimated 
magnitude of insulin secretion and the increase in plasma trigly-
cerides produced by carbohydrate-rich diets (32). Mann and Truswell 
(33) found that there was no difference between concentrations of fast-
ing serum lipids when starch replaced glucose, but the concentration of 
serum triglycerides was higher after mixed meals containing sucrose. 
They also found increased insulin release after meals of complex carbo-
hydrate as compared to sucrose. They correlated the insulin response 
to a significantly smaller degree of lipemia while consuming the starch 
diet. MacDonald (34) found the increase in serum glucose after sucrose 
ingestion slightly less than that after glucose ingestion. Because 
sucrose is composed of 50 percent glucose, and all of the fructose 
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moiety could not have been interconverted, the elevated glycemic re-
sponse was surprising. Their results were explained by postulati~g 
that an equal dose of sucrose would elicit a lower insulin response 
than an equal amount of glucose. They concluded that lipid levels 
would fall on high glucose diets because of increased lipoprotein 
lipase activation in relation to lipid response (35). This, however, 
was not the case, and the fall in triglyceride in three out of four 
experiments was greater with fructose than glucose. Hayford and Danney 
(36) found that elevated plasma insulins usually reflected decreased 
triglyceride levels, while Olefsky (37) found a positive relationship 
between insulin and hypertriglyceridemia. Hayford (36) felt that it 
was possible the insulin and t~iglyceride changes were both secondary 
to the dietary changes and were not related to one another. Since 
sucrose was associated with higher triglyceride concentrations, he 
could not resolve whether the inverse relationship was a function of 
the insulin response, dietary components, or a combination of both. 
Most of the experiments performed to evaluate carbohydrate 
influence on lipemic responses utilized low fiber liquid diets. The 
investigation of sucrose induced carbohydrate hyperlipemia was further 
confused by the report of Albrink and Newman (38) in which the effect 
of high and low fiber diets on plasma lipids and insulin were ascer-
tained. Two very high carbohydrate diets were administered, one with 
high fiber content, and one with low fiber. The glucose response to 
both test meals were similar while the insulin response to the low fiber 
meal was twice as great as that to the high fiber meal containing equi-
valent amounts of carbohydrate. Serum lipids increased when low fiber 
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meals were consumed and decreased after high fiber diets. These results 
suggest that carbohydrate-induced hyperlipemia does not occur if the 
carbohydrate diet is rich in dietary fiber. An interesting report was 
issued by Beck-Nielsen and Pederson in 1980 (39), examining the effects 
of high fructose feeding in normal subjects. They found high fructose 
feeding was associated with a drop in insulin sensitivity, and for the 
first time, increased insulin concentrations in certain individuals 
was observed. The high fructose diet resulted in a 30 percent reduction 
of insulin binding to monocytes but glucose feeding resulted in no 
change. They concluded that feeding a diet high in fructose can result 
in a reduction in the number of high-affinity receptor sites, i.e., a 
reduction in total receptor af~nity for insulin. High-sucrose feeding 
can result in a 36 percent decrease in specific cell binding fractions 
for insulin {40). When these results are compared to the above, one 
can conclude that sucrose, or its monosaccharide component, fructose, 
causes an altered insulin sensitivity, at least in part, explained by 
altered insulin binding. The decrease in insulin binding is associated 
with reciprocal changes in plasma insulin concentration. The decrease 
in cellular binding of insulin by fructose was attributed to the depres-
sion of both cellular levels of cyclic AMP and protein synthesis caused 
by the depletion of ATP. 
It is also possible to explain the higher insulin levels observed 
after sucrose feeding on the basis of adaptive changes of the small 
intestine. Sucrase activity was greater in humans who consumed 
isocaloric diets containing sucrose compared to glucose (41). The 
intestinal absorption of glucose and fructose was enhanced after rats 
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and baboons had adapted to diets high in sucrose (42-43). In human 
volunteers, a significantly greater secretion of the intestinal hormone, 
gastric inhibitory polypeptide (GIP), was found in response to a sucrose 
load when compared to a starch load (44). GIP stimulates insulin secre-
tion of the pancreas in response to oral (but no intravenous) glucose 
(45). Thus sucrose feeding could produce adaptive increases in intesti-
nal digestive enzymes and hormones which could be expected to increase 
secretion of insulin. This could be accomplished by increasing the rate 
of appearance of the component monosaccharide in the circulation or by a 
direct action on insulin secretion. Eaton and Nye (46) also found a 
positive correlation between insulin levels and triglyceride production. 
To ascertain if insulin was the direct cause of hyperlipemia in 
11 sensitive 11 patients, direct pharmacological inhibition of pancreatic 
insulin secretion was used to examine the effect of acute suppression of 
insulin on triglyceride concentrations. Their observations imply, that 
in normal weight lipemic subjects, the pancreatic beta cells are in a 
chronic state of hypersecretion, characterized by an increased carbohy-
drate-stimulated insulin secretion associated with increased basal tri-
glyceride concentrations. 
Hypertriglyceridemia in diabetics, resulting from increased intake 
of carbohydrates, could occur via three mechanisms. In some patients, 
as reported above, a decreased insulin release seems to be characterized 
by a decrease in both the secretion and removal of triglyceride-rich 
lipoprotein with the defect in removal being greater than the defect in 
production. Even in the absence of exogenous fat, the disparity between 
triglyceride rich lipoprotein (VLDL) production and removal is sufficient 
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to result in an increase in plasma triglyceride concentrations (47). A 
second mechanism through which carbohydrate induced lipemia can occur 
results from resistance to insulin-mediated glucose uptake. The compen-
satory hyperinsulinemia acts upon the liver to accelerate hepatic trigly-
ceride synthesis and secretion resulting in elevated triglyceride levels 
{37). A third mechanism that could induce hypertriglyceridemia was 
proposed by Reaven (48) who studied a non-insulin dependent diabetic 
patient population who were insulin resistant, but had normal fasting 
and postprandial insulin concentrations. Because of insulin resistance, 
normal insulin levels cannot stimulate proper glucose uptake or inhibit 
lipolysis. These subjects have marked elevations of fasting and post-
prandial glucose and free fatty acids levels. Thus, the increased 
hypertriglyceridemia could occur due to stimulation of the normally in-
sulinized liver by increased circulating FFA concentrations (49). 
Other reports have supported the concept of increased trigly-
ceride synthesis causing hypertriglyceridemia in relation to a carbo-
hydrate load (50-52). However, these reports deal with total blood 
triglyceride concentrations and the kinetic behavior of the plasma 
triglycerides in these patients is largely unknown. Reliable data on 
the transport and production of plasma triglycerides can be obtained 
by labeling them~ vivo. It has been shown that a glycerol-labeling 
technique (described later) can give useful information on human plasma 
triglyceride turnover kinetics (53-56) and has been used to characterize 
aspects of plasma triglyceride metabolism in carbohydrate induced 
lipemia. Nikkila and Kekki {57), in a landmark paper, evaluated dia-
betic hypertriglyceridemia and found this syndrome to be characterized 
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by a primary stimulation of hepatic triglyceride secretion. Tobey et al. 
(58) found significant relationships between insulin-resistance, 
insulin-response, VLDL-TG secretion and plasma TG concentrations in both 
normal and hypertriglyceridemic individuals, suggesting that insulin 
modulates plasma TG levels in both groups. However, some additional 
abnormality must be present to account for the elevated plasma TG con-
centrations in hypertriglyceridemic individuals. Adams and Kissebah 
(59) were able to demonstrate that a group of hypertriglyceridemic 
patients were hyperinsulinemic and showed increased triglyceride syn-
thesis with increased FFA release. These patients had an abnormality 
in the removal mechanism for plasma triglycerides, a decreased Vmax and 
an increased Km when compared t,o other hypertriglyceridemics. Adams and 
Kissebah (59) hypothesized that elevated FFA release due to lipolysis, 
because of insulin resistance, could inhibit lipoprotein lipase (the 
primary enzyme in plasma lipid removal) and lead to some impairment in 
triglyceride clearance. The primary change could be due to enzyme de-
rangement, deficiency of insulin receptors or an abnormality in circu-
lating insulin. Huttunen et al. (60) showed the fractional removal rate 
of endogenous triglyceride to be positively correlated to lipoprotein 
lipase activity. The mean activity of post heparin plasma lipoprotein 
lipase was also significantly lower in subjects with hyperprebetalipo-
proteinemia. 
Persson (61) did a comprehensive study of 249 patients with diff-
erent types of hyperlipidemia. His work clearly demonstrated a lower 
lipoprotein lipase activity per wet weight adipose tissue in type IV 
hyperlipidemic individuals compared to normal subjects. Brunzell and 
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Porte {62) studied untreated diabetic subjects and documented a defect 
in triglyceride removal related to lipoprotein lipase activity. They 
suggest an interesting mechanism, in which the increase in Km for the 
lipase system could be related to a change in VLDL protein cofactors. 
These proteins, designated apoproteins, are structural components of 
lipoprotein molecules, which serve as activators for lipoprotein lipase, 
or function as recognition proteins which aid in the peripheral removal 
of the lipoprotein from the circulation (212-218). These protein compo-
nents are described later in the text. 
An alteration in the lipoprotein cofactors, causing an ineffi-
cient removal of triglyceride from VLDL, has long been postulated as a 
mechanism for the induction of ;hypertriglyceridemia. Gabor and Spain 
{63) studied the apoprotein composition of VLDL and HDL by gel electro-
phoresis and found the VLDL of diabetics had an increased proportion of 
apo C, particularly apo CIII. They also demonstrated that diabetics with 
increased VLDL and serum triglyceride concentration had decreased ratios 
of CII to CIII. Bar-On and Roheim (64) noted a relative increase in 
CIII 1 apoprotein and a decrease in CIII 2 apoprotein in streptozotocin 
induced diabetic rats fed high sucrose diets. Varying CIII components 
differ only in their amount of sialic acid residues. Since diabetes has 
been correlated to increased concentrations of other serum glycopro-
teins, it is tempting to speculate that altered C proteins might influ-
ence lipoprotein lipase activity (65). Witzum and Schonfeld (66) gave 
carbohydrate-enriched diets to rats to investigate the effect on VLDL 
composition and structure. A rise in triglyceride and cholesterol in 
the carbohydrate fed rats and a fall in apo B concentration was 
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observed. The arginine-rich protein (ARP) 'also fell while apo C rose. 
These investigators also studied perfused livers of these animals and 
found changes in apoproteins to be parallel to those seen in plasma. 
This suggested the action of the diet on the liver was responsible for 
the plasma VLDL changes seen (66). Falko (67) showed that ingestion of 
high carbohydrate diets (88 percent total calories) caused apo CII and 
apo CIII levels to .increase by 30 percent in VLDL while these same levels 
fell in higher density lipoprotein fractions. Levels of apo C increased 
in proportion to VLDL-TG in normal individuals, but increased less in 
patients with type IV hyperlipemia. Falko postulated that short term 
feeding of high carbohydrate diets resulted in alterations in the meta-
bolism of lipoproteins in hype~lipemic subjects. 
Studies conducted by Lambert and Catapano (68, 69) tended to sub-
stantiate previous work. A large population of hypertriglyceridemic 
subjects were assessed for apo CII, CIII 1 and CIII2 levels. Good 
correlations were obtained between triglyceride levels and apo CII with 
apo CIII 1 increasing with hypertriglyceridemia. Apo CIII 2 followed 
the pattern of CII, but to a lesser extent. Definite results concerning 
C apoprotein levels were obtained by Matsuoka and Shirai (70). These 
investigators found that patients who had hypertriglyceridemia were de-
ficient in apo CII with maximum hydrolysis of VLDL occurring at 2.5 ug 
apo CII/mg triglyceride. The Km value of the lipoprotein lipase enzyme 
for apo CII deficient VLDL was 7.8 mol/L. When 2.5 ug of apo CII was 
added to the medium, the Km decreased to 1 mol/L. A possible explana-
tion of the affect of apo CII to decrease the Km is that the protein 
enhances the interaction between lipoprotein lipase and triglyceride 
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within the surface monolayer of the lipoprotein. 
studies have also been conducted concerning the effect of h~gh 
carbohydrate on apo B catabolism {71, 72). Ginsbert (71) found no pro-
duction change in apo B during the normal carbohydrate diet in which 40 
to 60 percent of VLDL apo B was converted to LDL. However, patients on 
high carbohydrate diets converted only 16 to 42 percent of VLDL apo B 
to LDL. In most cases direct catabolism of VLDL apo B occurred without 
conversion to higher density lipoprotein classes during the high carbo-
hydrate diet with essentially no VLDL apo B converted directly to LDL 
apo B. A fall in LDL-apo B concentrations did not follow the reduced 
input from VLDL and was explained by a reduction in the removal rate of 
LDL-apo B. Thus, significant a)terations in the routes of catabolism 
of apo B occurred with high carbohydrate diets. Others have reported 
that apo LDL turnover in hyperlipoproteinemic patients did not differ 
from the control {73). Since VLDL and LDL are in a precursor-product 
relationship, these results also suggest a defect in VLDL catabolism. 
VLDL are usually found to migrate as a single band with pre beta 
mobility during electrophoresis (74-76). Recently, two electrophoretic 
populations of VLDL were isolated from human serum {77-79). The 
mobility of the slow subunit has been found to have more beta (LDL) 
rather than pre beta characteristics. The reduced mobility of the slow-
er component was related to a loss of C apoproteins relative to B and E. 
This change in protein composition and increase in the ratio of choles-
terol esters to triglyceride was remarkably similar to the structure of 
remnant VLDL (breakdown products of VLDL lipolysis) (80). These results 
suggest that many individuals who are hyperlipemic could have large 
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amounts of the remnant lipoproteins present. These sVLDL have been 
found to cause macrophages to become loaded with massive amounts ~f 
cholesteryl esters (81-83). This effect was attributable to a high 
affinity binding site on the macrophage surface that recognizes sVLDL. 
The B and E apoproteins, major constituents of sVLDL, interact with this 
high affinity receptor. Similar studies were conducted demonstrating 
remnant particle uptake by rat aortic smooth muscle cells (84). Ali-
quots of VLDL and sVLDL were added to smooth muscle cell cultures and 
remnant uptake exceeded that of very low density lipoproteins. Avid 
uptake of remnants by aortic smooth muscle cells might have relevance 
to the close association between increased levels of circulating VLDL 
remnants and atherosclerosis. ~omologous studies were performed on cul-
tured human aortic smooth muscle (85) in which regular VLDL uptake was 
measured instead of sVLDL. In humans, VLDL uptake approximated 320 to 
1100 ng/100 ug of protein, whereas VLDL uptake by rat aortic muscle 
averaged only 5 ng/100 ug. Humans and rats differ markedly in their 
propensity to develop atherosclerosis. Since man appears to be parti-
cularly prone to accumulate lipid in arterial smooth muscle, these re-
sults are consistent with the possibility that these lipoproteins play a 
central role in atherogenesis. 
An interesting observation has been made by Brown et al (86) con-
cerning the accumulation of cholesterol in macrophages. LDL could not 
be incorporated into the cells unless the epsilon-amino groups of lysine 
in the lipoprotein had been removed or chemically modified, giving the 
protein an enhanced negative change. Naturally occurring reactions which 
would modify these sites were investigated. A fascinating observation 
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noted was that treatment of LDL with malondialdehyde stimulated choles-
terol LDL accumulation in monocytes {87). The importance of this re-
action derives from the fact that malondialdehyde (MDA) is produced by 
platelets as a byproduct of arachidonic acid metabolism during the syn-
thesis of thromboxanes {88). If liberated in high enough quantities 
(for example, regions of thrombosis), it is possible that (MDA) could 
modify LDL so that it is taken up by macrophages. If this is the case, 
platelet aggregation and developmental atherosclerosis may be closely 
linked. Platelet hyperactivity has been linked with diabetic maladies 
for some years since an increased platelet sensitivity to aggregation 
from ADP and epinephrine has been described many times in diabetes 
{89-92). Increased plasma pros,taglandin E levels were found in dia-
betic patients administered aggregating agents, suggesting that an 
increase in this biosynthetic pathway is one cause of increased plate-
let sensitivity (93). Platelet function also seems to be dependent on 
dietary fat (94). It was found that diets low in saturated and high in 
polyunsaturated fats prolonged the aggregation times and decreased 
aggregability of platelets in subjects receiving these diets. Other 
studies have shown that arterial thrombus formation is significantly de-
layed by a high polyunsaturated/saturated fat ratio (95, 96). 
Different types of endogenous hyperlipemia can also cause increas-
ed platelet function (97). The mechanism of platelet hypersensitivity 
in non-insulin dependent disorders is unknown. Alterations in platelet 
function may be related to an underlying metabolic abnormality in 
familial hyperbetalipoproteinemia. Platelets may incorporate total low-
density lipoproteins or components into their membranes and thus alter 
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their surface characteristics. To substantiate this, Bolton (98) has 
isolated lipoprotein fractions that are responsible for changes i~ the 
electrophoretic mobility of platelets. Zahavi et al. (99) demonstrated 
enhanced ~ vivo platelet release reactions and malondialdehyde forma-
tion in patients with hyperlipemia. The mechanism of the enhanced re-
lease reaction and MDA formation could be related indirectly to elevated 
serum lipids. Besides changes in membrane constituents, changes in the 
cholesterol content of platelets can influence the metabolism of arach-
idonic acid and increase the levels of thromboxane B2 (100). Finally, 
in a study measuring the effects of sucrose on insulin levels and 
platelet adhesiveness, Szanto (101) found that increased insulin levels 
correlated well with increased;platelet adhesiveness. 
Therefore, this introduction suggests a general mechanism to ex-
plain the relationships between diabetes mellitus, platelet aggregation, 
hyperlipoproteinemia and carbohydrate intolerance, all contributing 
factors in atherogenesis. Since the many reports about the effect of 
sucrose seem to conflict in the literature, the plan of this study is to 
administer both high sucrose and low sucrose diets employing natural 
food sources, to diabetic patients over a long term period to ascertain 
which atherogenic parameters are affected. 
The recent recommendation of the American Diabetes Association 
Committee on Food and Nutrition and a greater consumption of processed 
foods which have variable but large proportions of added unquantitated 
sucrose, necessitates the need to know how hypertriglyceridemic 
diabetics respond to graded amounts of sucrose. 
2. RELEVANT LITERATURE REVIEW 
A. Atherosclerosis Disease Description 
Pathologically, the atherosclerotic lesion consists of a plaque-
like thickening of the arterial wall. Moore (103) demonstrated that 
atheromata could be induced by placing a catheter into the aorta of 
rabbits for different periods of time, indicating that endothelial in-
jury is important in the atherogenic process (112). The plaque con-
sists of a thickening of proliferating smooth muscle cells surrounded by 
large amounts of interstitial substances that include collagen, elastin, 
glycosaminoglycans, and fibrin (104-106). The substance that is most 
detrimental to the atheromatous plaque is lipid, chiefly cholesterol. 
Compelling evidence has been established which include the following ob-
servations: 
1. Atherosclerosis, leading to myocardial infarction, can 
be produced in every species studied by increased 
cholesterol consumption (105). 
2. Endothelial damage in normal animals will usually pro-
duce a benign scar. However, if blood cholesterol and 
triglyceride levels are increased, lipid is deposited in 
the lesion and atherosclerosis develops (105). 
3. In the human population, in which mean plasma cholesterol 
levels are lower than 160 mg/dl, atherosclerosis is re-
duced even when other factors, such as diabetes, smoking, 
and hypertension exist. 
4. Myocardial infarctions are positively correlated with 
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a. 
serum cholesterol and triglyceride levels (107, 108). 
5. Finally, genetic diseases that cause elevations in 
cholesterol concentration usually produce athero-
sclerosis in early childhood (109). 
Cause of the Disease 
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In nature, injuries to the endothelium occur in a myriad of ways. 
Blood flow around irregularities, such as atheromata and branch points, 
could cause injury. Diabetes has also been associated with increased 
endothelial damage. Repeated immunization, such as insulin injection 
in insulin-dependent diabetics, could lead to antibody-antigen com-
plexes resulting in vascular injury {110). Ditzel (111) raised the 
question that diabetics may have impaired erythrocyte oxygen transport 
and may develop arterial injury by hypoxia. 
Platelets do not adhere to normal, healthy endothelium (114), but 
platelets interact with the collagen of injured endothelium through the 
effects of thromboxane. Further endothelial damage and the release of 
platelet-derived growth factor stimulates smooth muscle proliferation. 
The breakdown in the barrier function of the endothelium allows large 
amounts of plasma constituents, including lipoproteins, to penetrate the 
artery wall. Proliferating smooth-muscle cells migrate into the inner 
layer and remove foreign plasma constituents by endocytosis. These con-
stituents are hydrolyzed components of lipoproteins that are metabolized 
to relatively soluble materials (free fatty acids, amino acids, and 
monosaccharides). The cholesterol and free fatty acids that are ab-
sorbed by the endothelium are esterified and can not be removed by 
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simple solubilization. Thus, cholesterol and triglyceride accumulate 
in the arterial wall. These smooth muscle cells do not possess r~­
ceptor mediated uptake of lipoproteins but a type of scavenger mecha-
nism is in operation (118) and large levels of lipid can be accumulated. 
Other constituents of the arterial wall such as glycosaminoglycans have 
been shown to trap lipoproteins entering the endothelial space (116, 
117). These findings point to the fact that atherosclerosis is a multi-
faceted disease state in which many of the factors listed above are 
additive (107). 
B. SUCROSE 
a. History 
Sucrose, or s-D-fructofuranosyl-a-0-glucopyranoside, is composed 
of one molecule of glucose and one molecule of fructose joined by a 
glycoside bond. It is a non-reducing sugar and is stable against boil-
ing with very strong alkali solutions. However, it is more easily 
hydrolyzed by acids than are other common disaccharides. Sucrose is 
synthesized in the green leaves of plants and stored in the fruits and 
roots as a source of energy and carbon. Commercially, sucrose is ob-
tained primarily from sugar beet or sugar cane, accounting for 40 and 60 
percent respectively of world sucrose production (131). 
Like fat consumption, the amount of sucrose consumed per indivi-
dual increases with the average income of the country. In India, 
Pakistan, and China, daily consumption averages approximately 15 g of 
sucrose per person. In the U.S., England, and Scandinavia the daily 
individual consumption is 150 g of sucrose. From a nutritional point 
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of view, a high sucrose consumption is undesirable since it is a highly 
refined product containing no essential nutrients. Clearly, howe~er, 
humans and animals have a strong preference for its sweet taste. 
b. Digestion 
Sucrose must be hydrolyzed into its monosaccharide components be-
fore absorption in the small intestine. There is no significant absorp-
tion of unhydrolyzed sucrose. In animal experiments, sucrose adminis-
tered by injection was quantitatively excreted {140). Hydrolysis of 
sucrose is catalyzed by enzymes in the intestinal brush borders of the 
mucosal epithelial cells. Patients with congenital lack of sucrase are 
unable to absorb sucrose (133-1~5). Theoretically, the ability of a 
subject to absorb a specific disaccharide is dependent on the intes-
tinal activity of the enzyme which hydrolyzes the specific disaccharide. 
It is possible that dietary disaccharide stimulates the corresponding 
disaccharidase activity by induction. It is postulated that a regula-
tory gene codes for a repressor protein which binds the operator region. 
Glucose and other sugars may bind the repressor so that the operator 
gene can synthesize mRNA resulting in increased enzyme production. This 
concept of specific dietary regulation of jejunal disaccharidase activ-
ity has been postulated by Rosenweig and Herman (136). They studied the 
effect of isocaloric diets of glucose and sucrose or sucrose and maltose. 
Intestinal biopsies were done on each subject after either glucose, suc-
rose, or maltose consumption. It was found that the activities of the 
disaccharidases were higher with sucrose diets than with glucose and 
maltose diets. 
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Intestinal absorption processes also respond to dietary sucrose. 
Rats that were adapted to sucrose diets demonstrated enhanced absqrp-
tion of sucrose and constituent monosaccharides as compared to iso-
caloric diets of starch (42). Since disaccharidase activity has been 
shown to occur in proximal areas of the small intestine and glucose 
absorbed in this part of the intestine has been found to be a more 
efficient secretagogue for gastric inhibitory polypeptide (GIP), a more 
rapid absorption of glucose after a sucrose load in sucrose adapted in-
dividuals might partially explain the enhanced leveled of GIP in these 
individuals (138). GIP is an important stimulator of insulin secretion 
and the term enteroinsular axis has been used to describe the influence 
of this intestinal hormone on i~sulin secretion (139). The finding that 
sucrose is a much more efficient secretagogue for GIP might explain 
specific metabolic differences observed in sucrose as compared to glu-
cose ingestion. Rats fed disaccharides (sucrose rather than monosaccha-
rides) exhibited an increase in hepatic lipogenic activity (140). Dis-
accharides are hydrolyzed prior to their intestinal absorption and must 
have their effect at this level. The disaccharide effect could result 
from greater GIP stimulation. This stimulation produces hyperinsu-
linism, and signals a pattern of enzyme induction which directs carbo-
hydrate metabolism to lipogenesis. 
The idea that high sucrose diets led to an increase in hepatic 
fatty acid synthetase was supported by the work of Bruchdorfer and Khan 
(141). When the diet contained fructose or sucrose, a high correlation 
was found between hepatic synthetase and triglyceride concentration. 
The presence of these sugars in the diet could not be related to insulin 
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concentration. In another study of hyperlipemia due to sucrose in-
gestion, it was found that a majority of the triglycerides that were 
synthesized came directly from sucrose as the main carbon source (142). 
By using [14c] labeled sucrose Chlouverakis was able to demonstrate a 
greater [14c] content in triglycerides produced with sucrose feeding 
than with comparable glucose or starch feeding. Sucrose has also been 
found to cause greater weight gains in animals than isocaloric amounts 
of glucose or starch (143, 144). In general, these results imply that 
the organism metabolizes sucrose more efficiently than glucose. This 
agrees with theoretical calculations demonstrating that smaller amounts 
of sucrose are required to produce a unit of metabolizable energy than 
glucose (145). While the effects of sucrose on the liver and the endo-
crine pancreas point to increased lipogenesis, the cause of this hyper-
lipemia remains to be elucidated. 
C. HUMAN TRIGLYCERIDE METABOLISM 
a. Exogenous Incorporation 
Triglycerides are the principal form in which long chain fatty 
acids are stored and transported in the blood. This is true whether 
they arise from intestinal absorption or hepatic secretion. To be ab-
sorbed, these lipids must first be converted into more polar compounds 
by processes that take place primarily in the lumen of the small intes-
tine (119). The lipids are finely emulsified by the churning action of 
the small intestine, then further broken down by the action of pancre-
atic lipases and solubilized in detergent structures containing high 
amounts of free cholesterol and bile salts, called mixed micelles. 
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These structures are polar enough to transport lipid across the un-
stirred water layer that lies on the surface of the intestinal membrane. 
Once inside the intestine, these lipids are reesterfied with glycerol 
and are transported to the endoplasmic reticulum (148, 149}. Osmio-
philic particles of the same size, shape and staining properties, call-
ed chylomicrons (large lipoproteins of intestinal origin), are assembled 
at the endoplasmic reticulum of the mucosal cell with triglyceride added 
to the protein core. These particles first appear in the apical region 
of the cell within vesicular and tubular cisternae of smooth surfaced 
endoplasmic reticulum. Thereafter they appear in cisternae with some 
attached ribosomes. The newly-synthesized chylomicrons appear to mi-
grate from the smooth endoplasmjc reticulum to the Golgi apparatus 
(supranuclear in intestinal absorptive cells) (120). The Golgi appara-
tus is a tubular system through which the chylomicrons must pass. The 
particles accumulate in secretory vesicles of the Golgi and appear at 
lateral extracellular spaces between absorptive cells. The lipopro-
teins are subsequently extruded from these vesicles into the lacteals 
and course through the lymphatics gaining access to the systemic cir-
culation via the thoracic duct. This lymphatic route bypasses the liver 
and the bulk of the triglyceride is hydrolyzed in several extrahepatic 
tissues. After a fat-containing meal, the process of deposition begins 
when these chylomicrons enter the circulation and come in contact with 
the endothelial surface of adipocyte capillaries. FFA, and La glycero-
phosphate is then released and stored in the adipocyte. 
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b. Endogenous Production 
Most mammals can convert carbohydrate to fatty acids which can 
be deposited as adipose fat. The central argument concerning enzy-
matic triglyceride production from carbohydrate derived precursors 
concerns the role that processing of carbohydrate plays on fatty acid 
biosynthesis. Recent studies over the last two decades have led to a 
prodigious effort to uncover the mechanism involved in the physiologic 
regulation of fatty acid biosynthesis. There are two types of control 
mechanisms that regulate the complete synthesis of fatty acids by the 
de nova pathway. One is long term control which involves changes in 
the content of fatty acid biosynthetic enzymes including acetyl CoA 
carboxylase, fatty acid synthe~ase complex, citrate lyase, glucose 
6-phosphate dehydrogenase and malic enzyme, which are stimulated in the 
liver when glucose is fed. By contrast, the content of these enzymes 
in the liver decreases during starvation or in diabetes associated with 
insulin deficiency (122-124). In this way, the cell has large quanti-
ties of these enzymes needed for conversion of carbohydrate into fatty 
acid only when carbohydrate and ATP are available. 
There is also a short-term control mechanism that acts on acetyl 
CoA carboxylase, the rate limiting enzyme in fatty acid synthesis. It 
involves modulation of the activity of acetyl CoA carboxylase. Citrate 
activates the enzyme by causing aggregation, while long chain acyl CoA 
inactivates it (125). Other enzymatic steps may also be important in 
the regulation of fatty acid synthesis (126). For example, pyruvate 
dehydrogenase has been implicated as a site of control (127-128). 
It was found the intestine secretes triglycerides into mesenteric 
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lymph as VLDL sized particles. Studies by Cenedella et al. {129) demon-
strated that rats fed orotic acid, known to block liver release o~ lipo-
proteins, developed a sustained entry of triglyceride into the plasma 
pool. The labelled triglyceride was thought to be of intestinal origin 
because of the time course involved in the appearance of TG in the 
plasma of orotic acid fed animals. This observation was consistent with 
the idea that triglycerides released from the liver gain immediate ac-
cess to the plasma while those from the intestine must travel through 
the lymphatics. Orotic fed rats formed only ten percent as much circu-
lating triglyceride as control animals. This, coupled with a consider-
able less rapid triglyceride turnover suggests that the intestines could 
produce ten percent of the plasma triglycerides presumably derived from 
liver. 
The hepatic subcellular pathway of triglyceride secretion shares 
many common features with the intestinal pathway. In the liver, 
secretory vesicles near the cell surface fuse with the plasma membrane 
resulting in the discharge of VLDL into the Space of Disse. Recogni-
tion proteins probably exist in membranes of secretory vesicles and in 
the plasma membranes which result in fusion of the two. Reaven 
suggested that microtubule protein is essential in maintaining the 
structural integrity of Golgi membranes and associated structures (130), 
with the use of antimicrotubule agents leading to a disaggregation of 
microtubule protein structure. This disorganization of the Golgi re-
sults in impairment of VLDL (TG) secretion possibly because the mem-
branes of the formed VLDL-containing vacuoles lack a critical component 
normally acquired through the Golgi complex. The liver, the major site 
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of fatty acid biosynthesis, then releases these triglyceride laden lipo-
proteins for subsequent deposition of triglyceride into the adipo~yte. 
This synthetic mechanism is probably the main cause of diet induced 
hyperlipemia. Studies using radiolabeled triglyceride components have 
shown that this increased synthesis plays an important role in hyper-
lipemia (49, 57, 58). 
D. THE HUMAN LIPOPROTEINS 
I. Introduction 
The plasma lipoproteins have become a focus of intense study in 
recent years. This has resulted in part from new technical advances in 
electrophoresis for the separa~ion of lipoprotein classes (146). In 
1967, Fredrickson published a comprehensive survey of the plasma lipo-
proteins and suggested a method for defining hyperlipoproteinemia on the 
basis of five phenotypes (147). The use of plasma lipoprotein phenotyp-
ing became widespread with clinical interest in these proteins increas-
ing due to accumulating evidence which related elevated levels of plasma 
lipoproteins to premature coronary artery disease. It has become evi-
dent that the classification of different hyperlipemias is, in fact, 
based on changes in the subunit structure and distribution of the plasma 
lipoproteins. 
II. Composition and Identification of Lipoproteins 
a. Chylomicrons 
Dietary triglycerides are hydrolyzed in the duodenum to free fatty 
acids and 2-monoglycerides. After absorption, triglycerides are resyn-
28 
thesized and incorporated into the chylomicron particle in the intes-
tinal wall (148-149). Lymph chylomicrons are heterogenous in size, 
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ranging in diameter from 300 to 5000A. These particles mainly con-
sist of triglyceride (70-90%) and there is a direct relationship be-
tween the size of the chylomicron and triglyceride content. Chylo-
microns also contain a small fraction of phospholipid (8%) and 
cholesterol (5%). Phosphatidylcholine and sphingomyelin are the major 
phospholids present (150). The protein content of chylomicron is small 
but variable. Kastner (151) found that human chylomicrons isolated from 
the thoracic duct contain all of the apoproteins of VLDL. The approxi-
mate protein composition of chylomicrons is 66 percent apo C, 22 percent 
apo B and 12 percent apo A. A~ interesting point of this study was that 
apo A and apo A1 were present in approximately equal quantities in the 
chylomicron differing from the ratio of 3:1 found in HDL. 
b. VLDL 
In man, the very low density lipoprotein (VLDL) particle is the 
major transport vehicle for endogenously derived triglyceride (150). 
Streja and Kallai (152) found that VLDL molecules are very heterogenous 
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with sizes ranging in a continuum of 280A-750A. It was also observed 
that larger lighter VLDL particles were metabolized more rapidly from 
the plasma compartment than smaller heavier particles. The size of the 
VLDL particle is related directly to the triglyceride content and in-
directly to the phospholipid and protein content. Triglyceride is the 
most abundant lipid component (56 percent) of VLDL. The average VLDL 
lipid content is 19-21 percent phospholipid and 17 percent cholesterol. 
In VLDL the esterified to unesterified cholesterol ratio is approxi-
mately 1. Phosphatidylcholine and sphingomyelin are the predominant 
phospholipids. 
The protein composition of VLDL has been well characterized 
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through the use of various isolation techniques. The percent compo-
sition of soluble and insoluble apoproteins in VLDL remains fairly con-
stant regardless of sex and age of the individual. However, there are 
variations in concentrations of apoproteins in VLDL from one indivi-
dual to another. Observed variations in the absolute concentrations of 
apolipoprotein in the VLDL subfraction from individual subjects probably 
reflects their nutritional and metabolic status. Lee and Alaupovic 
{151) found that an increasing plasma triglyceride level in the post-
absorptive state is accompanied by higher levels of apo B and apo C. 
Esterification of fatty acids in the endoplasmic reticulum could stimu-
late apoprotein synthesis (154). Previous studies by Gustafson (153) 
found that the protein moiety is an integral component of the lipo-
protein particle providing structural stability for the molecule. In 
the presence of detergent (e.g. sodium dodecyl sulfate) apo VLDL can be 
solubilized and fractionated into respective apoproteins. VLDL con-
tains about 55 percent apo B and 45 percent apo A. Concentrations of 
apo A are immunologically detectable, but very low. AI and AII peptides 
accounted for less than one percent of the total protein. Other reports 
estimate the apo B concentration to comprise 35 percent of total VLDL 
apoprotein (154). Kane and Sata (155) found another apoprotein, apo E, 
rich in arginine, which represented approximately 20 percent of the 
total apoprotein content. Apo E was at first confused with apo B, 
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giving the relatively high value previously seen for apo B (155). These 
investigators also discovered a previously undetected entity of apo C 
having electrophoretic mobility compatible with an increment of one unit 
of charge over that of another apo C subgroup. These authors hypothe-
sized that this moiety was a sialoprotein since neuraminidase treat-
ment resulted in proteins migrating with decreased mobility (similar to 
typical apo C subspecies). 
c. Low Density Lipoproteins 
In the U.S., the average normal fasting adult concentration of low 
density lipoprotein (LDL) is 400 mg/dl in males and 340 mg/dl in fe-
males. LDL contains approximate)y 75 percent lipid and 25 percent pro-
tein. Lipid composition by weight is 50 percent cholesterol esters, 30 
percent phospholipids and 10 percent reesterfied cholesterol with 10 
percent triglyceride. Phosphatidylcholine and sphingomyelin account for 
65 percent and 25 percent of the total phospholipid respectively with 
linoleic acid as the major fatty acid in LDL (150). LDL particles 
appear almost spherical in size and are quite uniform in appearance when 
observed by electron microscopy with negative staining techniques (156). 
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Eighty percent of LDL particles are between 210 and 250A in diameter 
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with molecular weight ranges reported to vary between 2-35 X 10 daltons 
(159). Subfractions of LDL have been isolated using density gradient 
centrifugation between 1.019 and 1.063 g/L (154, 160). Although the 
molecular weight of the subfractions is different, each LDL particle 
contains a constant percentage of protein. Studies of the density sub-
classes of LDL (LDL1 and LDL 2) demonstrate that there is a constant 
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ratio of soluble (apo C, A, E) to insoluble {apo B) protein in both 
subclasses (154). However, marked differences in the apoprotein com-
position of these subclasses have been observed. In contrast to LOL2, 
the LOL1 fraction contains roughly as much apo C (38 percent) as VLOL 
and LOL 1 may represent an integral part or continuation of VLOL 
metabolism. All three apo C subclasses were identified in LOL isola-
ted in the 1.006-1.019 density ranges. The LOL2 subclasses represent 
the only segment of the lipoprotein density spectrum consisting pre-
dominantly of apo B. The soluble apolipoproteins account for only 4-9 
percent of the total protein content of LOL 2• Apo B content of this 
subgroup is in agreement with the observed LOL apo B content estimated 
by Lees using radial immunodiff~sion {161). Plasma LOL probably 
functions as a storage depot for cholesterol. Extrahepatic tissues can 
obtain LOL-cholesterol for membrane synthesis through a receptor 
mediated process. In metabolizing LOL for structural purposes, extra-
hepatic tissues constitute a major site of LOL catabolism. 
d. HOL 
High density lipoproteins (HOL) are relatively small aggregates of 
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lipids and proteins with diameters ranging from 90 to 120A (156). 
Lipids account for about one-half of HOL by weight. Phospholipids 
(42-51 percent), cholesterol (32 percent) and triglyceride (10 percent) 
are the main components (150). Phosphatidylcholine constitutes 70-80 
percent and sphingomyelin 12-14 percent of the total phospholipid. 
Phosphatidylserine and phosphatidylinositol are minor components. 
Linoleic acid is the predominant fatty acid of the esterified 
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cholesterol. 
Protein moieties of HDL have been identified using DEAE-cellulose 
chromatography and consist of two major components (165). About 90 
percent by weight of the protein in HDL is either apo AI or Ail. AI 
accounts for 70 percent and AII about 20 percent of the total protein. 
Other peptide components, C and E protein subunits, have been isolated 
from (HDL2) subfractions but comprise minor amounts of the total HDL 
protein (166). The ratio of apo AI to apo AII varies within each HDL 
subfraction. These peptides are remarkable in that they can function 
as detergents capable of solubilizing lipids and cholesterol in large 
quantities. In fact, 1 g of HDL AI can solubilize up to 2.5 g of phos-
pholipid in a disc-like micelle;(167), structures analogous to the 
lecithin-cholesterol-bile salt micelles found in bile. However, bile 
salts act as detergents in fat digestion, whereas HDL proteins are the 
detergents in plasma (168). 
A minor HDL component, HDL 1, has been isolated between 1.050 
and 1.063 g/L (HDL normally are between 1.063-1.21). HDL 1 has elec-
trophoretic and immunochemical properties similar to normal HDL2 
(162). Several HDL subspecies have been identified by analytical and 
preparative gel electrofocusing (163-164), but their physiological sig-
nificance is unknown. However, the human plasma HDL2/HDL3 ratio is 
affected by several pathologic and physiologic processes. 
e. Pre a Lipoprotein 
A pre a lipoprotein has been observed in human serum with electro-
phoretic mobility and staining characteristics in agarose gel similar to 
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albumin (160). Free fatty acids and a high content of the phospholipid 
lysolecithin are present in this fraction (170). The ability of ~1-
bumin to bind both types of lipids lends support to the theory that 
albumin makes up a substantial part of the pre a lipoprotein. The 
presence of other phospholipids and neutral lipids suggests that other 
apoproteins may be present in pre a lipoproteins. Wille and associates 
(171) characterized the protein fractions utilizing immunological 
methods. They found that one single band was found on PAGE electro-
phoresis, but double diffusion experiments disclosed the presence of apo 
AI as well. The total amino acid composition is similar to albumin ex-
cept for higher amounts of glycine, serine and glutamic acid. Use of 
mercaptoethanol to reduce disulfide bonds resulted in two bands on PAGE 
where one had been previously observed (172). One protein had a mole-
cular weight comparable to albumin (67,000) and the other to apo AI 
(28,400). Albumin may attach peptides through disulfide bridges, parti-
cularly at position SH-34 cysteine (173). Since apo AI does not contain 
a cysteine residue, the apo AI molecule might be enclosed within 
crevices in the larger albumin molecule (174). A functional role has 
previously been ascribed to a pre a lipoprotein in lysolecithin trans-
port (180) and may function as an acceptor for the lysolecithin gener-
ated by the lecithin-cholesterol acyltransferase reaction in plasma 
(175). 
f. Lipoprotein (A) 
Lipoprotein A (LpA) exhibits the same properties as LDL, but is 
considered an additional lipoprotein class. It is isolated in the 
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1.050-1.120 g/L density range and has a molecular weight of about 5 X 
1o6 daltons. LpA exhibits pre-s mobility on agarose gel electro-
phoresis and has a lipid composition similar to LDL, though its protein 
content is completely different (176). LpA, when delipidated, contains 
65 percent apo B, 15 percent albumin and a unique apoprotein called apo 
Lp(A) (177). The occurrence of LpA in the general population may be as 
high as 75-85 percent with an average plasma concentration of 14 mg/100 
ml. LpA concentration does not appear to correlate with age, sex, or 
lipid concentration, and the functional significance of LpA is not known 
(178-179). 
E. THE APOPROTEINS 
Until about ten years ago, lipoproteins were viewed as isolated 
families or species defined either by ultracentrifugation or by electro-
phoresis. This basis of classification provided little insight into 
causes of lipoprotein abnormalities or the role of the lipoproteins in 
lipid transport. Many processes involved in lipoprotein metabolism are 
regulated by enzymes whose activity is influenced by the apoproteins. 
It is generally accepted that there are at least seven different ape-
protein classes which differ in their primary, secondary, and tertiary 
structure. These proteins also differ in their function and distribu-
tion throughout the lipoprotein spectrum. (Table 1). 
a. Apo A 
Chromatography of delipidated apo HDL yields two pure polypeptides 
designated apo AI and apo AII, the major apoproteins of HDL (181). Apo 
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AI is a single polypeptide chain of 245 amino acids and has a molecular 
weight of 28,331 daltons. The amino acid content determined by B~ker 
indicated a protein composed primarily of cysteine, cystine, isoleu-
cine and carbohydrate (182). Glutamine is the carboxyterminal amino 
acid and aspartic acid is the amino terminal group. Heterogeneity has 
been observed by Nestruck et al. who found four isoprotein subgroups of 
apo AI {183). They had identical molecular weights and common anti-
genicity with antisera raised against apo AI. Each form had a similar 
amino acid composition except for A IV which contained one isoleucine 
residue .Per mole. All forms of apo AI were LCAT activators except for 
AIV which inhibited the enzyme {183). 
AI - Alii are considered ~quivalent polymorphic forms while AIV 
is considered a different form of unresolved heterogeneity. Apo AI has 
been isolated from a wide range of animal species, but all types have 
similar physiochemical properties (184). Results from many structural 
studies indicate lipid binding properties may be related to the degree 
of self-association of the proteins {185-188). Vitelli and Scanu {189) 
have found that the molecular weight of Apo AI can very between 30,000 
and 167,000 at protein concentration of 0.2-0.9 mg/ml due to a monomer-
dimer-tetramer-octamer equilibrium. A minor apo AI component has been 
isolated by Weisgraber et al. that coelectrophoresed with apo AI on SDS 
polyacrylamide gel (190). It was immunogenically similar to apo I 
except that it contained two amino acids, cysteine and isoleucine, which 
are not found in normal apo AI. By virtue of its cysteine group, apo AI 
is capable of forming disulfide bridges. 
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PROPERTIES OF LIPOPROTEINS 
Chylomtcrons VLDL LDL HDL2 HDL 
cholesterol, prote1n, MaJOr triglycerides tr!Qlycendes prote1n, phospholipid. Constituents phospholipid choles ter o1 
Apolipoprotell'\5 B,A,C B,C,E 8 A,C,D,E 
SIZe(,!.) >1000 300-800 180-250 100 75 
Oens1ty (g/ml) <095 0.95-1.006 1.006-1.063 1.063-1.125 1.125 -1.21 
Flotation (Sf 1 063) >400 20-400 0-20 (FL~l35-9 0-3.5 
Mobility or1g1n pre-beta beta a~ha-1 
Precipitation t~ t t~ t 
Table 1: Summary of the basic properties for the 5 specific lipo-
protein classes listed. 
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Apo All is the second most abundant apoprotein of human HDL. It 
consists of two identical polypeptide chains of 77 amino acids which 
are linked by a disulfide bridge at cystine-6 (199). Histidine, 
arginine, tryptophan and carbohydrate are absent from apo Ali. Stone 
and Reynolds (188) have calculated that apo All has a dimeric molecular 
weight of 34,000. Gwynne et al. (193) on the other hand, reported the 
molecular weight of apo All is dependent on concentration and obtained 
an equilibrium constant of 2.8 X 104M-1 for monomer-dimer equili-
brium. 
Studies from other animals indicate the disulfide bridge is not 
crucial for apo 11 to fulfill a lipid carrier role (194-195). The 
interactions between A apoprotejns and lipids have been extensively 
studied (196). Both apo AI and apo All bind phosphatidylcholine to 
form protein-phospholipid complexes (197). When apo Ali is added to a 
sonicated mixture of either lecithin or sphingomyelin, 79-90 percent 
of the apo AII can be isolated in the HDL density range. In contrast, 
only about ten percent of added apo AI is found in this range. 
b. Apo B 
Apo B is the least well characterized of the plasma apoproteins. 
Similar to integral membrane proteins, apo B is not readily soluble in 
aqueous solutions unless high concentrations of detergents are added 
(198-200). Results from solubilization studies have resulted in no 
general agreement concerning the number of subunits or the molecular 
weight of apo B. Reported weights range from 8000-275,000 daltons with 
the most commonly reported values between 25,000-30,000 daltons (201). 
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Apo B has been recently studied and found to have an amino acid com-
position similar to that of the other apoproteins (201). The concen-
tration of apo B in normal human plasma is between 70-110 mg/dl and 
primarily found in LDL (204-205). 
c. Apo C 
Fractionation of apo C into its component proteins can be 
achieved by ion exchange chromatography or isoelectric focusing (166). 
Apo CI is a single polypeptide chain of 57 amino acid residues (206). 
The protein contains about 55 percent a-helix which is increased in 
the presence of phospholipid (207). Upon fractionating the protein in 
SDS urea gels, certain bands a~e produced through carbamylation of the 
£-amino groups of lysine with urea. This carbamylation converts the 
positively charged lysine to neutral homocitrulline and results in 
greater anodal migration on alkaline polyacrylamide gels (208). Once 
precautions are taken, these artifactual polymorphs disappeared. 
Brown et al. (209) reported that all of the apo c•s aggregate to 
form high molecular weight species in the absence of dissociating 
agents. In addition to binding and transporting lipid, apo Cacti-
vates lipoprotein lipase and LCAT (210). 
Human apo CII contains 79 amino acids and has a calculated 
molecular weight of 9110 daltons (211). In addition to binding lipid, 
apo CII is a potent activator of lipoprotein lipase from post-heparin 
plasma, adipose tissue and cow's milk (212-218). The work of Matsuoka 
et al. (70) demonstrates that apo CII acts on lipoprotein lipase by en-
hancing the interaction between lipoprotein lipase and triglyceride 
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within the surface monolayer of the lipoprotein particle (70). His 
work with apo CII deficient patients has provided much information con-
cerning enzyme kinetics of the lipoprotein lipase-apo CII reaction. 
Phospholipids also appear to be necessary for optimal lipolysis. In 
the absence of lipid, apo CII forms a stable complex with purified milk 
lipoprotein lipase (214). Apo CII contains only 23 percent a-helix 
and undergoes self-association at protein concentrations greater than 
mg/ml (209). 
Apo CIII, the most abundant apo C constituent, contains 79 amino 
acids, has a molecular weight of 8764 daltons and is a glycoprotein with 
an oligosaccharide attached to threonine at position 74. The oligosac-
charide contains one residue of ;galactose and galactosamine and 0-3 
residues of sialic acid (215). The complete amino acid sequence has 
been determined with amino terminal threonine and carboxy terminal 
alanine. Polymorphism of the protein on polyacrylamide gel electro-
phoresis is caused by differences in sialic acid content (215-216). 
Nestruck et al. (217) have shown that sialylation occurs in the Golgi 
apparatus of rat liver and the extent of sialylation increases with 
residence time of VLDL in the organelle. While the physiologic function 
of apo CIII is uncertain, Brown et al. (218) have found apo CIII is an 
inhibitor of lipoprotein lipase. This is due to binding of apo CIII to 
the lipase substrate with resulting prevention of enzyme substrate 
interactions. If apo CIII exceeds 2 percent of the weight of the lipase 
substrate, it reduces the hydrolysis of lipoproteins con-
taining sufficient apo CII. Blood apo C concentrations are not stable 
and have been found to be influenced by diet and metabolic status. A 
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decrease in the ratio of apo CII/apo CIII has been observed in the 
of hypertriglyceridemia (69). In addition, high carbohydrate diets re-
sult in alterations in the metabolism of apo CII and apo CIII suggest-
ing the secretion of both apoproteins is increased or their clearance 
is delayed {67). 
d. Arginine Rich Apoprotein (Apo E) 
The arginine rich protein was first isolated by Shore and Shore 
(166) from VLDL and HDL. In normal VLDL, apo E content is approxi-
mately equal to that of apo CI and apo CII and exceeded only by that of 
apo Band apo CIII (219). A molecular weight for apo E of 33,000 
daltons was obtained by sos~polyacrylamide gel electrophoresis. 
Approximately ten percent of the total amino acids are arginine. Lysine 
and alanine are reported to be the amino and carboxy terminal acids re-
spectively (220). The arginine-rich protein has a high a-helical con-
tent (221). It is present in several polymorphic forms which can be 
separated by either ion exchange chromatography or isoelectric focus-
ing (222-225). In humans, a diet containing increased cholesterol 
causes elevations in plasma apo E levels, some of which are found in 
HDL. HDL containing apo E has been shown to have a greater affinity 
than LDL for the LDL receptor (226). Studies on patients with type III 
hyperlipoproteinemia have shown that plasma levels of total apo E are 
increased, but that a deficiency exists in one of the isoprotein sub-
units (227-223). The deficiency may be seen as a structural mutation 
of the isoprotein subunit causing a different migration on two dimen-
sional electrophoretic gels. Studies by Havel and Chao (228) suggest 
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another function of apo E. In perfused rat livers, treated with 
ethynyl estradiol for five days, there was a stimulated uptake of 
lamellar complexes of apo E. Human lipoproteins with apo E, con-
taining all of the major protein isoforms, were comparable to rat 
lipoprotein containing apo E, during estrogen stimulated uptake at the 
hepatic site. However, lipoproteins from patients with dysbetalipo-
proteinemia, Type III disease, were characterized by decreased hepatic 
uptake. Havel hypothesized that apo E is an essential component re-
quired for recognition by the hepatic receptor to remove remnant VLDL. 
Accumulation of remnant particles is often found in type III hyper-
lipoproteinemia. Further proof of the function of apo E was obtained 
by Weisgraber and Mahley (229) ~pon their discovery of a 46,000 MW com-
plex in VLDL and HDL. This protein was reducible with mercaptoethanol 
or dithiothreitol into two chains indicating the presence of disulfide 
bonds. The two subunits were identified as apo E All monomers by 
coelectrophoresis and immunochemical activity. It was found that con-
version of the complex to the E apoprotein resulted in a markedly en-
hanced binding activity of the lipoprotein, containing the (apo E-AII), 
to receptors. The dimer is thought to block the recognition sites on 
apo E for the receptor. Elevated levels of this dimer complex could be 
responsible for decreased uptake of VLDL remnants and HDL by their re-
ceptors: 
e. Apo D or Thin Line Apoprotein 
A protein has been isolated from human HDL and has been referred 
to as thin line protein or apo D (223-231). The name, thin line 
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protein, is derived from a characteristic thin precipitin line formed 
near the antigen well with either anti-HDL or anti-whole serum. ~po D 
has been found in HDL3, LDL and VLDL (232). A preliminary estimate 
indicates this protein accounts for 1-2 percent of the total protein 
content of normal HDL (233). The protein is characterized by the 
presence of all common amino acids, including half-cystine. The carboxy 
terminal acid is serine, and carbohydrate analysis demonstrates apo D is 
a glycoprotein of 22,100 MW (234}. Carbohydrate moieties present are 
glucose, mannose, galactose, glucosamine, and sialic acid (accounting 
for 18 percent of the dry weight of apo D). The lipid moiety contains 
cholesterol, cholesterol ester, triglyceride and phospholipid. The 
phospholipid content is charact~rized by a relatively high amount of 
lysolecithin and sphingomyelin and a relatively low amount of lecithin. 
Kastner (235) found that apo D activates LCAT and Olaffsson and 
Gustafson (236) have suggested it may be a specific protein carrier for 
lysolecithin formed by the action of LCAT on HDL. Chajek and Fielding 
(237} demonstrated that human plasma contains a specific lipoprotein 
apoprotein that catalyzes the net transport of cholesteryl esters from 
HDL to VLDL and LDL. The purified protein is identical to that of apo 
D. It is possible that the normal catabolism of VLDL to LDL requires 
the presence of both HDL and plasma cholesteryl ester transport protein, 
apo D. 
F. STRUCTURE OF PLASMA LIPOPROTEINS 
Serum lipoproteins are referred to as soluble proteins to specify 
their solubility in aqueous media. Since they are fundamental in lipid 
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transport, a knowledge of their structural makeup is necessary to 
understand their function. Scanu (238) reviewed the methods of analy-
sis used to ascertain membrane structure (238). Some of these methods 
include chemical and enzymatic studies, reassembly studies, ultra-
centrifugation, electron microscopy, Optical Rotatory Dispersion (ORO), 
Circular Dichroism (CD), IR, NMR, ESR, X-ray techniques and surface 
balance studies. 
The ability of plasma apoproteins to interact to form soluble 
complexes with phospholipids cannot be explained by amino acid content 
or from direct inspection of primary structure. The overall amino acid 
structure is similar to other soluble plasma proteins. Segrest et al. 
(230) built space filling models for apoproteins whose sequences were 
known and found a common structural feature in the phospholipid binding 
region. Based on model-building studies and the assumption that an 
a-helix is fundamental to the mechanism of phospholipid binding, he 
suggested that these regions, referred to as amphipathic helices, 
represented the binding sites of apo A and apo C for phospholipid. Such 
helices have both polar and non-polar sites each comprising 180° of the 
cylindrical surface. Such an arrangement fascilitates simultaneous 
interaction of the protein with water insoluble lipids and with the 
external environment. Negatively charged amino acid residues (aspartic 
and glutamic acids) are clustered toward the middle of the polar face 
while positively charged basic side chains (lysine, arginine) are 
oriented toward the lateral edges of the interface between the polar and 
non~polar sides. This topographical arrangement of charged amino acids 
led to the suggestion that steric zwitterions are created and electro-
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static attractions between the positively charged choline groups of 
the phospholipid with the glutamic acid or aspartic acid side chains 
and between the phosphate and the lysine or arginine residues could 
occur. Maleylation of apo Ali abolishes the binding of phosphatidyl-
choline suggesting that lysine plays a role in the binding mechanism 
(240). If such ionic interactions do exist, they are probably less 
important than the hydrophobic interactions that are found. 
Another possible function of these steric ion pairs is that they 
could produce an initial orientation of the apoprotein with respect to 
the phospholipid which favors the interaction of these species during 
the initial phase of binding. The steric zwitterions within the helix 
are composed of two amino acids: which occur in a 1, 2 or 1, 4 rela-
tionship (235). These 1, 2 and 1, 4 ion pairs are not found in globular 
proteins which suggests they are of importance in lipoprotein phospho-
lipid interactions (241). It has been suggested that these ion pairs 
could function to lock a section of the peptide backbone into an 
a-helix through preferential hydration of the polar side of the helix. 
Sparrow et al. (242) have synthesized a series of model peptides which 
would be expected to have characteristics of amphipathic regions (242). 
The ability of these synthetic peptides to bind phospholipid was shown 
to depend on the degree of hydrophobicity of the non-polar surface of 
the helix. By making a substitution of Try-Trp for Ala-Ala, Sparrow 
found it was possible to transform a non-binding peptide into one which 
binds lipid more readily (242). 
The mass of data on lipid and protein interactions have led to the 
development of three separate models for lipoprotein structure. The 
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lipid core model was proposed for VLDL and chylomicrons. The physio-
chemical problem of keeping a neutral lipid-rich particle in solution 
is overcome by putting triglycerides and cholesteryl esters into a 
central core while phospholipids and cholesterol are on the surface 
(243-245). Gustafson (246) has calculated that the quantity of pro-
tein, phospholipid, and unesterified cholesterol in VLDL is suffi-
cient to cover the surface of the particle. Schumaker (247) has 
suggested that as triglycerides are removed from the particle by the 
action of lipoprotein lipase, there is a concomitant reduction in sur-
face area affected through the removal of cholesterol by the action of 
LCAT. 
Models of LDL structure are based on small angle X-ray scatter-
ing, nuclear magnetic resonance, and neutron scattering techniques 
(248-250). Mateu et al. (248) have concluded, from X-ray scattering, 
that there are outer and inner high electron-dense regions separated 
by an immediate low-electron-dense region (248). The LDL model suggest-
ed by this work has a phospholipid bilayer with cholesteryl esters, 
cholesterol and triglycerides separating an outer protein shell and an 
inner protein core. However, other investigators using neutron dif-
fraction, demonstrated that the central core is predominantly occupied 
by hydrocarbon chains of lipid (250). Finer (249) has used NMR to probe 
the location of li~id and protein and has concluded that at least 30 
percent of the choline residues are immobile and inaccessible to sol-
vent. It has been suggested that LDL contains a trilayer structure that 
surrounds a central core of protein (249). 
To date, the bulk of the experimental data resulted from analysis 
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of the HDL lipoproteins. While the data is diverse, several common 
features are shared by the different models proposed (251-253). The 
particle is micellar with the head groups of the phospholipids and 
the polar end of cholesterol oriented toward the surface. The apolar 
ends of these molecules are oriented toward the center with the 
cholesteryl esters sequestered on the inside of the particle. The 
major point of disagreement between suggested models is the relative 
location of the principal apoprotein components and how they interact 
with the phospholipids. Studies by Shen et al. (254) using composi-
tional analysis have shown that a hydrophobic core of cholesterol ester 
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and triglyceride is surrounded by a 20A thick monolayer of cholesterol 
and phospholipid closely packed, on the surface of the core. The curva-
ture of the surface results in large gaps between the polar head groups 
of this monolayer. The unfolded protein fills these gaps and masks the 
polar head groups of free cholesterol. The essential features of this 
model are a sharply defined boundary between the hydrophobic core and 
the amphipathic layer surrounding it. This boundary is occupied ex-
clusively by phospholipids and cholesterol and their tight packing does 
not allow for the penetration of any other component. The apoprotein is 
located in the same surface layer as the phospholipid head groups with 
these two components competing for the same space. Therefore, Scanu has 
speculated that an identical structure for all lipoproteins could be 
assumed regardless of size. 
G. LIPOPROTEIN SYNTHESIS AND CATABOLISM 
The liver and intestine are the major sites of synthesis of the 
plasma lipoproteins. On a high fat diet, the bulk of triglyceride 
fatty acids are derived from chylomicrons synthesized in the inte~­
tine. Dietary carbohydrates may also be converted to fatty acids in 
both liver and adipose tissue. 
a. Chylomicron Synthesis 
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Absorption of dietary fat occurs mainly in the upper small in-
testine. Tytgat (255) found that the major site of chylomicron syn-
thesis in man is the jejunal mucosa. Electron micrographs indicate 
that the (SER) is the major cellular organelle involved in the trans-
port of newly synthesized triglyceride and suggest that chylomicron 
synthesis is completed there (2,56-257). Synthesis of chylomicron lipo-
proteins presumably occurs in the ribosomes of the RER (257). 
b. VLDL Synthesis 
Both the liver and intestine incorporate radioactive amino acids 
into the protein moieties of VLDL (258). But no radioactivity was in-
corporated into apo C proteins when intestinal perfusion systems using 
labeled amino acids were employed. This suggests that apo C proteins 
are synthesized in the liver and their occurrence in lymph is due to a 
transfer from lipoproteins of hepatic origin. Intestinal synthesis of 
apo B has been observed in rats fed a diet containing orotic acid (259). 
The mesenteric lymph of these rats has mean normal levels of apo B, 
whereas the plasma contains virtually no apo B. Orotic acid-fed indivi-
duals accumulate hepatic fat as a result of their inability to mobilize 
lipid from the liver (260). The liver and intestine share many common 
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features in the synthesis and excretion of these particles. Secretion 
is influenced by the availability of non-esterified fatty acids of 
either endogenous or exogenous origin. The lipid composition of the 
particles is influenced by several factors. Heimburg and Wilcox (261) 
have shown that approximately 50 percent more VLDL triglyceride is 
secreted when isolated rat liver is perfused with oleic acid than with 
palmitic acid. VLDL secreted during palmitate infusion are more dense, 
contain a higher proportion of cholesterol to phospholipid and have a 
lower proportion of triglyceride as compared to rats fed oleic acid. 
During the early stages of VLDL synthesis, the Golgi apparatus of 
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hepatocytes contain fat particles of 300-lOOOA in diameter, which have 
physical and chemical propertie.s similar to VLDL (262). 
Other types of dietary manipulations can also effect the secre-
tion of VLDL. Dolphian et al. (263) demonstrated that normal hepatic 
Golgi and secretory vesicles contain triglyceride-rich lipoproteins 
which have none or minimal amounts of apo CII and are deficient in apo 
E relative to serum VLDL. Hepatic fractions from hypercholesterolemic 
rats contained cholesteryl ester and apo E-rich triglyceride-depleted 
VLDL with size, immunodiffusion characteristics, and apo B to apo E 
ratios similar to hypercholesterolemic serum VLDL {263). He deduced 
that diet induced hypercholesterolemia resulted in lipoprotein secre-
tory products which contribute to the plasma pool of abnormal choles-
teryl ester and apo E-enriched lipoproteins. Witzum (66) observed that 
liver perfusion of rats on high carbohydrate diets resulted in increas-
ed triglyceride secretion. The VLDL isolated were larger, triglyceride-
enriched, less dense than normal. Although total VLDL protein rose, the 
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amount of VLDL apo B decreased. Both apo C and apo E levels rose 
while apo CIII subfraction levels were altered. Apo CIII1 increa~ed, 
while apo CIII 2 decreased. This suggests the amount of time spent in 
the Golgi was decreased because of the small amount of protein siali-
zation (reflected in decreased apo CIII2 levels). 
Finally, Zannis and Breslow (264) demonstrated that patients 
with Type III hyperlipidemia (Broad Beta Disease) had non-character-
istic apo E isoprotein patterns. They demonstrated a post-transla-
tional modification of apo E by showing that treatment of VLDL with 
neuraminidase prior to electrophoresis resulted in a disappearance of 
the non-characteristic band. This indicated that the group of faulty 
proteins occurred by sialation pf apo E. 
c. Chylomicron Catabolism 
Chylomicron catabolism has been found to occur rapidly with a 
half life of less than one hour. Initially, this catabolism involves 
triglyceride hydrolysis catalyzed by lipoprotein lipase followed by the 
removal of a triglyceride poor remnant by the liver. Phospholipids are 
hydrolyzed by both lipoprotein lipase and lecithin cholesteryl acyl 
transferase. The role of the apoprotein components in chylomicron meta-
bolism has been reported by Havel (271) to consist of net transfer of 
apo CII proteins from HDL to chylomicrons and back to HDL. Other apo C 
proteins are transferred at the same time. The presence of apo err on 
the surface of the chylomicron could promote hydrolysis by stabilizing 
triglyceride emulsions. The apo C proteins very likely modulate the 
catabolism of triglyceride-rich chylomicrons through this cycling 
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mechanism involving HDL. The chylomicron particle that remains after 
hydrolysis forms the remnant particle which is removed by the liv~r 
(272). This observation is based on studies of the catabolism of 
lipoproteins from hepatectomized rats. Radiolabeled chylomicrons were 
injected into these animals and remnant particles enriched with phos-
pholipids and cholesteryl esters were isolated from plasma (273). 
Cholesterol taken up by the liver is converted to bile and released 
from the liver. 
d. VLDL Catabolism 
The degradation pathway of VLDL is similar to that of the chylo-
microns. It is believed that c~ylomicrons and VLDL share a common 
catabolic pathway and their triglycerides are hydrolyzed at extra-
hepatic tissues by the same lipoprotein lipase system (267). Labeling 
studies with the apo C component of VLDL have shown that these apopro-
teins rapidly appear in HDL fractions after the addition of LPL (274). 
In addition to the radioactivity found in the HDL fraction, transfer of 
radioactively labeled proteins was observed in the 1.006-1.019 density 
range and then in the low density lipoprotein range. This would indi-
cate a precursor-product relationship between VLDL and LDL. Eisenberg 
et al. (275) demonstrated that lipolysis induces transfers of apo CII 
and apo CIII from VLDL to HDL. This transfer was proportional to the 
extent of triglyceride hydrolysis and similar for the two apoproteins. 
Their results suggested that there is no preferential removal of CII or 
CIII from VLDL particles. The redistribution of apo C between VLDL and 
HDL during lipolysis may be caused by deletion of core VLDL consti-
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tuents, surface VLDL constituents and changes in mass ratios between 
the two lipoprotein classes. Glangeaud et al. (276} demonstrated that 
the presence of HDL is not always an obligatory requirement for the 
lipolysis of VLDL to occur. Their observations showed that in the ab-
sence of albumin or serum, extremely minimal lipolysis occurred and apo 
c was not released. However, with albumin present, lipolysis occurred 
with release of apo C protein. HDL, though it acted as a pool for apo 
c, was not necessary for lipolysis, and in the absence of HDL the apo C 
proteins were isolated in several density regions with different lipid 
composition. Eisenberg (277) had demonstrated this same phenomenon 
when he found that surplus surface constituents, phospholipids, apo C, 
and cholesterol were freed from the VLDL to form a surface fragment 
particle. In a system devoid of plasma or lipoprotein, he observed a 
decrease in the VLDL surface area that was independent of any acceptor 
protein. The remaining VLDL remnants had the same chemical and physical 
properties as those which underwent lipolysis. 
During the catabolism of VLDL, the loss of surface components con-
verts the lipoprotein into a progressively smaller particle designated 
as the intermediate density lipoprotein. VLDL remnants are taken up 
more rapidly than larger VLDL particles by cells in culture (278). This 
partial hydrolysis of the triglyceride-rich lipoprotein appears to be 
necessary for efficient cellular uptake. The LDL receptor recognizes 
two apoproteins, apo B and apo E, both of which are contained in the 
VLDL remnant (279). The enhanced reactivity of remnants with cells may 
be due to several factors: 1) As larger lipoproteins are converted to 
smaller remnants, steric hindrance to their interaction with receptors 
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is reduced. 2) The selective retention of apo B and apo E could con-
centrate apo B and E over lipoprotein surfaces. 3) The conformations 
of the binding sites of apoproteins could be altered as the surface 
area of the lipoprotein is reduced. Binding sites could also be un-
masked as a consequence of lipid and protein removal (280), a possi-
bility recently investigated by Shelburne and Windler (281-282). They 
studied the effect of different apo C proteins on liver removal of tri-
glyceride emulsions incubated with apo E and found that emulsions con-
taining both CI and CII proteins did not effect the increased hepatic 
uptake of either the synthetic emulsion or chylomicron produced apo E 
remnants. However, the CIII protein had a pronounced inhibitory effect 
on hepatic uptake which could b~ influenced by the state of apoprotein 
sialation. It is possible that this glycoprotein is similar to other 
sialated glycoproteins that demonstrate a negative correlation between 
neuramminic acid content and hepatic receptor affinity (283). The ob-
servation that at least two apoproteins control hepatic uptake provides 
a mechanism for denying the lipoproteins hepatic access until the appro-
priate peripheral metabolism has occurred. If CIII were not present, 
an ineffectual recycling to the liver might result. 
The second step in VLDL metabolism is remnant or intermediate up-
take by the parenchymal liver cells (284). Formation of low density 
lipoproteins has been postulated to follow the uptake of IDL by the 
liver with a subsequent release of apo B-cholesterol ester-rich 
particles. Man, who has the highest LDL concentration, is the only 
species in which almost all VLDL apo B is recovered in LDL (285). 
Deckelbaum et al. 286) have shown that in humans, a direct conversion 
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of VLDL to LDL can occur solely by the action of extrahepatic lipase. 
These particles have many features in common, but are not identical to 
normally formed plasma LDL. This pathway could function as a major 
non-hepatic VLDL catabolic route. Recently, data from the labs of 
Janus and Nicoll (287) have demonstrated that in some patients, not all 
VLDL is converted to LDL, but that some lipoprotein is degraded direct-
ly. In normal controls, VLDL-B derived LDL-B production was found to 
be virtually identical, suggesting that all LDL-B is produced from VLDL. 
However, in hyperlipemic individuals, the mean conversion of VLDL to 
LDL was only 45 percent, suggesting a direct catabolism of VLDL not 
previously observed (287). Since IDL has been shown to be as potent as 
LDL in suppressing receptor mediated HMG CoA, it is not unreasonable to 
assume that binding and degradation of IDL to cells might form an inte-
gral part of this observed effect (288) (Figure 1). 
e. Lipoprotein Lipase 
A description of the catabolic events that occur when chylomicrons 
or VLDL are broken down would be incomplete without and understanding of 
the lipoprotein lipase (LPL) enzyme system. Recent studies have shown 
that the lipase activity released by heparin is actually a combination 
of lipoprotein lipase, extra-hepatic triglyceride lipase, hepatic tri-
glyceride lipase, monoglyceride hydrolases, and phospholipases (265). 
There are at least two triglyceride lipases related to post-heparin 
lipolytic activity which differ in substrate specificity and other 
physiochemical properties (265). Lipoprotein lipase (LPL) has a pH 
optimum of 8.0, requires a serum cofactor, and is inhibited by prota-
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mine sulfate. The lipoprotein lipase component of post heparin lipase 
activity (PHLA) is a composite of enzymes from adipose tissue, skeletal 
muscle, heart, mammary gland, lungs, and aorta (266). These enzymes 
are assumed to be on the capillary surface since their release occurs 
almost immediately following heparin infusion. 
In 1955, Korn and Quigley (267) described a serum factor which 
activated lipoprotein lipase. This protein activator, found in VLDL 
and chylomicrons is CII (212-218). Recent studies have shown that apo 
CII is the major cofactor in human serum for adipose tissue, skeletal 
muscle, and purified plasma LPL. Apo CII stimulates product formation 
and has been found to increase the catalytic rate of LPL. Jackson and 
Matsuoka (268) have found that ~here is a direct relationship between 
the amount of lipoprotein lipase bound to VLDL or chylomicrons, and the 
amount of apo CII present. By adding I125 lipoprotein lipase and HDL 
to VLDL they were able to show that as apo CII was transferred to HDL 
the amount of lipase bound to VLDL diminished proportionately. Other 
apoproteins activate lipoprotein lipase. Ekman and Krauss (269-270) 
demonstrated that apo AII activated LPL but apo E, apo CI, apo AI, and 
apo CIII inhibited LPL. These investigators hypothesized that inhibi-
tion of the lipolytic processes by high concentrations of these ape-
proteins in certain disease states may be a contributory factor in the 
development of hypertriglyceridemia since the proteins decrease sub-
strate availability to the enzyme active site. 
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VLOL-LOL ~THWAYS 
Figure 1: Schematic ~epresentation of VLDL-LDL catabolic pathways. The 
VLDL produced in the liver is partially catabolized in the 
periphery at the lipoprotein lipase site releasing trigly-
ceride and FFA into the blood and adipocytes. Apo C protein 
is also lost from the VLDL and is scavenged in the plasma by 
circulating HDL which acts as a pool for apo C. After loss 
of the apo C, partial surface destabilization of the VLDL, now 
called a remnant, occurs. These remnants are returned to the 
liver. Apoprotein E found on the surface of the remnant is a 
recognition marker for the liver cell receptor which binds the 
remnant and removes it from the circulation. The remaining 
triglyceride is released to the hepatocyte and a molecule rich 
in cholesterol and containing primarily apoprotein B is re-
leased into the plasma pool. 
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f. LDL-Synthesis and Catabolism 
Synthesis of LDL presumably occurs after hepatic lipolysis of 
remnant VLDL. Direct synthesis may also occur in the liver. As the 
size of the VLDL particle diminishes, it becomes an intermediate den-
sity lipoprotein. Excess surface material, mostly phospholipid and 
cholesterol, are transferred to HDL. HDL particles interact with LCAT, 
(lecithin cholesterol acyltransferase) which esterifies the excess 
cholesterol with fatty acids from the 2-position of lecithin. The 
synthesized cholesteryl ester is transferred back to IDL, apparently 
through apo D. The IDL is then absorbed in the liver sinusoids where 
most of the remaining triglyceride is lost and a pure LDL is released 
into the circulation. 
In humans, LDL is the principal lipoprotein carrier for choles-
terol. Approximately three-fourths of the cholesterol is esterified 
and half of the cholesterol esters contain oleic acid. Low density 
lipoprotein receptors were first discovered by Goldstein (289) using 
cultured human fibroblasts. The initial event in cellular LDL metabo-
lism involves the binding of LDL to this receptor. This binding ex-
hibits saturation kinetics, high affinity and specificity. In addition, 
the process is stimulated by the presence of calcium and severely in-
hibited by pronase. LDL binding involves ionic interaction between the 
protein component and the surface receptor which appears to be a glyco-
protein (290-291). In order to achieve the physiological effect, the 
LDL that is bound to the receptor enters the cells by endocytosis. A 
low affinity uptake can also occur and may represent a non-specific 
endocytosis since uptake is proportional to the lipoprotein concentra-
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tion in the system, is not affected by pronase, and shows no apparent 
saturation (291). The degradative process appears to be similar re-
gardless if the LDL is bound to a specific high affinity receptor or 
low affinity receptor (291). Goldstein (289} hypothesized that LDL is 
catabolized through the formation of endocytic vesicles called endo-
somes, which fuse intracellularly with lysosomes. The protein compo-
nent of LDL is then catabolized to amino acids and the cholesteryl 
ester component of LDL is hydrolyzed by a lysosomal acid lipase. Intra-
cellular accumulation of unesterified cholesterol regulates the activi-
ties of two microsomal enzymes. A reduction in cholesterol synthesis 
results from modulation of HMG CoA reductase (3-hydroxy-e-methylglutaryl 
coenzyme A reductase) and an increase in cholesterol esterification re-
sults from activation of acyl CoA: cholesteryl acyltransferase (292). 
The net effect of the LDL receptor-mediated process is to transfer free 
and esterified cholesterol from LDL to the cell altering the fatty acid 
composition of cholesteryl esters from polyunsaturated to a more satur-
a ted form (293). 
The activity of the LDL receptor is regulated by a feedback mech-
anism. Brown et al. (290) observed that incubation of fibroblast mono-
layers with LDL progressively reduces the ability of the cells to bind 
1125 labeled LDL due to a reduction in the number of receptors synthe-
sized (290). More than 90 percent of the cholesterol produced in the 
body comes from the liver or the intestine, even though all non-hepatic 
tissues need cholesterol and possess the enzymatic capacity to synthe-
size it (294}. Brown (295) proposed that cholesterol synthesis is 
suppressed, in vivo, in non-hepatic tissues because these tissues pre-
ferentially take up and utilize LDL cholesterol through the LDL high 
affinity receptor. 
Human fibroblasts produce a maximum of 20,000-50,000 receptors 
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per cell. Brown (296) characterized the receptor which requires a 
divalent cation (either calcium or manganese), is sensitive to differ-
ent proteases, but resistant to glycosidases. The receptor recognizes 
both apo B and apo E, but not AI or Ali apoproteins. The receptor is 
extremely efficient with high amounts of LDL internalization occurr-
ing within 15 minutes due to receptors located in coated pits (297}. 
These represent specialized regions of the cell surface that are in-
dented and coated on the cytoplasmic surface with a fuzzy surface 
material. The coated pits take; up only two percent of the cells sur-
face but contain 50 to 80 percent of the receptors. Pearse (298) ob-
served that the fuzzy coat is composed of a protein of 180,000 MW call-
ed clathrin. The LDL receptor is synthesized in membrane bound poly-
ribosomes, glycosylated in the Golgi apparatus and inserted into the 
plasma membrane at random sites (296}. The genetic data suggests that 
the receptor has two active sites (296). One, the binding site for LDL, 
must be on the external membrane surface, and the second, the inter-
nalization site, allows the receptor to be recognized as a component of 
the coated pits. Receptors that contain a functional internalization 
site migrate laterally and cluster in the coated pits. Brown (296) 
postulated that this clustering occurs as a result of the specific 
interaction of the internalization site of the receptor with the coat 
protein clathrin. The receptors escape destruction as LDL endosomes 
attach to the liposomes and are likely recycled to the cell surface 
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where they again cluster in the coated pit regions (299). 
several lines of evidence indicate that the hepatic uptake of 
chylomicron and VLDL remnants is mediated by a receptor that resembles 
the extrahepatic LDL receptor and recognizes apo E (300). Both re-
ceptors promote the uptake of lipoproteins by endocytosis, are sub-
ject to metabolic regulation and bind apo E-containing lipoproteins 
with higher affinity than LDL (300). But extrahepatic receptors take 
up LDL, in vivo, whereas hepatic receptors take up chylomicron rem-
nants. This may stem from the large size of the remnant particles as 
compared to LDL. Remnants can cross the endothelium of extrahepatic 
tissues slowly, if at all. The rapid hepatic uptake of remnants im-
plies that these particles eros? the endothelium that lines the hepatic 
sinusoids either by bulk flow through the fenestrated sinusoidal epi-
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thelium, which permits passage of particles up to lOOOA in diameter or 
by a specific transendothelial transport (301). 
Kovanen and Bilheimer (302) have recently discovered that the 
liver can also manufacture LDL receptors in response to pharmacological 
interventions with colestipol (a bile acid sequestrant) and mevinolin 
(a cholesterol synthesis inhibitor). Colestipol is a bile acid-binding 
resin that produces an increased requirement for cholesterol for con-
version to bile salts. Mevinolin is a specific inhibitor of 3 HMG CoA 
reductase, the rate limiting enzyme in cholesterol synthesis. These 
two drugs can act synergistically raising the hepatic demand for 
cholesterol. These investigators observed that membranes prepared from 
livers of normal animals treated with this drug combination showed an 
increase in the number of lipoprotein binding sites. The resulting 
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combination of decreased cholesterol synthesis and increased choles-
terol removal led to a 70 percent drop in plasma LDL levels. This 
study raises the possibility that mevinolin and colestipol may have a 
useful effect in lowering human plasma LDL-cholesterol levels thera-
peutically {303). 
Chait and Bierman (304) have also discovered that insulin, which 
stimulates cholesterol synthesis by enhancing HMG CoA reductase acti-
vity, also enhances the degradation of LDL by increasing LDL receptors. 
This could have the effect of depositing cholesterol in cells that are 
actively synthesizing this compound causing an overabundance and accumu-
lation of cholesterol in these cells. 
Another route of removal of LDL from the plasma is by the action 
of macrophages and other scavenger cells (305-306). These cells become 
so swollen with cholesterol droplets that they are called foam cells. 
The mechanism by which the macrophages take up LDL differs in three im-
portant respects from the high affinity receptor system (86). These are 
1) the cellular antigens that activate each pathway; 2) the specificity 
of the surface binding sites; and 3) the fate of cholesterol liberated 
from the degradated lipoprotein. The macrophages internalize only 
modified lipoproteins and possess at least 3 binding sites for these 
proteins. The first is an acetyl LDL binding site which recognizes an 
epsilon amino group of lysine that is acetylated on the surface of the 
LDL. Other receptors recognize and incorporate maleylated LDL and 
malondialdehyde LDL into the macrophage (86). 
The cholesterol liberated from cellular receptor-mediated uptake 
of LDL regulates receptor concentration and de novo cellular synthesis 
of cholesterol so that overaccumulation will not occur. The macro-
phage scavenger pathway shows no such regulation. About half the 
cholesterol that enters the macrophage through this pathway is ex-
creted in the presence of a substance capable of binding the choles-
terol. Red blood cells, albumin, and in particular, HDL are effec-
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. tive in this process. The other half is re-esterified and stored as 
cholesteryl ester droplets which can result in excessive accumulation. 
g. HDL Synthesis and Catabolism 
HDL precursors appear to originate from two sources: direct 
secretion by the liver or intestine of discoidal HDL into plasma or 
lymph; and from the surface components of VLDL and chylomicrons. 
Studies in the rat have shown that discoidal HDL is produced in per-
fused rat liver and the small intestine (307-308). 
During the transformation of chylomicrons and VLDL to their rem-
nant form, triglyceride, soluble apoproteins (A and C), and phospho-
lipids are rapidly transferred to the HDL fractions. In man, 90 per-
cent of labeled apo A peptides from chylomicrons and VLDL are found 
localized in HDL one hour after intravenous injection (309). The action 
of lipoprotein lipase on VLDL and chylomicrons has been documented. 
The shrinkage of the lipid core probably causes a redundance of the 
polar surface constituents. The increase in lateral pressure on the 
surface causes the monolayer to fold into bilayers that protrude from 
the cell surface. Some of the bilayers may be dissolved as discoidal 
micelles in association with the detergent A or C apoproteins present 
on the VLDL surface. Since there are not enough A or C apoproteins to 
convert all the bilayers to discs, most of the fragments probably 
leave the surface as larger sheets that can seal into phospholipid 
vesicles (310). Subsequently, these vesicles are converted into 
spherical HDL by their interaction with circulating HDL and LCAT. 
Apo AI, released from the HDL pool, leads to the formation of sol-
uble phospholipid apoprotein complexes (311). During the trans-
formation of precursor particles into HDL, a large influx of choles-
terol occurs. The driving force for this influx is the relative de-
ficiency of cholesterol in the VLDL derived precursor of HDL which 
results in a concentration gradient for the movement of cholesterol 
into HDL. 
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Plasma HDL half-life valu~s are reported to range from 3.3 to 
5.8 days (312-313). HDL catabolism is enhanced in nephrotic patients 
and in hypertriglyceridemic subjects, especially on high carbohydrate 
diets (312-314). Studies in animals indicate that the liver and 
kidney lysosomes play an important role in HDL catabolism (315-316). 
More recent research is consistent with the concept that extrahepatic 
tissues may play a predominant role in HDL catabolism. Normal human 
fibroblasts have been shown to take up, internalize, and degrade HDL 
in vitro (317). Another possible mechanism for HDL catabolism was sug-
gested by Tall and Small (310). Since apo AI is loosely integrated 
into the HDL molecule, plasma HDL acts as a pool of AI for VLDL and 
chylomicron formation. As a consequence of HDL losing some of this apo 
AI emulsifier, the spherical HDL particle becomes thermodynamically un-
stable and can fuse with another lipoprotein. Since remnants are avidly 
taken up by the liver, their fusion with unstable HDL could provide 
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another route for HDL catabolism to the liver. 
H. Role in Clinical Disorders 
Increased plasma lipoprotein concentrations may be seen as either 
a primary manifestation associated with a genetic defect or a secondary 
hyperlipoproteinemia due to a primary disease state. 
The classification of the hyperlipoproteinemias proposed by 
Fredrickson and Lees (318) in 1964 is based on plasma concentrations 
of the various lipoprotein types (Table 2). In patients suspected of 
having hyperlipoproteinemia, analysis of fasting triglycerides or 
cholesterol usually gives a reasonable estimate of their lipoprotein 
phenotype. Type I is a primar~ hyperchylomicronemia; this is followed 
by Type V, which is mixed familial lipoproteinemia with elevated VLDL 
and chylomicrons. Types IIA and IIB usually show a predominant eleva-
tion in LDL with Type IIB indicating an increase in VLDL as well. Type 
III or broad beta disease dysbetalipoproteinemia is characterized by 
VLDL and LDL lipoproteins which electrophoretically comigrate. Finally, 
Type IV hyperprebetalipoproteinemia is characterized by an elevation of 
the VLDL lipoprotein. 
Abetalipoproteinemia is an uncommon disease in which levels of apo 
Bare either reduced or non-existent (319-320). The patients appear 
normal at birth, but at some time in infancy develop foul-smelling 
diarrhea due to malabsorption of fat. The defect involves a critical 
factor in the synthesis or secretion of the lipoproteins that contain 
apo B. Thus, undetectable levels of chylomicrons, LDL, and VLDL are 
usually observed in this disease. 
Table, S, Disorders of Lipoprotein tletabolism Characterized by Elevations in Lipoprotein Classes 
Chylomicron& 
Type I 
Chylomicron& + VLDL 
Type V 
Increased Levels 
Lipoprotein Faailial 
lipase hypertri-
deficiency glyceridemia 
(severe) 
ApoC-II 
deficiency 
Familial com-
bined hyper-
lipidemia 
ApoE4 variant 
combined ApoC-II 
and i.'ipoprotein 
Lipase Deficiency 
VLDL 
Type IV 
Familial 
hypertri-
glyceridemia 
Familial com-
bined hyper-
lipidemia ' 
VLDL 
Type Ill 
ApoE2 homo-
zygosity 
ApoE de-
ficiency,. 
ApoE1 
phenotype 
VLDL + LDL 
Type lib 
Familial hyper-
cholesterolemia 
( LDL receptor 
abnormalities) 
LCAT deficiency 
Familial com-
bined hyper-
lipi4emia 
I 
Hepatic lipase 
deficiency 
LDL 
Type IIa 
Familial hyper-
cholesterolemia 
(LDL receptor 
abnormalities) 
Betas ito-
aterolemia 
Familial com-
bined hyper-
lipidemia 
llypcrapobcta-
lipoproteinem ia 
IIDL 
llyperalpha-
1 ipoproteinem ia 
Table 2: Description of Fredrickson's Classifications of Hyperlipemia. The disease stages 
and primary cause of the elevat~d plasma lipid are represented. 
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Familial dysbetalipoproteinemia or broad beta disease is 
characterized by the accumulation, in the density range of VLDL and 
LDL, of an unusual class of lipoproteins with reduced electrophoretic 
mobility relative to normal lipoprotein groups. Chemical studies show 
that this B-VLDL differs from normal VLDL in having more cholesterol 
esters and fewer triglycerides in their core (219-223}. Studies have 
shown that the particles have a disproportionate amount of apo E with a 
missing or altered apo EIII (223, 227-228}. Schneider et al. {321} 
demonstrated that apo E isolated from the plasma of these patients is 
markedly defective in binding to LDL receptors. 
It is believed the VLDL from dysbetalipoproteinemic individuals 
is normally metabolized in the ;periphery by extrahepatic lipoprotein 
lipase. The lipoproteins lose triglyceride and apo C with remnant-like 
particles remaining, containing more apo E and apo B, that are not 
cleared by the liver because of the mutant apo EIII. Thus an elevated 
concentration of VLDL is present in the plasma pool of these patients. 
Familial hypercholesterolemia is one of the best defined clinical 
disorders of lipoprotein metabolism. The disorder is characterized by 
elevated concentrations of LDL-cholesterol and deposition of cholesterol 
in specific sites to form subcutaneous lipid deposits called xanthomas 
(322}. The disease is inherited as an autosomal dominant and is ex-
pressed phenotypically as a deficiency in the LDL receptor that regu-
lates the uptake and degradation of LDL (323). The mean total choles-
terol in these affected individuals is twice normal. Although the con-
centration of LDL is increased in the plasma of patients with familial 
hypercholesterolemia, the lipoprotein is of essentially normal campo-
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sition and structure (324). 
The primary hypertriglyceridemias are manifested in two forms, 
familial endogenous hypertriglyceridemia and familial multiple lipo-
protein-type hyperlipidemia. Familial endogenous hypertriglyceridemia 
is a disorder inherited as an autosomal dominant in which heterzygotes 
manifest an isolated elevation in plasma VLDL (325-326). In addition 
to hypertriglyceridemia, the affected individuals have one or more of 
the following metabolic disturbances: adult obesity, insulin resis-
tance coupled with fasting hyperinsulinemia, glucose intolerance and 
hypertension (326). Most patients demonstrate an elevated VLDL con-
centration in excess of 1000 mg/dl with larger particles of chylo-
micron-like characteristics obs~rved. These patients are carbohydrate 
sensitive and will develop fasting chylomicronemia by increasing carbo-
hydrate intake (327). 
Familial multiple lipoprotein-type hyperlipidemia (familial com-
bined hyperlipidemia) has been recently studied. In affected indivi-
duals, elevations in VLDL, LDL or both, could occur, making diagnosis 
of the disease difficult. Patients with familial multiple lipoprotein-
type hyperlipemia exhibit elevated LDL, but this disorder is genetically 
distinct from endogenous familial hypercholesterolemia and hypertrigly-
ceridemia. First, the plasma lipid level, while significantly in-
creased, tends to be lower than in other disorders (326, 328). Second, 
the pattern of lipid abnormalities is unique. About one-third of the 
affected relatives have isolated hypercholesterolemia, about one-third 
have hypertriglyceridemia and one-third have both. Third, in contrast 
to the findings of familial hypercholesterolemia, plasma cholesterol 
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concentrations in children with the combined disease are normal (326). 
In patients with primary endogenous hypertriglyceridemia, VLDL are 
larger, contain more core triglycerides and cholesteryl esters and 
fewer surface components. Particles of comparable size from multiple 
lipoprotein type hypertriglyceridemic individuals usually contain 
more cholesterol esters and fewer triglycerides in the lipoprotein 
core (331). VLDL size is a combined function of synthetic, secretory 
and catabolic rates (330). The differences in VLDL between the two 
groups may reflect a longer plasma half-life of these lipoproteins 
and a greater transfer of cholesteryl ester to VLDL from HDL in the 
patients with mixed hyperlipoproteinemia. VLDL from these patients 
also tend to have more apo CI t~an apo CII protein (155). 
There are numerous secondary disorders of lipid transport, but 
the major category in which some of the selected patients for this 
dissertation study can be grouped, is diabetic hyperlipemia associated 
with insulin resistance. As the key anabolic hormone, insulin has a 
major role in the transport and utilization of fatty acids and glucose. 
All states of insulin deficiency and/or resistance are accompanied by 
hyperlipemia, mainly involving triglyceride-rich lipoproteins. Insulin 
deficiency is commonly seen in type I (insulin dependent) diabetes, 
whereas insulin resistance is normally found in type II (non-insulin 
dependent) diabetes. The pathogenesis of these forms of diabetes are 
characterized by a deficiency in the action of insulin in peripheral 
tissues causing a mobilization of fat from adipose tissue. Although 
much of the fat is utilized by the liver for energy, an appreciable 
fraction is esterified to form triglycerides (332). Initially, the 
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increased production of triglyceride is accompanied by augmented VLDL 
excretion. After a few days however, a reduction of hepatic VLDL 
secretion is observed along with a reduction in lipoprotein lipase 
activity (333-334). Fatty acids not taken up in the periphery are re-
cycled back to the liver, leading to a futile cycle in which the liver 
eventually becomes engorged with fat. Reports on VLDL transport in 
poorly controlled diabetics suggest that FFA and VLDL secretions are 
often increased along with ineffective VLDL catabolic mechanisms (335). 
The abnormalities of lipid transport in obesity and diabetes may combine 
to increase hepatic secretions of VLDL, reduce removal, or both. Many 
questions still remain unanswered regarding the effect of diet and car-
bohydrate intake on triglycerid~ concentrations. Low fat diets, which 
are inherently high in carbohydrate, have been used effectively in the 
management of diabetes. However, these diets still remain to be evalu-
ated for their effects on diabetic hypertriglyceridemia. 
I. INSULIN & GLUCAGON: ROLE IN HYPERTRIGLYCERIDEMIA 
a. Introduction 
Mammals have developed elaborate homeostatic requisites in the 
regulation of energy supply and consumption. They must maintain blood 
glucose levels within a very narrow range and have an optimal storage 
level of glycogen for emergency fuel needs with the capability to con-
vert any excess carbohydrate calories into fat. Mammals also must main-
tain an optimal supply of protein for both enzyme production and struc-
tural development. They must also have the ability to preferentially 
use fat for energy during times of caloric need. All of these meta-
bolic guidelines are accomplished by the dynamic equilibrium of two 
well-studied hormones, insulin and glucagon. 
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Insulin, with a molecular weight of 5734 daltons is manufactured 
in the cells of the islets of Langerhans in the pancreas. Circulat-
ing insulin serves to coordinate fuel storage and fuel mobilization 
· into and out of various depots according to the needs of the organism. 
High insulin levels reflect a non-fasting state. Insulin's main effects 
occur in peripheral tissue where it exerts many metabolic effects on re-
sponsive cells, altering membrane characteristics such as glucose per-
meability, amino acid transport and potassium flux. Insulin modulates 
RNA, protein, and fat synthesis intracellularly and lowers cyclic AMP 
levels in target tissues. Insulin also inhibits lipolysis in adipose 
tissue and probably proteolysis in muscle. Its versatility is undoubt-
edly due to the initiation of second messengers, which in turn alter 
enzymes involved in the aforementioned mechanisms. 
Glucagon is an antagonist to insulin. It is synthesized in the 
alpha cells in the islets of the Langerhans of the pancreas and has a 
molecular weight of 3485 daltons. Constant availability of glucose for 
the brain and other organs depends on glucagon mediated maintenance of 
hepatic production of glucose at whatever rate is required to prevent 
hypoglycemia. In periods of starvation, glucagon stimulates the pro-
duction of ketones which substitute for glucose as cerebral fuel. 
Such glucagon mediated catabolism (the production of fuels from the 
macromolecules, glycogen, protein and fat) is modulated by the anti-
catabolic effect of insulin. Both the rate and direction (anabolic vs. 
catabolic) of fuel fluxes are therefore governed by the relative con-
centrations of these two antagonistic hormones. 
b. Role in Diabetic Hypertriglyceridemia 
Since insulin plays a critical role in both the production of 
triglyceride rich lipoproteins and their removal from plasma, it is 
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not surprising that alterations in insulin secretion can lead to hyper-
triglyceridemia. At one extreme, severe insulin deficiency associated 
with untreated symptomatic Type I insulin dependent diabetes mellitus, 
leads to impairment of tissue lipoprotein lipase (LPL) activity and 
consequently impaired clearing of circulating triglycerides (443). The 
insulin deficient state is also associated with accelerated mobiliza-
tion of free fatty acids (FFA) from adipose tissue which adds to the 
hyperlipemic condition (444}. 
Endogenous hypertriglyceridemia can also occur when Type II non-
insulin dependent diabetic patients ingest high carbohydrate diets. 
This hypertriglyceridemia is proportional to the postprandial hyper-
insulinemia produced by the diet {445}. The underlying abnormality in 
most Type II diabetic patients with endogenous hypertriglyceridemia is 
resistance to insulin mediated glucose uptake {446). In an effort to 
maintain glucose homeostasis these insulin resistant patients secrete 
increased amounts of insulin. The compensatory hyperinsulinemia in 
turn acts upon the liver to accelerate hepatic triglyceride synthesis 
and secretion resulting in elevated plasma triglyceride levels. Thus, 
the central role in the control of triglyceride metabolism may be in-
sulin concentration. Evidence that insulin can directly promote 
hepatic VLDL-TG production was observed by Salans et al. {447) who 
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demonstrated in liver slices that insulin increases incorporation of 
carbon atoms from 14C-glucose into hepatic total lipid and trigly~ 
ceride. Using perfused liver slices, Letarte and Fraser (448) showed 
insulin promotes the incorporation of 14C-glucose into fatty acid 
moieties of hepatic lipid and increases their subsequent release into 
the media. Other in vitro studies show considerable evidence that 
hyperinsulinemia in the diabetic could influence VLDL-TG levels by 
promoting hepatic TG synthesis and secretion (449-450). 
Glucagon is closely linked with insulin secretion, not only be-
cause of its antagonistic properties, but because the alpha cell 
belongs to a family of sensitive cells in which insulin is necessary for 
permitting glucose entry into t~e cell resulting in inhibition of 
glucagon release. The hypersuppressibility of plasma glucagon after 
oral glucose, reported by Hatfield (451) in hyperinsulinemic patients, 
contrasted against the lack of suppressibility of the lean insulin de-
ficient diabetic subject supports the concept that insulin, when 
present, may permit glucose to inhibit glucagon secretion. In type II 
diabetics with hypertriglyceridemia, abnormalities in glucagon secre-
tion exist despite the persistence of insulin. In these patients, a 
hyper-response to arginine or protein infusion accompanied by de-
creased suppressibility by glucose are two of the major malfunctions 
(452). A possible reduction in the sensitivity of cells to insulin 
could be possible. Glucagon dysfunction is most probably linked ex-
clusively to the hyperinsulinemia caused by insulin resistance in 
these patients which seems to be the leading causative factors in 
hypertriglyceridemia. 
J. THE PLATELET 
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Platelets are approximately two ~m in diameter and normally 
number 200,000 to 400,000 per cubic millimeter of human blood. They 
are produced in the megakaryocytes of bone marrow by the coalescence 
of cytoplasmic membranes formed by invaginations of the megakaryo-
cyte surface (339). Under normal circumstances, platelets circulate 
in the blood for ten days as smooth, disc-shaped cells that are non-
adherent to each other and to vascular endothelium. When the endo-
thelium is ruptured, platelets can adhere to a variety of substances 
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such as collagen, basement membranes and microfibrils associated with 
elastin. Adhesion initiates a process during which substances found 
in platelet secretory granules such as adenosine diphosphate are ex-
truded (340-342). The term primary or first phase aggregation refers 
to the direct aggregation of platelets by exogenous ADP and other sub-
stances such as epinephrine, serotonin, thrombin and ristocetin. 
Aggregation mediated through the release of endogenous ADP from plate-
lets is sometimes referred to as second phase aggregation. 
b. Structural Properties 
The platelet is found to have a trilaminar plasma membrane 
similar to that of other cells covered with an amorphous coat 100-
o 
200A thick (339). Many of the plasma proteins that are absorbed to 
the platelet surface (for example, fibrinogen and IgM) are probably 
located within this amorphous coat. Platelet specific proteins appear 
to be arranged asymmetrically within the membrane with only a few of 
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the membrane glycoproteins exposed extracellularly (343). The plate-
let surface contains adenyl cyclase and various glycosyl transferases 
which may influence adhesion and aggregation (344,345). Another dis-
tinguishing feature of the platelet membrane is its invagination at 
many points to form a network of channels that burrow through the 
platelet cytoplasm. This system enlarges the surface area of the 
platelets, serves in the uptake of plasma-borne substances and allows 
for the extrusion of granule-bound secretory products during the re-
lease reaction. 
Two types of granules have been identified in platelets. The 
major form is the alpha granule which is of moderate electron density 
and contains enzymes such as aci9 hydrolases and cathepsins character-
istically associated with liposomes (346). The second type of granule 
is found to contain calcium, serotonin, ATP and ADP complexed in high 
molecular weight aggregates (347, 348). 
Platelets also contain a circumferential band of hollow, cylin-
drical structures similar in appearance to microtubules observed in 
many other cells (349). The walls of these microtubules contain proto-
o 
filaments approximately 35A in diameter and are composed of tubulin 
(350, 352). White (351) has suggested the theory that microtubules 
provide a cytoskeleton which orients contractile activity in the 
platelet. 
c. Role in Coagulation 
Platelets can adhere to a variety of substances present in the 
vessel wall and in the perivascular tissue (354). Injury to the endo-
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thelial cells causes the exposure of subendothelial tissues such as 
collagen and basement membrane to platelets. Platelets adhere to 
collagen, become degranulated, and recruit other platelets to form a 
superimposed platelet thrombus. Basement membrane and non-collagenous 
substances appear to be much less effective than collagen in inducing 
platelet release reactions or platelet aggregation (355). These obser-
vations suggest that collagen is the most platelet-reactive material 
present in the vessel wall and that the adhesion of platelets to 
collagen may be a critically important step to arrest bleeding (356). 
Once adhesion has occurred, release of ADP and thromboxane trig-
gers the formation of platelet aggregates. The release reaction is the 
secretory process whereby substances are packaged and extruded from the 
cell. Studies by Nachman and Ferris (360) suggest that ADP may bind a 
specific receptor on the platelet membrane. Present evidence suggests 
that the binding protein may be related to actomyosin and the surface 
actomyosin may mediate ADP-induced aggregation. In addition to ADP, 
substances released from platelets include serotonin, a product that can 
neutralize heparin, acid hydrolases, and other factors that modify vas-
cular permeability (349, 362). 
When platelets are stimulated by release inducers, arachidonic 
acid, probably made available by hydrolysis of membrane phospholipids, 
is converted by cycle-oxygenase to a labile cyclic endoperoxide that 
is a precursor of prostaglandin E2 and F2 a (364). The endoper-
oxide can directly induce the release reaction resulting in second 
Phase aggregation (365). 
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d. The Platelet and Diabetes 
Many reports have emphasized the abnormalities in platelet ad-
hesion and aggregation that occur in patients with diabetes mellitus 
(88-91, 374, 375, 380). An increased tendency for thrombosis and a 
higher incidence of occlusive vascular disease in patients with dia-
betes mellitus is generally recognized. Abnormal factors in diabetic 
plasma could alter the platelet response and cause hyperaggregation 
(Figure 2). Kwaan et al. (376) discovered that normal platelet-rich 
plasma, mixed with small amounts of diabetic platelet poor plasma, re-
sulted in normal platelets aggregating as if they were from diabetic 
subjects. Colwell (93) postulated that von Willebrand's factor may be 
the cause of the increased aggr~gation. He also found increased levels 
of cyclo-oxygenase which converts arachidonic acid to prostaglandin E2 
and suggested the increased activity of the enzyme plus excess arach-
idonic acid could cause platelet hypersensitivity. Halushka (374) found 
that prostaglandin endoperoxidases and one of their byproducts, throm-
boxane A2 could be responsible for initiating the platelet release re-
action as well as aggregation. He observed that platelets obtained 
from diabetic subjects synthesized much greater amounts of PGE-like 
material than those of control subjects when (luM) ADP was given ~ 
~· Increased PGE synthesis seen in diabetic platelet-rich plasma 
may reflect increased activity of the prostaglandin synthetase sys-
tem. 
It has been demonstrated that impaired glucose or insulin meta-
bolism could lead to an increased activity of the prostaglandin syn-
thetase system. Tannebaum (378) demonstrated that increased glucose 
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concentrations and blood osmolality can increase malondialdehyde for-
mation, a product related to the thromboxane pathway. Recently, 
Halushka (379) found that platelets from diabetic subjects synthesize 
much greater amounts of thromboxane A2 and that malondialdehyde was 
formed in equimolar quantities with thromboxane A2. He also found 
that hyperglycemia may be associated with enhanced platelet aggrega-
tion and thromboxane A2 synthesis. 
e. Hyperlipemia and the Platelet 
The effect of long chain saturated fatty acids on platelet aggre-
gation was studied by Haslam in 1964 (381). He found that palmitate, 
stearate, arachidate, beherate,. and ligrocerate at a concentration of 
0.1mM caused rapid platelet aggregation in the presence of 1.1mM calcium 
chloride. Haslam believed that fatty acids functioned by releasing ADP 
through direct damage to the plasma membrane or by activation of an ab-
sorbed protease (381). Previous investigations had shown that injec-
tion of unbound long chain fatty acids in dogs was followed by general-
ized thrombosis and death (382, 383). Since most fatty acids travel 
in the plasma either bound to lipoproteins or to albumins, Hack et al. 
(384) evaluated the effect of albumin-bound fatty acids on thrombus 
formation and found the platelet aggregation and thrombus was increased, 
but the hypercoagulability was not as great as with unbound fatty acid 
injection. In a later paper, the same group went one step further and 
stated that thrombus does not result from the effect of bound fatty 
acids until the concentration is such that the two tight binding sites 
on albumin are no longer available (385). If fatty acid levels climb 
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Figure 2: Graphical representation of platelet aggregation response to 
different aggregating agents. Both normal and diabetic 
patients are represented. These curves were generated from a 
chronolog platelet aggregometer, Model #330. Note the second 
phase response of the diabetic platelet is more exaggerated 
than the normal platelet response. 
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above a threshold value of 1150 to 1200 u Eq/liter, as can be found in 
certain disease states, than the unbound fatty acids could cause throm-
bogenic complications. Renaud et al. (386) studied the effects of 
different types of fat on platelet aggregation. Butter and stearic acid 
are highly thrombogenic, but corn oil and linoleic acid appear to in-
hibit the potentially thrombogenic effect of cholesterol and butter. 
Oleic acid, despite its effect on inducing hypercholesterolemia, did 
not induce hypercoaguability or increased susceptibility of platelets 
to aggregation. 
Dietary manipulations and their effects on platelet aggregation 
have been investigated {387). Thrombin-induced platelet aggregation 
was much greater in platelet-ri~h plasma (PRP) prepared from blood 
taken from rats fed stearic acid than the (PRP) from rats fed oleic 
acid. This study was the first to clearly demonstrate alterations in 
platelet function related to dietary fat. Evidence that dietary sat-
urated fat produces changes in platelet function suggests alterations 
of the fatty acids in platelet membranes may be involved. Similar 
studies were conducted in humans with comparable results indicating de-
creased aggregatability of platelets in subjects receiving diets low in 
saturated fat as compared to those who consumed diets high in such fat 
levels (94). 
Shattil and Cooper (388) studied platelet membrane microvis-
cosity with the fluorescent probe, 1, 6 diphenyl, 1, 3, 5-hexatriene 
(DPH) under conditions where the platelet membrane had larger amounts 
of cholesterol and fat (in patients with type IIB hyperlipidemia). 
Platelets with high membrane cholesterol showed increased microvis-
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cosity over platelets that had low membrane cholesterol. Cholesterol 
decreases molecular motion of the hydrocarbon chains within the hydro-
phobic core of the lipid bilayer and increases the degree of order in 
the platelet membranes leading to increased membrane viscosity. Thus, 
changes in membrane viscosity could be assumed to cause increased 
platelet aggregation. 
Since platelets acquire cholesterol by an exchange or fusion 
fashion, the lipoproteins that carry fat and cholesterol are thought 
to be important in membrane changes observed in the platelet. 
Farbiszewski et al. (389) investigated the effect of alpha, beta and 
chylomicron lipoproteins on platelet aggregation, finding that LDL had 
a distinct effect on platelet aphesiveness. Chylomicrons also affect 
platelet aggregation, but only at elevated levels. It seems the 
lipoprotein interacts with certain receptor sites on the platelet sur-
face. This was demonstrated in experiments in which lipoproteins 
altered platelet electrophoretic mobility (98). Platelets may incor-
porate total low density lipoproteins or components into their mem-
branes altering surface characteristics when they circulate for long 
periods of time in hypercholesterolemic plasma. Shattil (390) demon-
strated this exact phenomenon in platelets from type IIA individuals, 
in which he found an increase in the C/PL ratio caused by cholesterol 
enrichment of the membrane. A good correlation was found to exist 
between the magnitude of free cholesterol in the platelet membrane 
and the amount of LDL in the plasma. Receptors for LDL were isolated 
from platelets quite recently by Aviram (391). The LDL interaction 
with platelets is similar to the LDL interaction with fibroblasts. 
Using chemical modification, Aviram et al. (392) concluded that 
arginine and lysine, but not tyrosine and histidine, are importan~ 
amino acids for the binding of LDL to platelets. 
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An interesting observation on the effect of increased choles-
terol and lipid incorporation into the membrane of platelets was re-
ported by Sinha and Shattil (398). They investigated the membrane 
enzyme adenyl cyclase and the production of CAMP in normal platelets 
and those of hypercholesterolemic individuals. Since CAMP is a potent 
inhibitor of platelet aggregation, a decrease in CAMP concentration 
would cause increased platelet aggregation. These studies demonstrated 
that increased membrane cholesterol in platelets is associated with de-
creased stimulation of adenyl c,yclase and decreased amounts of CAMP. 
These investigators concluded that phospholipids were found to be in-
volved in adenyl cyclase activity and therefore cholesterol might in-
hibit the phospholipid-adenyl cyclase interaction by competing direct-
ly with the enzyme. Alternatively, cholesterol could restrict phospho-
lipid mobility and impair transmembrane events necessary for stimula-
tion of the enzyme (398). Finally, Zahavi et al. (99) demonstrated en-
hanced in vivo platelet release reactions and MDA formation in patients 
with hyperlipemia. The mechanism of the enhanced release reaction and 
MDA formation could be related to the elevated serum lipids observed. 
3. PROPOSED INVESTIGATION AND SPECIFIC OBJECTIVES 
The relevance of diet in the production of metabolic disease 
states such as hyperlipemia and atherosclerosis is of prime importance 
in the diabetic population. Knowledge of the specific effects of the 
disaccharide sucrose on lipid production is contradictory, if not absent 
in many respects. Therefore, investigations must be undertaken to 
determine the effects of sucrose on lipid production in diabetic 
patients prone to hypertriglyceridemia. Since many studies used normals 
or hyperlipemic individuals who were obese, the patient population must 
be well defined as diabetic with specific attention given to the 
metabolic state of the individual upon entry into the study. In 
addition, most reports dealing with the effects of sucrose on a given 
population used artificial diets, either composed of liquid nutrients 
or extremely high in carbohydrate proportion. In this study, the diets 
are composed of natural nutrients which more closely mimic the intake 
pattern observed in these diabetic individuals. 
The experimental work will involve the characterization of the 
specific effects of sucrose on blood lipid concentrations over an ex-
tended period of time. This will include individual measurements of 
these lipids, along with the hormones insulin and glucagon, which are 
important in lipid production and catabolism. Specific correlations 
will be made as to the concentrations of both hormone and lipid as they 
relate to each other during ingestion of the study diets. To ascertain 
the metabolic effect of high sucrose, high carbohydrate diets on dia-
betic homeostasis, blood glucose and urinary glucose output will also 
be monitored during the entire study. 
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In an effort to determine if dietary manipulation results in 
hyperlipemia, due to increased lipid synthesis, a part of the study 
will attempt to characterize the triglyceride production and removal 
rates of these individuals. The most commonly used technique, trigly-
ceride turnover, labels the endogenous pool of triglyceride with radio-
. active precursor (either labeled glycerol or free fatty acids). Assum-
ing that at equilibrium, synthesis equals removal, the rate of loss of 
the label from the pool is used to calculate the synthetic rate of tri-
glyceride. 
Another line of approach will involve the assumption that high 
sucrose, high carbohydrate diets could alter apoprotein composition of 
VLDL in sensitive individuals a~d thus affect the removal of the lipo-
protein from the plasma pool. Using SDS-polyacrylamide gel electro-
phoresis and isoelectric focusing, I hope to separate the different 
apoproteins that comprise the VLDL and determine if changes occur in 
these proteins when different diets are administered. Total lipo-
protein electrophoresis will also be done in an attempt to monitor all 
lipoprotein fractions and determine their changes in relation to VLDL. 
It appears likely that hyperlipemia could be caused by a combination 
of events in which increased synthesis could be coupled with decreased 
peripheral removal. The studies with apoproteins of VLDL will provide 
the opportunity to compare their concentrations in relation to trigly-
ceride levels over a long term ingestion of a study diet. It is hoped 
that some correlation will be found between individual apoproteins and 
triglyceride concentrations. 
In a parallel study, the relationship of sucrose ingestion to 
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hyperlipemia will involve study of the effects of this diet on plate-
let aggregation. Since sucrose may cause hyperlipemia, and consider-
ing it has been demonstrated that hyperlipemia causes increased plate-
let aggregation, a natural link is developed between sucrose consump-
tion and platelet aggregation. I hope to demonstrate changes in 
· platelet aggregation during sucrose ingestion by using sensitivity 
studies of platelets to different concentrations of aggregating agents. 
The turbidometric method of platelet aggregation will be used to 
measure platelet sensitivity. The percent of primary and secondary 
aggregation will be compared from control to study diets to determine 
the change in platelet response to different amounts of sucrose con-
sumption. 
Finally, since three dietary levels of sucrose will be given to 
the patients, I hope to ascertain the amount of dietary sucrose needed 
to elicit these metabolic changes. It could be possible that a critical 
level of sucrose may have to be reached in order to metabolically alter 
an individual's metabolism toward hyperlipemia. Perhaps, low levels of 
sucrose may be well tolerated by the patient population in question. 
From these different studies, it is hoped that the objectives of 
this work will gain some insight into the physiological complications 
involved in the hyperlipemic response when different levels of sucrose 
are ingested in these sensitive patients. 
4. MATERIALS AND METHODS 
A. Description of Patients Used in this Study 
Patients for this study were recruited from in-patient subacute 
and chronic care facilities, as well as outpatient clinics at Hines V.A. 
Hospital, Hines, Illinois. All observations and studies were done on 
hospitalized patients in the Special Diagnostic and Therapeutic Unit 
(SDTU) at Hines. Informed consent was obtained from these patients 
prior to their entry into the study. Participation was strictly volun-
tary and patients were informed that they could withdraw from the study 
at any time. Subjects for this study were overt adult onset male dia-
betics, 30 to 70 years old, who did not require insulin or oral hypo-
glycemic agents and had fasting; hypertriglyceridemia (exceeding 1.5 g/L 
or higher). Patients with type V hyperlipemia of the Fredrickson•s 
classification were excluded as well as those whose weight exceeded 20 
percent of ideal body weight. 
I. Patient Type 
a. Description of Procedure to Evaluate Patients 
Patients were incorporated into the study only if the previous 
criteria were satisfied. The patients were judged as diabetic by the 
NIH criteria for the classification of diabetes, frankly overt hyper-
glycemia (394). The patients selected for the study had to have per-
sistent fasting blood sugars of at least 140 mg/dl a minimum of 3 times 
prior to admission. These diabetics has to be insulin independent, not 
ill and non-ketotic (type II diabetics). The study patients had to be 
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within 20 percent of normal body weight as classified by the method 
developed by Abraira et al. (395). Ideal Body Weight (IBW) was deter-
mined by the following: height (without shoes) 5 ft. = 105 + 5 lbs. 
for each additional inch of height. All patients were weighed in 
issued hospital clothing. Patients with complicating diagnoses that 
could independently affect weight or diet (such as congestive heart 
failure, cirrhosis of the liver, or renal insufficiency) were not ad-
mitted into the study. Finally, patients who were receiving any drugs 
known to affect blood lipid levels (such as clofibrate, cholestyramine, 
nicotinic acid, or glucose sulfonylureas) were not allowed in the study. 
Before patients entered the study, blood samples were drawn for 
triglycerides, blood glucose, ~lectrolytes, BUN, creatinine, liver en-
zymes and total protein analysis. Any patient with triglyceride levels 
of less than 150 mg/dl at the initiation of the study was released. · 
Also, patients who had abnormal SMA-12 values, (excluding glucose) be-
fore the study began were dropped from the study if the values did not 
return to normal after hospitalization. 
Finally, a lipoprotein electrophoresis was done to determine the 
patient•s hyperlipemic classification. Fredrickson•s guidelines were 
used indicating all of the patients to be type IV hyperlipemic indivi-
duals. Type I and V individuals were dropped from the study because the 
interest in this study was limited to VLDL 1 s and endogenously derived 
tri glycerides. 
b. Informed Consent 
Written informed consent was obtained from patients prior to study 
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initiation. All procedures and protocols were explained to patients 
before admission and patient compliance was monitored by the SDTU 
technician and dietitian. The study was sanctioned by the Research 
committee at Hines V.A. Hospital. Human studies approval at Hines and 
IRB board approval at Foster G. McGaw Hospital have been obtained for 
the project (along with the written consent). The project has also 
received approval by the Department of Nuclear Medicine at Hines, with 
all Food and Drug Administration guidelines followed from the U.S. 
Department of Health, Education and Welfare's report on 11 Clinical Test-
ing for Safe and Effective Drugs 11 (296-297). Participation was on a 
voluntary basis with certain procedures exempted upon patients request. 
c. Care of Patients 
Subjects were followed under the usual inpatient clinical care 
scheme and seen by medical residents spending a 3 month rotation on the 
ward. Each patient was seen by a clinical dietitian twice weekly and 
instructed on compliance procedures for the study. The residents re-
ported directly to Dr. M. Emanuele who was one of the physicians re-
sponsible for and in charge of patient care. Any manipulations or drug 
therapy prescribed for the patients were first assessed to determine 
any potential effect on the planned experiments. When patients entered 
the study, all diabetic medication was halted. The only medications 
allowed were Tylenol or sleeping pills (Dalmane R.). Though ambulatory, 
the patients were restricted to the SDTU and only allowed occasional 
off-ward activities. Direct supervision of all patients and clinical 
responsibility was assumed by Dr. C. Abraira. Once patients were in-
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corporated into the study, they were hospitalized a minimum of six 
weeks to a maximum of eight weeks. During this time, they were UDder 
strict supervision by the SDTU technician and the author so that no 
breach in protocol occurred. Any meals which were not eaten or other 
changes in study protocol were noted and results from that day•s test-
ing were discarded for that patient. 
d. Dietary Description and Study Protocol 
One week prior to entry into the hospital all patients were given 
dietary instructions for an individual weight maintenance diet similar 
to the regular diet at Hines V.A. Hospital consisting of 50% carbohy-
drate, 35% fat and 15% protein.~ One hundred and fifty grams of carbo-
hydrate must be sucrose or other definable disaccharides. Once the 
patients enter the hospital, they are given a diet designated as the 
control diet (intermediate sucrose content) which is isocaloric with 
the outpatient diet except the sucrose intake is recalculated to be 120g 
per day. The 120g approximation is based on the average intake of suc-
rose in the American population (11). After two weeks consumption of 
the control diet, the patients are randomized to a high sucrose diet 
(HSD) approximately 225g or low sucrose diet (LSD), approximately 3g 
daily. All of the nutrients were composed of natural food stuffs and 
were made from normal trays given to the rest of the patient population 
to approximate a mixed American diet. Dietary intake was divided into 
three meals per day, with 20% of the calories consumed during breakfast, 
40% during lunch and 40% during dinner. No bedtime snack was given. 
Fiber was kept constant at 20g per day along with sodium at 150 mmol 
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(approximately 4g per day) (461). Each diet was individualized accord-
ing to the size and weight of the patient. There were approximate)y 30 
different nutrients which could be consumed, several of which were 
singled out to be kept as constant as possible (10% variation). 
Calories, protein, fat, carbohydrate, sodium, fiber and sucrose content 
remained constant in the individual diets. The dietary pattern from one 
diet to another remained the same, with each patient receiving veget-
ables, meat, potatoes, and salads for lunch and dinner, with eggs and 
high fiber cereals consumed at the breakfast meal. Sucrose content was 
altered by adding or subtracting sweet jellies, different juices and 
different types of sucrose containing soft drinks. Vitamins, though not 
specifically monitored, were as~umed to be constant because of the repe-
tition of the diet and substitution of similar foods with varying suc-
rose content during the study (137). Patients were ambulatory, but were 
confined to the metabolic unit during the six-week period. Study com-
pliance was excellent with the dietary trays prepared and checked in the 
metabolic kitchens of Dr. H. Spencer. Intake was monitored by the meta-
bolic dietitian who checked the trays to ensure complete nutrient con-
sumption. 
The study was six weeks in duration, the first two weeks compris-
ing the control period, with the subsequent four weeks comprising the 
study diet period. The study is novel, in that each patient acts as 
his own control, with most experimental results compared against those 
previously determined while the patient was consuming the control diet. 
Since we were interested in the mechanism by which sucrose induced 
hyperlipemia occurs, we wanted to study these patients before dietary 
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adaptation to sucrose content began. A four-week study period was 
chosen because the effect of sucrose had been observed to maximize and 
remain relatively constant after this time (453). A total of 30 pat-
ients were studied, 17 consuming the high sucrose diet with 13 consum-
ing diets low in sucrose. 
B. Description of Methodology for Basic Clinical Tests 
The different procedures used to ascertain the blood levels of 
glucose, triglyceride, cholesterol and HDL-cholesterol were basic 
techniques routinely used in hospitals. Routine quality control pro-
cedures were performed with these assays since some of the values were 
also used in patient monitoring~ during the study. Blood and urine 
glucose values were measured in the Special Diagnostic and Therapeutic 
Laboratory by myself and the technician in charge. All other blood 
chemistries were done in the diabetes research laboratories using 
manual methods. 
I. Serum Glucose 
a. Specimen Collection 
Samples were drawn for serum glucose three times weekly, both 
fasting and three hours postprandially. A small amount of whole blood 
was placed in a 500 ul microfuge tube and allowed to clot. It was spun 
at high speed for three minutes on the Beckman Microfuge, Model #152 
(Beckman Instruments, Palo Alto, California). The serum was collected 
using a Pasteur pipette and immediately assayed for glucose. 
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b. Procedure for Glucose Determination 
The Y.S.I (Yellow Springs Instrument) glucose analyzer, Mod~l 23A 
(Yellow Springs Instrument, Yellow Springs, Ohio) uses an oxidase en-
zyme hydrogen peroxide sensor. This technique allows direct readout of 
glucose concentrations and no sample modifications are required. 
Twenty-five (25) microliters of serum is needed per sample (all samples 
were run in duplicate). The principle involves the conversion of glu-
cose and oxygen to gluconic acid and hydrogen peroxide. 
The H2o2, generated in proportion to glucose concentration is 
oxidized at the platinum anode. The subsequent oxidation at the anode 
and reduction at the silver electrode creates a current that is propor-
tional to the amount of H2o2 wh)ch diffused in. This is directly 
calculated as a glucose reading on the instrument utilizing an analog/ 
digital converter (414). 
c. Calculation of Results 
Precision of the assay was determined using Monitrol I and 
Monitrol II Standards (Dade Scientific Co., Miami, Florida). Percent 
coefficients of variation were calculated as mean divided by standard 
deviation times 100. Interassay variation of glucose measured at con-
centration level of 104 mg/dl and 230 mg/dl were 0.96% and 1.3% re-
spectively. 
II. Urine Glucose Measurement 
a. Specimen Collection for 24-hour Urine 
Patients were instructed to collect 24-hour urines in receptacles 
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provided by the SDTU. At the beginning of the collection period 
(usually when the patient awakens) the bladder was emptied, the speci-
men discarded, and the time noted. All urine specimens passed there-
after were collected for a 24-hour period with the bladder being emptied 
at the same time the following day and this urine specimen being added 
to the collection. To prevent loss of glucose via bacterial glycolysis, 
the jugs contained 5 ml of glacial acetic acid. All urine collection 
bottles were refrigerated during collection. 
b. Procedure for Determination 
The urine samples were collected from the refrigerators every 
morning and the volumes were measured and recorded. An aliquot was sent 
to the clinical labs at Hines for creatinine measurement. Another ali-
quot was used to determine the urinary glucose concentration with the 
sample procedure and analyzer utilized for serum glucose assays. 
c. Calculation of Results 
Glucose concentrations outside the instrumental range of linearity 
were appropriately diluted with total 24-hour glucose excretion in the 
urine calculated by multiplying the urinary concentration of glucose by 
the total volume of the daily urinary output. Coefficient of variation 
(CV) determinations for the assay were similar to those determined for 
the serum controls. Fisher Urichem Level I with a spiked glucose at 
100 mg/dl was used for control purposes. cv•s for the urine were com-
parible with plasma having a value of 1.7%. 
111. Triglyceride Determination 
a. Specimen Collection 
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Patients were instructed to fast for 12 hours before blood was 
drawn for fasting triglyceride levels. They were allowed to drink water 
or take prescribed medications. The patients sat quietly for 10 minutes 
before blood was collected (generally obtained from the antecubital or 
another convenient arm vein). A tourniquet was used, but released be-
fore drawing samples because an artifactual increase in plasma lipid 
concentration can occur with prolonged interruption of venous blood flow 
(398, 399). The blood was allowed to stand at room temperature for 30 
minutes, a time in which the blood should completely clot. The sample 
was centrifuged at 2000 RPM for 15 minutes at 5°C. The serum was im-
mediately transferred to an ice bath and kept at 2-4°C for subsequent 
analyses. Duplicate samples were drawn, and if gross hemolysis did 
occur, the sample was discarded. 
b. Specimen Storage 
Samples for triglyceride measurement were immediately transferred 
to a clear 12 X 75 mm Falcon polystyrene tube and capped. The sample 
could be stored at 4°C for a few days or for longer periods at -20°C. 
Samples were removed from the freezer and allowed to thaw at room 
temperature prior to analysis. Since certain serum components tend to 
concentrate at the bottom of the storage vial when the sample is frozen 
and water from the plasma may condense on the inner walls and cap of the 
vial during storage, the vial was mixed by gentle inversion before un-
sealing until a homogenous sample was observed. 
93 
c. Assay Protocol 
Triglycerides were assayed in the laboratory by the manual method 
of Biggs et al. (400). In this extraction technique, serum is mixed 
with water, sulfuric acid, isopropanol and heptane. Any hemolysis that 
occurred was negated by this extraction procedure. The resulting two-
layer system is allowed to separate with triglycerides entering the 
heptane phase once the sulfuric acid loosens the lipid-lipoprotein 
bonds. Saponification of an aliquot of the heptane (upper) layer with 
a solution of sodium methoxide converts triglycerides to glycerol and 
free fatty acids. On addition of sodium periodate solution contain-
ing acetic acid and ammonium acetate, glycerol is converted to formal-
dehyde and formic acid (the Mal~prade Reaction). On treatment of the 
formaldehyde with acetylacetone, a yellow cyclic 3, 5-diacetyl-1, 4-
dihydrotutidine compound is formed (the Hantzach Reaction) which can be 
read at 410 nm on a Gilford spectrophotometer, Model #240 (Gilford 
Instruments, Oberlin, Ohio). 
c. Calculation of Results 
A calibration curve is prepared to check the linearity of the 
instrument and is performed every 6 months. The assay is linear over 
a range of 0-500 mg/dl. Patient samples higher than these values must 
be diluted with saline, reassayed and final results multiplied by the 
appropriate dilution factor. Triglyceride concentrations may be deter-
mined by comparing the absorbance of the unknown with that of the 
standard. Interassay variation at a triglyceride level of 508 mg/dl = 
3.9%. 
IV. HDL-Cholesterol Determination 
a. Specimen Collection 
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Blood was drawn from the antecubital vein and serum specimens were 
assayed both fasting and postprandially for HDL-cholesterol. 
b. Specimen Storage 
The serum can be stored at room temperature up to three days or at 
2-8°C up to six days. Refrigerated or frozen specimens which have com-
pletely thawed require a 24-30 hour period to fully resolubilize the 
lipoproteins at room temperature. Specimen results determined before 
the required equilibration period may be artificially low. 
c. Assay Protocol 
Many different methods have been used to analyze cholesterol and 
HDL-cholesterol {402-402). The kit used for cholesterol determinations 
is the Pierce Rapid Stat Kit (product #44100, 44102, Pierce Chemical 
Division, Lancer Chemical, Rockford, Illinois) which utilizes choles-
terol oxidase and esterase with a peroxidase/phenol/4-aminoantipyrine 
system. The method involves selective precipitation of LDL and VLDL by 
a magnesium/phosphotungstate precipitant reagent (403). The HDL-
cholesterol fraction present in the supernatant is then analyzed with 
the enzymatic cholesterol reagent. The enzymatic reagent breaks all 
cholesterol ester bonds via cholesterol esterase and the total free 
cholesterol is oxidized in the presence of 02 by cholesterol oxidase 
to give cholest-4-ene-3-one and H2o2• The peroxide and phenol react 
with 4-aminoantipyrine via peroxidase enzyme to give a quinoneimine dye, 
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which is colored pink and read at 510 nm on a spectrophotometer. 
d. Calculation of Results 
The procedure for HDL-cholesterol is linear over a concentration 
range of 0-150 mg/dl. HDL-cholesterol concentration is calculated by 
comparing the absorbance of the unknown to that of the standard and 
multiplying by the known concentration of the standard. Since the 
original sample was diluted with the precipitant reagent, a factor of 
2 is needed to correct for the dilution. 
Lipemic specimens on occasion may give a supernatant that is tur-
bid after addition of precipitating reagent and centrifugation. If an 
additional centrifugation at 12,000 X g (5000 RPM) does not clear the 
supernatant, the specimen is diluted 1:1 with saline and the precipita-
tion step is repeated. The final result is multiplied by 2 to obtain 
total serum HDL cholesterol. Interassay variability was 6.3% at an HDL-
cholesterol level of 30 mg/dl. Calibration curves for HDL-cholesterol 
were performed every six months to check spectrophotometer response and 
calibration. 
V. Cholesterol (total) Determination 
a. Specimen Collection 
Collection procedures for total cholesterol were exactly the same 
as those for HDL-cholesterol. Serum collected from patients was used 
for the determination of total cholesterol. 
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b. Specimen Storage 
Specimens for cholesterol determinations were stable up to six 
days at 2-8°C or 2 days at 20-25°C. Storage for longer periods of time 
require freezing at -5°C. Samples to be assayed should be thawed at 
room temperature and serum mixed by inversion until homogenous. A re-
solubilizing period for total cholesterol is not needed and samples 
may be assayed after complete thawing and mixing. 
c. Assay Protocol 
The identical chemical procedure for HDL-cholesterol determina-
tions were also used for total cholesterol measurements. Sample volumes 
were changed, however, and no ~recipitation step was performed. 
d. Calculation of Results 
The range of linearity for this assay was from 0-500 mg/dl. 
Again, the absorbance of the standard was compared to that of the un-
known patient sample. A ratio was obtained, the value of which was 
multiplied by the known value of the standard. Since no dilutions were 
made except in cases where total cholesterol was greater than 500 mg/dl, 
a dilution factor was not used. A standard curve was again determined 
for this assay to measure the linearity at differing cholesterol concen-
trations. Interassay variation at a level of 200 mg/dl cholesterol = 
5.9%. 
C. The Development and Use of the Radioimmunoassay for Insulin and 
Glucagon 
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I. Introduction 
Radioimmunoassay, introduced by Yalow and Berson for the measure-
ment of insulin concentrations (404), is based on competition for an 
antibody between a known amount of radioactively labeled antigen and 
its unlabeled counterpart in the unknown. The amount of bound radio-
active antigen is inversely proportional to the concentration of this 
same antigen in the patient•s sample. Different methods have been used 
to separate the bound insulin from the unbound moiety (405-406). The 
two antibody system described by Morgan et al. (407) was used because 
of its greater sensitivity and specificity. In summary, the two step 
reaction is as follows: 1) insulin forms a soluble complex with its 
specific antibody usually raise~ in guinea pigs (Ains-GP); 2) this 
soluble complex is precipitated by an antibody to guinea pig serum 
which is obtained from a goat. The percent of radioactivity in 
the precipitate is inversely proportional to the concentration of un-
labeled insulin in the reaction mixture. Temperature ranges between 
O-l0°C caused relatively little change in antibody-antigen binding. At 
37°C however, the binding of the complex is much less (407). 
In order to determine the amount of unknown in the sample, the 
amount of competitive inhibition observed in the unknown is compared to 
that obtained in separate solutions in which known amounts of purified 
antigen are added. A standard curve plotting the known concentrations 
of antigen against the ratio of bound to unbound antigen can thus be 
obtained (Figure 3). This curve is used to ascertain the level of un-
known antigen in the sample by comparing its ratio of bound to unbound 
With that of the standard curve. 
Ratio 8/Bo 
Radioactive C* 
0.25 
0o~--~------~IO~----~IO_O _____ IO~OO 
Concentration of Unlabeled 
Purified C )Ju/ml 
Figure 3: Standard calibration curve for radioimmunoassay. 8/Bo 
represents the ratio of bound to unbound antigen present. 
C* represents cold unlabeled antigen. 
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In the double antibody system, the first antibody which is 
directed against the antigen to be measured is added at a level that 
enhances competition between labeled and unlabeled antigens for bind-
ing sites. The second antibody (anti-antibody) is added in excess to 
ensure complete immunoprecipitation of the first antibody antigen com-
plex. 
II. Insulin RIA 
a. Preparation of Insulin Standards 
Stock purified insulin was obtained from Eli Lilly and Company 
(Indianapolis, IN) at a concentration of 21.7 ~/mg protein/ml. Appro-
priate dilutions of the stock i~sulin must be made to obtain concen-
tration ranges which would be normally found in patients. A 1:1000 
dilution of stock insulin was first made (stable for 10 days at 2-8°C). 
50 ul of this solution was diluted to 2 cc with V/A buffer (final 
concentration of standard was 542 ~U/mg/ml). Serial dilutions were 
done to this standard with gelatin buffer 0.1%. Once standard dilutions 
were prepared they were pipetted into the assay tubes in triplicate, 
with one set of NSB tubes per standard curve. 
b. Assay Protocol 
The performance of this specific assay was dependent on antibody 
concentration, amount of labeled antigen added and incubation times 
which all influence the specificity and reactivity of the assay. Bind-
ing studies were done with varying concentrations of insulin antibody to 
obtain the correct antibody dilution to perform the assay. A 1:16,000 
100 
dilution of first antibody was found to produce the greatest re-
activity. A subsequent study was performed to ascertain the amount of 
antibody that could be added to obtain the greatest reactivity between 
insulin and insulin antibody (Figure 4). Insulin excess will use all 
antibody added and give the most accurate binding results. A volume 
of 100 ul of the 1:16,000 dilution of first antibody was determined to 
be the best. The second antibody is a goat-antiguinea pig antibody 
(Pel-Freeze, Rogers, Arkansas) specific for the a globulins of the 
guinea pig first antibody. A 1:12 dilution of this second antibody 
was found to give the optimum degree of precipitation of insulin. 
c. Data Reduction-Insulin Radioimmunoassay 
All radioactivity was counted on a Micromedic System 2/200 gamma 
counter (Micromedic Systems, Philadelphia, PA). Assay data reduction 
was performed using a Hewlett-Packard Clinical Laboratory Radioassay 
Computer {programmed by cassette tape) (Hewlett Packard, Loveland, CO). 
This program evaluates the standard curves by weighted and unweighted 
least square regressions using the log dose vs. % bound, logit of % 
bound and probit of% bound (Figure 5). These data reduction transfor-
mations are automatically analyzed for best fit and the curve plus all 
pertinent data are printed via automatic printout. All samples were 
done in triplicate with each sample having an (NSB) tube run. 
Spiked insulin buffer samples {100 ~U/ml and 50 ~U/ml) were used 
as internal controls on 20 insulin assay runs. CV% of 10% or less was 
deemed acceptable. At levels of 103 uU/ml and 49 ~U/ml, coefficients of 
variation were 9.7% and 10.2%, respectively. 
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Figure 4: Precipitin curve for monospecific system, one antigen and 
corresponding antibody. This binding study was performed to 
ascertain the amount of insulin antibody that should be add-
ed to obtain the greatest reactivity between insulin and 
antibody. 
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III. Glucagon (RIA) 
a. Preparation of Glucagon Standard Curves 
Stock purified glucagon was obtained from Lilly and Company 
(Indianapolis, IN) at a standard concentration of 1 mg/ml. Appro-
priate dilutions of stock glucagon must be made in order to obtain 
physiological concentration ranges approximating patient•s samples. 
40 of stock solution was diluted to 4 cc (1:100 dilution) to obtain 
10,000 pg/ml concentration. 
Once standards were prepared (0-10,000 pg/ml), they were 
immediately used for assay. Standards were pipetted in triplicate with 
one set of NSB tubes. 
b. Assay Protocol 
For the glucagon assay, binding studies similar to the insulin 
assay were performed with different antibody dilutions. Anti-glucagon 
guinea pig antibody, lot number (OJA-G2) obtained from Dr. A. Lawrence•s 
lab was used for the study. Final dilutions of first antibody which 
gave best binding results were 1:17,500. 
10 ul (OJA-G2) was diluted to 17.5 ml with glucagon buffer. 5 
ul/cc of normal guinea pig sera (NGPS) was added as a carrier. All 
assays were incubated at 4°C with assay tests run in 12 X 75 culture 
tubes. 
c. Data Reduction-Glucagon Radioimmunoassay 
Radioimmunoassay data were treated similarly for the glucagon 
assays as for insulin determinations. Weighted regression and best 
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fit analysis for the standard curves were performed (Figure 7). All 
unknown samples were determined by comparison to the standard curve. 
Normal ranges for human serum glucagon are 0-300 pg/ml. Internal 
control was monitored by spiked glucagon buffer. At levels 1011 and 
495 pg/ml, coefficients of variation were 13.4% and 11.3% respectively. 
IV. Specimen Collection Procedures 
Fasting (14 hour fast) and postprandial, insulin (3 hours) 
samples and fasting glucagon samples were collected. Patients were 
asked to sit quietly for 10 minutes. Blood was then drawn from the 
antecubital vein and placed directly into tubes containing 0.3 ml of 
the aprotinin trasylol which inh,ibits protease breakdown of insulin 
and glucagon (Mobay Chemical Corp. FBA Pharmaceuticals, New York, NY). 
These samples were immediately placed in ice baths and after 45 minutes 
the blood was spun in a refrigerated centrifuge at 3000 RPM. In the 
rare instances when gross sample hemolysis occurred, the sample was dis-
carded. After centrifugation, the serum was aspirated with Pasteur 
pipettes and placed in 12 X 75 em polystyrene tubes with snap caps and 
frozen at -20°C. Frozen samples were thawed at room temperature and in-
verted several times to provide a homogenous sample for assay. 
D. Triglyceride Turnover Methodology 
I. Introduction 
The use of 3H-glycerol in the labeling and measurement of tri-
glyceride transport in the plasma pool is well-documented (53-59, 408-
411). The method first developed by Farquhar (412) was used to directly 
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assess the input and removal rates of human plasma triglycerides. 
Using glycerol tritiated on carbon number two instead of a fatty ~cid 
carbon is preferable since glycerol recycling by the body is minimal. 
The procedure is based on the principle that plasma concentrations of 
any solute will change as a function of its removal from or release 
into the plasma. After radioactive glycerol is injected into the 
patient, the appearance and disappearance of radioactivity from the 
plasma pool is monitored from the monoexponential portion of the curve. 
A K value or decay constant is then calculated. Biphasic decay curves 
have been observed suggesting either two triglyceride pools, one rapidly 
removed from the plasma and one removed slowly possibly due to recycl-
ing, or one single pool in whi~h stepwise removal of triglyceride is 
slowed as the case in remnant VLDL formation (413). 
II. Preparation of Labeled Glycerol for Injection 
a. Purification and Dilution of Label 
23H glycerol in ethanol, 1 mCi/ml, was obtained from Amershame 
Searle (Arlington Heights, IL). The stock solution was diluted with 
saline to an approximate concentration of 10 uCi/ml. This working 
solution was lyophylized to dryness to remove radioactive water and then 
resolubilized with saline. No loss in radioactivity was observed. 
All glassware and instruments were autoclaved for 15 minutes at 
120°C and a sterile hood was used to prepare the radioactive label for 
injection. Pharmacological purity was insured by pouring the samples 
through a Nalgene membrane filter with a 22 urn pore size. Once the 
sample was filter sterilized it was poured into autoclaved pharmaceu-
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tical serum vials and capped. An aliquot of this solution was given 
to the Chief Research Microbiologist for culturing of bacterial g~owth. 
No evidence of bacterial growth after seven days culturing was consid-
ered proof of sample sterility. Standard procedures for radioactive 
handling and spillage were utilized. For added safety, sterilized 
samples for injection were refiltered upon injection by the use of a 
Swinex syringe filter (Millipore Corp., Bedford, Mass.). 
b. Calculation of Total Body Dosage by Tritium Injection 
Approximately 50 uCi per patient of 23H-glycerol was injected 
for each turnover procedure. FDA policy stipulates that calculated 
radiation absorbed dosages be e~timated and total body dose estimates be 
obtained. Amershame Searle Data indicates the maximum body burden for 
tritium (3H) to be 1 mCi per dose with an effective biological half 
life of 12 days. Safe dosages for any drug according to FDA rulings 
have to be less than 3 RADS. Maximum penetratable range for tritium in 
tissue is 6 X 10-3mm. Dosage rate was calculated from the MIRD index 
' for dosimetry (MIRD pamphlet #1 and #10) (396-397). 
III. Specimen Collection Procedures 
a. Injection of Label 
A 20 gauge polyethylene catheter was inserted into the patient•s 
left antecubital vein with extension tubing leading into a 3 way flow 
stopcock. A slow intravenous saline drip was initiated and blood flow 
from the stopcock was checked. In the right antecubital vein, a butter-
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fly catheter was implanted momentarily and the radioactive bolus was 
injected. During the interim course of the study the patient was 
fasted. Water was taken ad libitum and a small evening meal (broth and 
dietetic lemonade) was consumed. The total turnover procedure is 24 
hours in duration with the catheter in place for eight hours. Patients 
were continually monitored throughout the period with P.M. blood 
collections obtained by the medical staff. 
I 
b. Specimen Collection and Processing 
During the 24 hour period, specimens were drawn from patients 
using both the indwelling catheter and venupuncture methods. Specimens 
collected during the first eigh~ hours were drawn by the indwelling 
catheter and stopcock. After this time, the I.V. system was removed 
and the remaining samples were collected by venupuncture. Seventeen 
samples (12 ml each) were drawn from the patients at different times 
during the twenty-four hour period. 
The blood was allowed to clot at room temperature (approximately 
45 minutes) and then centrifuged at 1000 X g/15 min (2000 RPM) to 
separate red cells from serum. The serum was collected without a pre-
servative and stored at 4°C. At the end of the procedure, all samples 
were frozen in polystyrene vials at -28°C. Two turnovers were performed 
on each patient during the study, one at the end of the control diet and 
one after two weeks on the study diet. 
IV. Assay Protocol 
a. Isolation and Purification of Radioactive Triglyceride Sample 
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A chloroform-methanol extraction procedure was used in the separation 
and purification of lipids. The non-polar triglyceride was solubil-
ized in chloroform and the polar lipids which were solubilized in the 
methanol layer were discarded. Once the lipids were isolated and 
washed, they were concentrated and resolubilized in a fluor scintillant 
used for counting. P.C.S. {phase combining system), (Amershame Searle, 
Arlington Heights, IL), the scintillation fluor used, is a complete 
xylene surfactant which contains all ingredients necessary for counting 
organic and inorganic samples. The P.C.S. fluor and samples were poured 
into Kima glass scintillation vials. The vials were cooled and allowed 
to dark adapt. They were then counted along with a blank and tritium 
standard for 20 minutes on a Packard Tricarb liquid scintillation 
counter, Model 3390 (Packard Instruments, Downers Grove, IL), with an 
appropriate external standard to correct for quenching. 
b. Scintillation Counting Procedures 
The external standard method for quench correction employs Compton 
electrons derived from the interaction of y -rays with the counting 
glass vial and the scintillation solution. Different color intensity 
blanks were run with the external standard in place for a period of 
time. The changes in counts from the non-colored blank as compared to 
the different intensity colored blanks were used to determine the count-
ing efficiency of the colored samples. 
VI. Calculation of Results 
a. Fractional Turnover Rate 
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Quench corrected counts were obtained from all patient samples. 
Radioactive time curves were plotted on semilogarithmic scale paper 
with plasma activity plotted against time. A Hewlett Packard Model 
7830A computer was used to obtain the slope and intercept from linear 
regression analysis of the monoexponential portion of the decay curve. 
The line was extrapolated back to zero and total injected dose of tri-
tiated glycerol was determined. Ascertaining the time when half the 
total number of counts has disappeared (T 1/2) allowed calculation of 
k by the following equation: 
K = 0.693 T 1/2 where 0.693 = 1n 2 
b. Total Turnover Calculations 
The fractional turnover rate (k) of the total plasma triglycer-
ides was used to calculate the turnover rate (V) which equals the re-
moval rate as mg/kg/hr and was calculated from the following formula: 
V = k (h~) X S{mg/dl) X 0.45 (~)X b {57) 
s = the triglyceride concentration in mg/dl 
0.45 = indicates a mean plasma volume of 0.45 expressed as 
deciliters/kg 
b = a body weight correction factor. Since plasma volume is 
b = 
less in excess adipose tissue, all turnovers must be weight 
corrected. 
4500 + a x c 
100 + c 45 
a = plasma volume/kg adipose 
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c = excess of relative body weight (RBW) (RBW %-100) 
c. Kinetic Determinations and Statistical Calculations 
Enzyme kinetic data was calculated by plotting triglyceride con-
centration/turnover ( [S] /V) versus triglyceride concentration ([S]). 
This is comparable to a linear regression analysis performed on turn-
over plots after control diets and study diets were consumed. In this 
type of plot the point at which the lines intercept the X-axis gives 
the value for Km with Vmax estimated as 1/slope. 
The relationship between radioglyceride determined triglyceride 
turnover and triglyceride concentration was determined by plotting one 
against the other. The lines of best fit were determined by linear re-
gression analysis. Again control values were compared to study diet 
values (high and low sucrose diets). 
Correlation coefficients were calculated to determine if any re-
lationship exists between fractional turnover and plasma TG levels after 
the control diet and after two weeks on the study diet. 
E. Total Lipoprotein Electrophoresis 
I. Introduction 
The principles of lipoprotein electrophoresis are based upon the 
fact that a charged particle placed in an electric field will migrate 
toward one of the electric poles of the field (419). After electro-
phoresis, proteins are visualized by specific chemical detection. Pro-
tein levels can be interpreted qualitatively (by visual inspection) or 
quantitatively (subjected to densitometric scanning). 
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11. Specimen Collection and Storage 
Blood samples were drawn for lipoprotein electrophoresis by tech-
niques similar to those for triglyceride and cholesterol measurement. 
Lipoproteins are unstable and easily disturbed by sheering forces or 
hemolysis. Therefore, samples for lipoprotein analysis should be 
collected in EDTA tubes with enough anticoagulant to produce a final 
concentration of 1-1.5 mg/ml (the EDTA also protects against lipopro-
tein oxidation). The collection tubes were filled to capacity (6 ml) 
and immediately immersed in an ice bath. The specimen was next placed 
in a refrigerated centrifuge and spun at 1500 x g (3000 RPM). The 
plasma was transferred to a clean storage vial using a Pasteur pipette. 
Lipoproteins will not tolerate freezing or long term storage in solu-
tion without undergoing changes that are reflected in alterations in 
their ultracentrifugal and electrophoretic characteristics (415-417). 
Lipoprotein concentrations are therefore most accurately measured in 
fresh samples as soon as possible. If samples were stored for longer 
periods of time (7 days), the plasma fraction was kept in the dark at 
4°C. 
III. Agarose Gel Method 
a. Importance in Lipoprotein Measurement 
The agarose gel system was used to detect lipoproteins by means of 
charge and size separation. A sample densitometric scan of a few of the 
basic lipoprotein types representing patients from our study is seen 
(Figure 9}. 
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Figure 9: Graphical representation of lipoprotein patterns obtained in 
normal, type IV and type III hyperlipemic individuals. In 
type III individuals, the pre-s band is again elevated, and 
migrates similarly to the s -1 ipoprotein band; causing the 
broad s band observed. 
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b. Assay Protocol 
The agarose gel electrophoresis system used was the Beckman 
Microzone system (419). In this system, electrophoresis must be per-
formed after rehydration of the gel. Excessive equilibration (longer 
than 45 minutes) was avoided since this may result in high current 
levels and joule heat which distorts the appearance of the patterns. 
c. Staining Procedure 
After fixing and drying the gel, it was stained with Sudan Black 
B in a flat tray of appropriate size for 5-10 minutes. If overstaining 
of the gel occurred it was destained by placing it in the gel/fixative 
solution until the background co~oration disappeared (usually 10-20 
minutes). 
d. Densitometric Scanning and Data Interpretation 
All gels were scanned with a Gelman Computing Densitometer, Model 
#ACD 18 (Gelman Instruments, Ann Arbor, Michigan). All gels were 
scanned at a wavelength of 500 nm and the area under each peak inte-
grated to determine the percent of total lipoprotein present. 
Data Interpretation 
Densitometric scans were compared to the standard electrophoretic 
patterns of the Fredrickson classification of hyperlipoproteinemia and 
patients were classified accordingly. Normal values for percentages of 
the different lipoprotein fractions have been established and these were 
used in objective classifications (420). 
F. VLDL Apoprotein Analysis by SDS-polyacrylamide Gel Electro-
phoresis and Isoelectric Focusing 
I. Introduction 
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The reliability and resolution capabilities of SDS (sodium dodecyl 
sulfate) polyacrylamide gel electrophoresis and isoelectric focusing 
have made these techniques invaluable in lipoprotein determinations 
(421). The measurement of apoprotein species from different lipo-
proteins, by these high resolution techniques, have enabled quantitation 
of individual apoprotein subunits (63, 64, 66-72, 422-426). These gel 
systems were used to isolate individual apoproteins in sufficient 
quantity and purity. 
II. Sample Collection and Storage 
Sample collection procedures were identical to those for trigly-
ceride and lipoprotein determinations except that blood was placed in 
tubes containing sodium citrate. These samples were placed in an ice 
bath for 10 minutes and plasma was separated in a refrigerated centri-
fuge at 1000 x g/15 min (2000 RPM). The plasma was removed carefully 
with Pasteur pipettes and placed in polystyrene storage vials. One 
mg/ml of EDTA was added to prevent oxidative breakdown of some of the 
protein constituents. Samples were refrigerated at 4°C and analyzed 
within one week of collection. 
III. Isolation of VLDL Apoprotein 
a. Ultracentrifugation of Total Plasma for VLDL 
The method of Havel et al. (431), based on flotation ultracentri-
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fugation, was used to provide VLDL lipoprotein for quantitative analy-
sis of apoprotein subfractions. Density adjustments were made with 
solutions containing NaC1 and KBr up to a density of 1.006 (gm/ml). 
The plasma mixture was gently poured into 5/8 x 3 polyallomer 
ultracentrifugation tubes (total volume 13 ml) which were filled to 
capacity, sealed with flat gasket caps and placed in a Ti-50 fixed angle 
rotor. Samples were centrifuged at 105,000 x g (40,000 RPM) for 20-22 
hours at 10-15°C in a Beckman Spinco Ultracentrifuge, Model #L2-65B 
(Beckman Instruments, Palo Alto, CA) (Figure 10). 
Following the centrifugation, lipoproteins of less than the sol-
vent density of 1.006 were concentrated at the top in a layer approxi-
mately 1/2 inch thick. Beneath" this layer, occupying 1/2 of the length 
of the tube, a clear zone was observed. Concentrated at the bottom, 
the remaining serum was stratified below the clear zone. The lipid 
layer at the top and approximately 2/3 of the clear zone were carefully 
collected by aspiration with a Pasteur pipette. The collected fraction 
was then purified and delipidated. 
IV. Purification Procedure 
a. Dialysis and Delipidation of VLDL 
Separated VLDL lipoproteins were placed in cellulose dialysis 
membrane tubing 1-1/8 mm inflated diameter. The sample solutions were 
dialyzed against a bath containing 0.05 M tris buffer, 0.05% EDTA, and 
4.0 M NaC1, pH 8.6 for 48 hours at 4°C. 
PLASMA LIPOPROTEINS 
CHYLOMICRONS VLDL LDL HDL 
Oo~ 0 0 0 
Density, g/ml: 0.95 1.006 1.063 1.21 
Major Ape-
protein: 1--------apo-B --------1 
TRIGLYCERIDE 
apo·A·I 
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Figure 10: Schematic representation of plasma lipoproteins separated by 
size and lipid composition. The largest lipoproteins are the 
least dense and contain the most triglyceride. The smallest 
lipoproteins are the most dense and contain the largest 
amount of lipid as cholesterol. Apo B is found in all lipo-
protein classes with the exception of HDL. 
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The dialyzed VLDL solution was then poured into a serum bottle 
and quick frozen in an acetone dry ice bath. Samples were then freeze 
dried on a Virtis lyophilizer for approximately eight hours. The 
freeze dried samples were removed and immediately delipidated with 10 
mls of chloroform: methanol (2/1, V/V). Lipid-free protein was washed 
twice with 10 ml volumes of chloroform/methanol and placed in 15 ml 
conical glass tubes and centrifuged at 1000 x g for 10 minutes (2000 
RPM) at 5°C. Protein samples (pelleted after centrifugation) were 
dried under a stream of nitrogen for three hours. 
b. Solubilization Procedure for Isolated Apoprotein 
Delipidated apoprotein wa~ solubilized in a series of steps that 
involve reduction with mercaptoethanol and dialysis against dithio-
threitol. For 24 hours at room temperature, the apoprotein pellet was 
suspended in 1.0 ml of a solution consisting of 2.5% sodium dodecyl 
sulfate, 1.0% Na2co3 and 10% B-mercaptoethanol, pH 8.5. After this 
time, partial solubilization of protein occurred. The protein suspen-
sion was gently poured from the conical tubes into 1-1/8 mm dialysis 
tubing where it was dialyzed for 48 hours at room temperature against 
200 ml of 0.1% SDS, 1.6 M urea, 0.05% dithiothreitol and 0.01 M tris-
HC1, pH 8.6. Solubilized protein was removed from the dialysis bath 
and poured into 12 X 75 mm glass culture tubes. One gram of sucrose 
was added to each tube and the sucrose was allowed to dissolve in the 
apoprotein solution to increase the density. 
c. Protein Analysis of Sample 
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To determine the protein concentration of the solution, a Lowry 
protein assay modified to assay SDS solubilized proteins was perform-
ed (432). High backgrounds developed upon addition of folin-phenol 
reagent during color development and it was determined that the inter-
ference was due to residual mercaptoethanol which was not dialyzed out 
of solution. A method was employed which is considerably less suscept-
ible to interference. This is the dye binding technique developed by 
Bradford et al. (433). In this assay, the absorbance of an acidic 
solution of Coomasie Brilliant Blue G250 (BioRad Laboratories, Richmond, 
CA) shifts from 465 nm to 595 nm when binding of the dye by protein 
occurs. Thus Coomasie Dye can be used for quantitative protein deter-
minations by measurement of optical absorbance at 595 nm. 
An aliquot of mercaptoethanol buffer, dialyzed with the patient•s 
samples was used as a reagent blank with bovine serum albumin, treated 
similarly to the patient•s samples used as a standard. The protein-
dye mixtures were incubated for 60 minutes at room temperature. Absor-
bance at 595 nm was quantitated on a Gilford Spectrophotometer, Model 
#240 (Gilford Instruments, Oberlin, Ohio). 
d. Calculation of Protein Concentrations 
All spectrophotometric measurements were done with the absorbance 
of the instrument set to zero with the reagent blank. The concentration 
of the unknown was determined by comparison of the absorbance of the un-
known with a known standard or read against a standard curve (Figure 
11). 
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Standard Curve Protein Assay 
1.0 
0.8 
~ 0.6 
10 
0 
0 
0.4 
0.2 
Bovine albumin (Protein Standard) 
mg/dl 
Figure 11: Standard curve determined from the dye binding technique of 
Bradford et al. (433). This method is used to determine the 
amount of unknown VLDL lipoprotein collected by ultracentri-
fugation of human plasma samples. 
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v. SDS - Polyacrylamide Gel Electrophoresis 
a. Explanation and Brief Summary of the Principles 
The methodology for disc electrophoresis and its application to 
human serum proteins was introduced by Davis et al. (434). Shapiro, 
et al. (435) reported that the separation of proteins by polyacrylamide 
electrophoresis in the presence of the anionic detergent sodium dodecyl 
sulfate is dependent on the molecular weights of their polypeptide 
chains. Since the dodecyl sulfate ions negate any charge related migra-
tion, the proteins separate strictly on the basis of their diameters and 
thus, their molecular weight. Thus, with this system, the pore size is 
tailored to the dimension of the molecule to be separated by varying 
polyacrylamide gel concentratio~ (437). 
b. Protocol 
Preparation for Electrophoresis 
The electrophoretic unit used was a Canalco Model #12, (Canalco 
Instruments, Rockville, Maryland) electrophoresis cell, designed for 
disc gel separations. Both stacking and separating gels were used in 
the determination of VLDL apoproteins. The separating gel was a 10% 
SDS gel and the stacking gel was 2.5%. The dense sucrose-protein sample 
was added to the top of the gel with a Hamilton syringe. The addition 
occurs in the cold room at 5°C with the gel tubes in the electrophoretic 
cell. The protein solutions were layered on the gel through the upper 
tank buffer (approximately 150 ug of protein per gel). 
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~lution Used to Prepare Gels were Modified from Existing Procedures 
Separating Gel 
10% gel pH 8.6 
Solution A 
0.12 M tris-HC1 buffer, pH 8.6 
0.23% V/V TMED (N,N,N1,N1-tetramethylethylene diamine) 
0.02 M sodium dodecyl sulfate solubilized with 8 M Urea 
Solution B 
40% W/V acrylamide 
1.1% N, N 1 -methylenebisac~ylamide solubilized and diluted to 
100 ml with 8 M Urea 
Solution C 
0.01 M (NH4)2 s2o8 (ammonium persulfate) in 8 M Urea 
Gel solutions were mixed in the following ratio: 
4 ml (A) + 8 ml (B) + 4 ml (8M Urea) + 16 ml (C) 
Stacking Gel Solutions 
2.5% gel pH 6.6 
Solution D 
0.7 M Tris-HC1 buffer pH 6.6 - 6.8 
1N HC1 
TMED 
8 M Urea 
Solution E 
5% W/V acrylamide solution 
2.5% NN methylene bisacrylamide 
8 M Urea 
Solution F 
1 X 10-4 M riboflavin 
8 M Urea 
Solution G 
40% sucrose in 8 M Urea 
123 
The solutions for the stacking gel were mixed in the following 
proportions: 
1 ml (D) = 2 ml (E) + 1 ml (F) + 4 ml (G) 
Photoflo 600 Solution 
0.17% V/V Photoflo 600 (Eastman Kodak Co., Rochester, N.Y.) 
Upper Tray Cathode Buffer pH 9.0 
0.04 M Tris 
0.05 M glycine 
1N HC1 
8 M Urea 
Lower Tray Anode Buffer pH 8.1 
0.12 M Tris 
IN HCl 
Bromphenol Tracking Dye 
10 mg dissolved in 1000 ml H20 
Electrophoresis 
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Samples were electrophoresed for 8 hours at approximately 3mA per 
tube at 5°C. 1.5 hours after the marker dye migrates off the gel, the 
flow of current was halted and gel tubes were removed from the cell. 
Since the apoproteins migrate mu.ch slower than the tracking dye, the 1.5 
additional hours were found to be the time of maximum migration of the 
apoproteins. The gels were recovered for protein staining by placing 
them in an ice bath. After five minutes, they were removed and gently 
rimmed free from the gel tube with a stream of water. 
c. Staining Procedures 
The recovered gels were placed in 12 X 75 mm tubes and were 
stained with a solution of 1% Amidoschwarz lOB in 7.5% acetic acid for 
16 hours at room temperature. Gels were removed from the stain and ex-
cess dye was removed by repeated washings of 7.5% acetic acid (48 hours 
is the usual destaining time). The gels were scanned densitometrically 
and peak integration was used to obtain a quantitative measurement of 
the constituent apoproteins. 
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VI. Isoelectric Focusing 
a. Explanation and Brief Summary of Principle 
The technique of isoelectric focusing has been applied to the 
analysis of many proteins, including human apolipoproteins (423, 426). 
Proteins of similar molecular weight but different charge will also 
separate in this system enabling the identification of isoprotein 
species. 
b. Assay Protocol 
The protein preparations were electrophoresed in the electro-
phoretic apparatus as described IV, b, 1. However, the system was 
equipped with a larger lower taDk to accommodate gels which were poly-
merized in tubes 12 em long with an J.D. of 5 mm, 7.5% polyacrylamide 
gels, with added ampholytes, were poured into the tubes to a depth of 
approximately 11 em. 
Gel Solutions 
Acrylamide Solution 
37.5% acrylamide solution 
0.8% NN1 methylenebisacrylamide 
Ampholine carrier ampholytes were obtained from commercial pre-
parations by LKB Instruments, Inc., (Rockville, MD). The ampholyte 
solution consists of different aliphatic polyamino-polycarboxylic acids. 
The pH range chosen for this assay was pH 4-6. 
Ammonium Persulfate Solution 
1.07% ammonium persulfate 
Upper and lower chamber buffers are prepared as follows: 
Upper Chamber (cathode buffer) pH 13 
0.02 M NaOH 
Distilled H20 
Lower Chamber Buffer (anode buffer) pH 1 
0.01 M phosphoric acid 
Distilled H20 
126 
The cell unit containing the gels was placed in a cold room at 
5°C and the gels were prefocused at 1mA/tube for 30 minutes to establish 
the pH gradient. Electrophoresis was terminated and protein samples 
were directly applied to the buffer gel interface with a Hamilton or 
tuberculin syringe (400 ug of protein in 500-700 ul volume). 
c. Electrophoresis 
Proteins were electrophoresed at 400 volts until the current 
stabilizes at around 1-1.2 rnA for 12 gels (12-15 hours). One gel in 
each run was used as a blank for pH gradient determinations. Gels were 
removed after electrophoresis by rimming the tube with water. The gels 
containing the separated protein were fixed and stained, as described 
previously. The blank gel was sliced with a razor blade into 5 mm seg-
ments. These segments were transferred to small test tubes, 1 ml of 
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deionized water was added, the tubes were capped and stored at 4°C. 
subsequently, the pH of the 1 ml solution was measured at room tem-
perature with a Model 26 Radiometer pH meter (Radiometer, Copenhagen, 
NV, Denmark). 
d. Staining Procedure 
A method developed by Malik and Berrie (438) utilizes Coomassie 
Brilliant Blue, but eliminates the need for fixing, deampholyting and 
destaining. This method avoids intense background staining and has 
resolution capacities comparable to other procedures using Amidoschwarz 
and Coomasie Brilliant Blue. After focusing, the gels were removed and 
placed directly in the stain fi~ative (1% stain solution). Protein 
bands appear within 15 minutes and intensify with longer staining 
periods (overstaining has not been encountered with treatment times as 
long as 48 hours). Gels were typically stained for 12 hours and were 
transferred to distilled H20 (a suitable storage media). A short 
immersion in 0.2% H2so4 will decolorize unwanted background, if de-
sired, but prolonged exposure to H2so4 will eventually remove all 
stain. 
Stained and fixed gels were photographed and then placed in 
scanning tubes. The Gelman densitometer used previously to scan and 
integrate the protein peaks of the SDS polyacrylamide gels was also 
used to determine the protein content of the isoelectrically focused 
gels. All apoproteins were identified by their isoelectric point which 
was compared with tables of known standard apoproteins (Table 3). Pro-
tein peaks were expressed as percent of total apoprotein present. 
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Multiple samples were collected for apoprotein determination 
during the control and study diet periods. Therefore, any change~ in-
duced by the diet would conceivably be detected since each patient can 
serve as his own control. Changes in apoprotein composition determined 
from the values obtained while consuming an isocaloric control diet 
could thus easily be identified. 
G. Platelet Aggregation Analysis 
Platelet aggregation is a term used to denote the adherence of 
one platelet to another. A variety of agents to which platelets may be 
exposed in vitro cause them to change shape, aggregate and release the 
constituents of their storage granules. Some of these constituents are 
collagen, thrombin, ADP, epinephrine, serotonin and vasopressin. 
a. Sample Collection and Preparation for Platelet Aggregation 
By sterile venupuncture of the antecubital vein, 9 ml of whole 
blood was drawn into a vacutainer containing 1 ml of 3.8% sodium 
citrate. The blood was drawn after an overnight fast with the patient 
seated and rested 15 minutes before drawing. The blood was collected 
in 17 X 100 mm polypropylene tubes and spun and assayed within two 
hours. 
The blood was centrifuged at room temperature at 150 X g/15 
minutes (800 RPM). The upper plasma layer was syphoned off (approxi-
mately 2 ml) and transferred to polypropylene tubes with plastic trans-
fer pipettes. This was designated platelet-rich plasma (PRP). The re-
maining plasma was centrifuged at 2000 X g/15 minutes (2100 RPM). The 
TABLE 3 
TABLE Classification of apolipoproteins of HI)L and VlDL 
laoelccaic ProteiD Estinwcd Sephadc:s;· 
Daignation Designation" Mol. WL Fraction 
>6.00 C-1 7,000 HS-3 
(VS-3) U!l 5.75 
5.65 A-I 27,000 HS-2 
5.55 
5.46~ 
·~I 5.41 ARP 55,000 HS-1 5.!9 and (VS-2) 
5.56 A-IV. 46,000 HS.I 
5.51 
4.85 A· II 8,000 HS-3 
4.74 C-11 8,000 
4.67 C-111..0 10,000 
4.61 C-111-1? HS-3 
4.57 C-111-2? (VS-3) 
4.50 e-m..:s 11,000 
4.45 C-111-4? 
Isoelectric points of all apolipoproteins found in HDL and 
VLDL lipoproteins. Apo B is considered insoluble because 
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of its large size and is not represented. ARP is synonymous 
with apoprotein E, the arginine rich protein. Data represented 
from reference 430. 
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remaining plasma was pipetted off the red cells and this is designated 
platelet poor plasma (PPP). These two plasma preparations were used in 
the platelet aggregation assay. 
b. Description of Aggregometer 
The platelet aggregometer measures changes in light transmission 
scattering through platelet-rich plasma that is maintained at 37°C and 
constantly stirred at 1000 RPM (440-442). The instrument used was a 
Chrono-log Aggregometer, Model #330 with a Linear Instrument Chart 
Recorder #702. (Chrono-log Corp., Havertown, PA). The instrument 
operates on the principle that platelets in a stirred solution will 
adhere to one another and fall 9ut of solution when an aggregant is 
added. The platelet-rich plasma situated in a small cuvette is slight-
ly turbid due to the presence of platelets in suspension. When aggre-
gating agents were added, the turbidity decreases because of the clump-
ing action of the platelets. When a light beam is passed through the 
cuvette containing platelet-rich plasma, the amount of light transmitted 
will increase as turbidity decreases. This quantity was recorded on a 
linear strip chart recorder and the resultant curve was a record of the 
rate and amount of platelet aggregation. 
c. Assay Procedure 
Platelet solutions were counted and (PRP) concentrations were ad-
justed by dilution with (PPP). 2.5 ml of the working (PRP) was made 
with a final concentration of platelets set at 200,000 ± 20,000 
platelets/ml. For each separate patient, a platelet poor blank was made 
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by taking 0.45 ml of (PPP) and adding 0.05 ml of saline to it. This 
blank was used to adjust the baseline of the instrument to zero. 
Triplicate tubes of patient platelet-rich plasma (PRP) were made with 
0.45 ml of the working solution. The cuvettes were allowed to warm 
up to temperature (37°C) and then 0.05 ml of aggregating agent was add-
ed (adrenaline chloride, final concentration of epinephrine-hydro-
chloride in saline was 0.1 mg/ml, Parke-Davis, Grand Rapids, MI). 
d. Sensitivity Studies 
Platelet sensitivity to the aggregating agent was monitored when 
serially diluted epinephrine mixtures were added to the (PRP). The 
concentration of aggregating mixture at which both first and principally 
second phase aggregation was lost is considered to be the threshold 
level of epinephrine needed to elicit an aggregation. The solutions 
used range from a concentration of 50 ~m to 0.1 ~m. None of the 
patients from the study demonstrated an aggregation response with con-
centrations of less than 0.1 uM. 
The maximum change of OD = ODf- ODi. ODf was measured at 
the maximum point of aggregation and ODi was measured at the initial 
point, before the aggregant was added. The values were expressed as 
percent aggregation using the (PRP) working solution as 0% and the (PPP) 
as 100%. Aggregation curves obtained were compared between the control 
and study diet periods. The changes in aggregation response or sensi-
tivity of the platelets from control diets were recorded. 
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H. Statistical Analysis of Data 
Except in experiments where statistical evaluations of data are 
listed, results were analyzed by the paired or nonpaired two tailed 
t test. In essence t is the ratio of the difference between two means 
to the standard deviation of the difference. Since there is no justi-
fiable basis for selection of pairs of subjects which can be expected 
to behave or respond more nearly alike than any other two, the unpaired 
t test for significance treats the individuals from each sucrose group 
as independent samples from a common population. The t value is based 
on the number of degrees of freedom (the number of samples or subjects 
involved minus two). Since the unpaired tallows each series to be 
summed independently to obtain ~wo sample means, 2 restrictions to the 
number of degrees of freedom are usually imposed. The t value is used 
to find the significance level or probability level that the two sets 
of data are the same. In this study, a 5% significance level (p<.05) or 
below is considered significant. Thus, if t were found to have a P 
value of < .01 this would indicate that the two sets of data have a less 
than 1% chance of being the same. Paired t analysis was used to compare 
values from the same patient when consuming the control diet or study 
diet. 
5. RESULTS 
A. Description of Patient Population at Time of Entry Into Study 
All patients matriculated into the Sucrose Study were adult on-
set diabetics who were hypertriglyceridemic and non-insulin dependent. 
Pertinent patient information is given in Table 4, including age and 
weights, along with fasting serum glucose, triglyceride, HDL-choles-
terol and cholesterol ranges and means. TC/HDL-C, a ratio used in 
assessing susceptibility to atherosclerosis and coronary heart disease, 
was also determined indicating the majority of patients to be in a 
range consistent with their age group. All patients were type IV 
hyperlipemic individuals. Fasting serum chemistries for all test sub-
jects were indicative of hyperlipemic adult onset diabetes. Fasting 
mean values observed were a serum glucose level of 198 mg/dl, a serum 
triglyceride level of 300 mg/dl and a serum cholesterol level of 207 
mg/dl. A total of thirty patients participated in the study for a six 
week time period. 
B. Results of Chemical Determinations During Study Diet Period 
Serum glucose levels were obtained fasting and postprandially 
along with a 24 hour urine glucose determination. Daily weights were 
also obtained from the patient population during the study. The re-
sults are depicted in Figures 12-15. 
a. Fasting and Postprandial Serum Glucose 
Fasting and postprandial serum glucose levels were monitored on 
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TABLE 4 
DESCRIPTION OF PATIENT POOL USED FOR SUCROSE STUDY 
.-
Number Subject Subject Fasting Fasting Fasting Fasting Lipoprotein 
of Age Weight Serum Serum Serum Serum TC /HDL-C Pattern 
Subjects Glucose Trigs HDL-C Cholesterol 
Range Range Range Range Range Range Range Type nr 
30 39-74 144-282 96-308 150-752 14-46 142-310 3.9-12.5 elevated 
pre 8 
Mean Mean Mean Mean Mean Mean Mean 
60 202 198 300 35 207 6.4 
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all patients during the control and study diet periods. The data in 
Figure 12 demonstrates that fasting blood sugars in both study groups 
fell from control values when patients consumed either the high or the 
low sucrose diets. However, a more significant decrease {p < 0.02) in 
serum glucose was observed in patients consuming high sucrose diets. 
The mean control values for this group were approximately 195 mg/dl 
with study diet mean fasting glucoses as low as 160 mg/dl. Decreases 
of this magnitude were not observed in the low sucrose study group. 
The mean postprandial serum glucose levels showed no significant 
changes from the control values. Again, a slight decrease in mean 
postprandial serum glucose was observed in the high sucrose study indi-
viduals. An interesting observation is noted concerning the patients 
consuming the low sucrose diet. Their mean serum postprandial glucose 
showed a small increase from the control values until the fourth week, 
at which time glucose levels were comparable to those observed during 
the control diet period. 
The data in Figure 13 demonstrates the direct relationship be-
tween fasting and postprandial serum glucose levels while consuming 
the different study diets. No significant differences were observed 
between fasting and postprandial mean serum glucose levels at any time 
point for either diet. 
b. 24 Hour Urine Glucose Measurements 
24 hour urine glucose measurements were obtained on all patients 
during the study and Figure 14 summarizes the pertinent data. Since 
many of the patients had markedly different levels of glucose excretion 
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Figure 12: Fasting and postprandial serum glucose levels averaged from 
17 patients consuming high sucrose diets and 13 patients con-
suming low sucrose diets. C represents a control period in 
which patients consumed an intermediate diet consisting of 
120 g of sucrose per day for. 2 weeks. The value represents 
the last 2 measurements from this period. The Wl-w4 values represent the weekly periods of high and Tow sucrose 
dietary consumption after the control period. All weekly 
values are compared to the control period values for that 
particular group. Three values obtained per week with the 
mean and S.E.M. of all patients per group per week are 
represented by each point. 
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Direct relationship between fasting and postprandial serum 
glucose is demonstrated. Control period fasting (F) and 
postprandial (PP) values along with W and W of the 
study diet periods are represented. ~ach po1nt is the 
mean and S.E.M. of weekly glucose values obtained per 
group. The difference between fasting and postprandial 
serum glucose is measured for significance. 
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into the urine, the average of the results from each group did not re-
flect the changes that occurred. In order to obtain the best represen-
tation of the spread in urine glucose excretion, the patient population 
was divided into two groups, those excreting in excess of 15 g of glu-
cose daily (>15g) and those excreting less than 15 g of glucose daily 
{<15g). Results were expressed as the change from the mean urinary 
glucose excretion during the last 5 days of the control diet to the 
particular week of the study. Urine glucose excretion showed little 
change from control values regardless of the study diet in individuals 
who excreted low amounts of glucose in their urine, in contrast to the 
substantial changes observed in those who excreted high amounts of glu-
cose in their urine. When pati~nts began consumption of the low sucrose 
diet an immediate drop in urine glucose from the control values was ob-
served. Patients consuming the high sucrose diet showed little change 
from control values during the first two weeks on the study diet. Both 
groups, however, showed significant decreases in 24 hour urine glucose 
output after 4 weeks. By this time, high sucrose study patients de-
creased their urinary glucose output an average of 10 grams/day 
{p< 0.01) and low sucrose study patients lowered their urinary glucose 
output by approximately 25 grams/day {p = 0.05). 
c. Average Weekly Weights 
An important aspect for this study was the assurance that the dif-
ferent diets administered were kept relatively isocaloric and the 
patients metabolically stable. Large decreases or increases in weight 
can not be tolerated because of the metabolic consequences of weight 
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Figure 14: 24 hour urine glucose levels obtained for both high and low 
sucrose diet study groups. Two subgroups consist of those 
excreting more than or less than 15 grams of glucose per 24 
hours. All values are expressed as changes from the control 
period values which are averaged for the last 5 days before 
the study diet is initiated. All figures represent means 
and S.E.M. for all patients sampled per group per week. 
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changes on hormonal levels and fatty acid metabolism. Figure 15 is a 
graphical representation of patient weight change from the control 
period during the administration of the two study diets. A weight 
change of ±5% was considered tolerable for the study. As observed, 
the mean weight change from control values was insignificant for both 
study groups. 
C. Lipid Levels During High and Low Sucrose Diets Compared Against 
Control Diet (120 gm Sucrose Level). 
Fasting and non-fasting lipid levels were obtained on all of the 
patients studied. Triglycerides, HDL-cholesterol and serum cholesterol 
were measured three times weekly in all test subjects. Results were 
averaged and in all cases were depicted as alterations from the con-
centration obtained during the control period. These results are sum-
marized in Figures 16-21. 
a. Serum Fasting and Non-Fasting Triglyceride Levels 
Blood for fasting serum triglycerides was usually drawn following 
a 12 hour fasting period. The results are shown in Figure 16. Patients 
switched to a high sucrose diet showed a large and rapid increase in 
their fasting triglyceride concentration from control diet levels. 
Within the first two weeks of consuming the high sucrose diet, trigly-
ceride concentration in these patients averaged 65 mg/dl higher than 
their control period values (p <0.01). This increase reached approxi-
mately 70 gm/dl by the third week (p <0.01}. However, patients on the 
low sucrose diet demonstrated minor fluctuations in triglyceride 
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Figure 15: Patient weights were taken daily, averaged weekly per patient 
and combined by study group. Each point represents the mean 
and S.E.M. for all patients per group per time sequence in 
diet. 
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Figure 16: Fasting serum triglycerides measured from both patient popu-
lations. All values are compared to the control period 
value which was designated as the average of the last 3 
measurements during the control (intermediate) diet. Each 
point represents the mean and S.E.M. for all patients per 
group measured during that time sequence. Significance is 
calculated as the difference from the values obtained dur-
ing the control period. Each patient value per week is an 
average of 3 values obtained during that time period of the 
study. 
concentration. The displacement from control diet triglyceride 
values was neither large nor sustained in this group. 
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The results delineated in Figure 17 represent the change in non-
fasting triglycerides fro~ control period levels. Both groups of study 
patients increased their non-fasting triglyceride concentrations by the 
fourth week. However, the patient group consuming the low sucrose diet 
showed the largest jump in triglyceride concentration with an average 
increase of 75 mg/dl over control values by the fourth week {p< 0.01). 
This can be compared to a 20 mg/dl increase over control values in 
patients consuming high sucrose diets. The rise in postprandial tri-
glyceride concentration during low sucrose consumption is almost in-
stantaneous with diet change and~may reflect the type of diet adminis-
tered. This diet contained higher (10%) proportions of fat compared 
with the control diet. 
b. Serum Fasting and Non-Fasting HDL-Cholesterol Levels 
Figures 18 and 19 represent HDL-cholesterol levels during both 
fasting and non-fasting periods respectively. It can be observed in 
Figure 18 that the mean increase in HDL-cholesterol levels is 5 mg/dl 
over control diet values with consumption of low sucrose diets {p = 
0.05). High sucrose diet group patients showed a slight decrease in 
HDL-cholesterol levels during the first two weeks which was not signi-
ficant (p = 0.198). 
Figure 19 illustrates HDL-cholesterol levels obtained during non-
fasting periods. These values were relatively unchanged from control 
values when either study diet was consumed. Non-fasting HDL-cholesterol 
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Figure 17: Non-fasting serum triglycerides measured from both patient 
populations. The description of the graph and the relative 
relationships are the same as described in Figure 17. 
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Figure 18: Fasting serum HDL-cholesterol changes from the control per-
iod values are observed for both groups of patients studied. 
The points represent the mean and S.E.M. values for all 
patients per group measured during each particular time 
sequence. All values are expressed as mean change from the 
control period point which is the mean of the last 3 days 
averaged during the control period. Significance is ex-
pressed as the difference from the control point. 
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Figure 19: Non-fasting serum HDL-cholesterol changes from the control 
period values are observed for both groups of patients 
studied (high and low sucrose). The description of the 
graphical relationships is identical to and found in 
Figure 19. 
levels were found to average 5 mg/dl lower than the fasting values 
observed. 
c. Serum Fasting and Non-Fasting Cholesterol Values 
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The data presented in Figure 20 shows the effect of diet on fast-
ing serum cholesterol levels. A mean decrease of 17 mg/dl in choles-
terol concentration is observed during the second week of the study 
period with consumption of high sucrose diets (p = 0.05). Patients who 
were given the low sucrose diet after the control diet showed no sig-
nificant changes in fasting cholesterol concentrations, although a 
slight increase in serum cholesterol concentrations from the control 
period can be observed during w~eks 2 and 3. 
Figure 21 illustrates the changes in non-fasting serum cholesterol 
levels from control values. Again, patients consuming high sucrose 
diets showed a significant decrease of approximately 10-15 mg/dl in 
serum cholesterol concentrations (p = 0.05) relative to serum values 
when consuming the intermediate control diet. Patients consuming the 
low sucrose diet after the control diet showed no significant change 
during the first two weeks of study diet consumption. However, during 
weeks 3 and 4 a slight decrease in non-fasting cholesterol was observed 
from control values. 
D. Effect of (120 gm) Intermediate (control) Diet on Patient 
Population Subgroups 
Administration of 120 grams of sucrose per day to patients prone 
to hyperlipemia could cause their lipids to increase. The 120 g/day 
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Figure 20: Fasting serum cholesterol changes from the control period 
values are observed for both groups of patients studied. 
Each point represents the mean and S.E.M. for all patients 
per group measured during each time sequence. Significance 
is expressed in the difference from the control period 
value. 
::0 Control 6. Period 
E 
0 
.... 
c 
0 
u 
<l 
20 
-20 
* p=0.05 
SERUM CHOLESTEROL (Non-fasting) 
--... HSD 
o---o LSD 
149 
* 
Figure 21: Non-fasting serum cholesterol levels expressed as changes 
from the control value are observed for both groups of 
patients. The description of the graphical relationships 
and points is identical to Figure 21. 
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value is representative of the average daily sucrose consumption in 
the American diet (11). In order to determine the effects of the con-
trol or intermediate diet on the patient population, two studies were 
done. All patients who were incorporated into the study were monitor-
ed during the control period. Fasting and postprandial blood sugars 
and triglyceride levels were used as measures of the dietary effect of 
120 gm of sucrose on all patients. Patient values were monitored at 
day 0 (entrance into the study) and at day 10 of the control diet. 
Also, six additional patients who were incorporated into the study 
were kept on the control diet for two weeks and then maintained for an 
additional 4 weeks on the same intermediate or control diet as before. 
The results of these two studie$ are presented in Table 5 and Figure 22. 
a. Blood Glucose and Triglyceride Values Compared During the 
Control Period 
Table 5 shows the changes that occur in triglyceride and blood 
sugar levels in fasting and postprandial specimens from day 0 and day 
10 of the control period. Fasting glucose decreased from admission 
values by an average of 18 mg/dl while postprandial serum glucose de-
creased by an average of 10 mg/dl. Fasting triglycerides remained 
fairly constant with a mean decrease of only 20 mg/dl from the ad-
misston values in all patients studied. Postprandial triglycerides 
showed a similar mean drop of 30 mg/dl from admission values. 
TABLE 5 
EFFECTS OF CONTROL DIET (120GM SUCROSE) 
ON PLASMA GLUCOSE AND TRIGLYCERIDE LEVELS 
<ALL SUBJECTS) 
DAY 0 (ADMISSION) DAYlO 
FBS 211 ± 16 193 i 14 
4PM BS 218 ± 19 208 ± 19 
FASTING TG 290 + 31 270 + 21 
4PM TG 378 ± 53 358 ± 26 
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The effects of the control diet given to all subjects before they were 
randomly assigned to the study diets. All values are expressed as mean 
and S.E.M. for all patients (36) studied. Day 0 represents their fast-
. ing admission blood values and day 10 represents that number of days 
consuming the control diet. 
b. Fasting Blood Glucose, Weights, Triglyceride, Cholesterol, 
HDL-Cholesterol and Urine Glucose Results Monitored in 
Control Subgroup 
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Results of basic chemistries obtained from a subgroup of patients 
on the control diet for four weeks are illustrated in Figure 22. All 
routines and protocols were identical to the study diets except no 
dietary changes were incurred after the two week control interval. 
Average weekly weights for this subgroup showed relatively little change 
from the control period weights. This demonstrates that weight loss 
and gain is not a contributing factor for the changes observed while 
consuming the control sucrose diet. 
Fasting serum triglycerid~s for the control subgroup decreased 
when patients were administered the 120 gm sucrose diet for an addi-
tional 4 weeks after the initial 2 weeks. These results parallel those 
of the low sucrose subgroup which showed no change or a decrease in 
triglyceride values compared to control period values. Although a de-
crease was noted in the triglyceride concentration from the control 
during the four additional weeks on the intermediate diet it was not 
significant (p> 0.05). 
Mean cholesterol values showed no significant change from those 
of the initial two week control period when patients were given the 
intermediate diet for four extra weeks. In contrast, HDL-cholesterol 
rose significantly (p< 0.05) with continuation of the control or inter-
mediate diet. A mean rise of 5 mg/dl was observed at week four of the 
study portion of the diet following a steady rise from week 1. Again, 
these changes are comparable to those observed in patients who were 
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Figure 22: The effects of a prolonged intermediate (120g) sucrose con-
trol diet on a patient population subgroup. The composite 
graph represents some of the blood chemistry changes ob-
served in 6 patients who continued the control diet after the 
initial 2 week period. All values, with the exception of 
urine glucose, were determined from fating samples and were 
expressed as changes from the control period. Each point 
represents the mean and S.E.M. of all patients in this sub-
group. 
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consuming the low sucrose diet during the study period. 
As demonstrated in Figure 22, urine glucose decreased slightly. 
The decrease was non-significant when compared to control period 
values (p<0.2), but does reflect the general trend observed when the 
other two study diets were consumed. Fasting blood glucose in these 
control patients showed a drop after week two of the control period 
similar to high and low sucrose study groups. A mean drop of 15 mg/dl 
was observed during weeks 3 and 4 which was not significant (p> 0.1). 
Other values of interest were the insulin and glucagon values 
(data not shown) which did not change appreciably during the 4 weeks 
after the control period. These observations suggest that inter-
mediate sucrose consumption seems~ to have little effect on lipid 
values in non-insulin dependent diabetic hypertriglyceridemic patients. 
Results with this group seem to reflect similar trends observed in 
individuals consuming sucrose restricted diets. 
E. Serum Glucoregulatory Hormone Levels 
The effect of high and low sucrose consumption on the glucoregu-
latory hormones is expressed in Figures 23-26 and Table 6. Insulin re-
sults are expressed as a weekly mean of all patients in each group dur-
ing the control and study diet periods. Glucagon values and insulin/ 
glucagon ratios were determined per group from one dietary period to 
another. 
a. Fasting Serum and Postprandial Insulin Levels 
Figure 23 illustrates the effect of sucrose consumption on serum 
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Figure 23: Fasting insulin concentrations observed during high and low 
sucrose consumption. Each point represents the mean and 
S.E.M. for all patients per group per time sequence studied. 
Significance is measured in difference from the control per-
iod value. Each patient's weekly sample is the average of 
3 samplings throughout the week. 
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insulin following a twelve hour fast. The control values indicate 
that many non-insulin dependent hyperlipemic diabetics are also hyper-
insulinemic (445). This patient population had a mean fasting insulin 
concentration of 23-25 uU/ml, higher than mean normal fasting insulin 
levels of 10-15 uU/ml. Patients consuming the low sucrose diet demon-
strated a consistent decrease in I.R.I. (immunoreactive insulin) levels 
of 5 uU/ml below the control value of 23 uU/ml by the third week of the 
study. However, these values were insignificant compared to the effects 
of high sucrose consumption on fasting serum insulin. Patients on high 
sucrose diets after the control period showed increases in fasting serum 
insulin as high as 11 uU/ml over control levels by the third week of the 
study (p <0.05). 
The effects of sucrose consumption on postprandial insulin levels 
are illustrated in Figure 24. Only weeks 2 and 4 of the study diet are 
illustrated along with the control period. Control period values in 
both groups were similar with mean insulin levels of approximately 50 
uU/ml. A large highly significant increase was observed after two weeks 
of high sucrose consumption with mean values of 75 uU/ml after 2 weeks 
and 80 uU/ml after 4 weeks (P< 0.05). Patients ingesting the low suc-
rose diet showed little change from control period insulin values with 
slight decreases of approximately 5 uU/ml observed during weeks 2 and 4 
of the study diet period. 
Figure 25 combines the results of both fasting and postprandial 
insulin values from the control period with those from weeks 2 and 4 
of the study diets to demonstrate the concept of insulin increments. 
Increments in insulin concentration demonstrate the effect of diet on 
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Figure 24: Postprandial serum insulin during the control period and 2 
and 4 weeks of the study period. H represents the high 
sucrose diet, L represents the low sucrose diet. Signifi-
cance is expressed as differences from the baseline on 
control period. All figures represent means and S.E.M. for 
all the patients measured per group. 
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Figure 25: Fasting and postprandial serum insulin relationships during 
control period and week 2 and week 4 of the study diet 
period. F represents fasting and PP represents postprandial. 
Significance in this figure is determined by the difference 
between the fasting and postprandial insulins within each 
group. Points are determined by mean and S:E.M. of all 
patients per group per time period measured. All patients 
values are expressed as the mean of 3 values taken during 
the week of measurement. 
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insulin release. The significance obtained is the difference be-
tween fasting and postprandial levels of insulin in each group of 
patients during each study period measured. During the control per-
iod, both high and low sucrose study diet groups showed approximately 
a 24 uU/ml increase in insulin levels after a meal. During week 2 of 
the study diet, the patients consuming high sucrose showed a signifi-
cant postprandial increase of almost 50 uU/ml (p< 0.01) as compared 
to approximately 15 uU/ml for patients consuming low sucrose diets 
(p< 0.05). This difference in incremental insulin response between 
high sucrose and low sucrose consumption was maintained through the 
fourth week of the study diets ( p = 0.05). 
b. Fasting Glucagon Levels 
Serum glucagon levels are shown in Figure 26. The results are 
expressed in mean concentration changes from control period values. 
The third week data is not included in this set because several of the 
third week samples were accidentally thawed and an incomplete number 
of results could only be obtained for the high sucrose group. This 
figure shows that fasting glucagon levels fluctuated from control values 
while consuming the low sucrose diets. But at 4 weeks, glucagon values 
were similar to control period levels. No substantial pattern of de-
crease or increase could be ascertained. Serum glucagon values from 
individuals on the high sucrose diet showed a significant decrease from 
control levels. Values dropped by 40 pg/ml during the first two weeks 
(p <0.05). These depressed levels were maintained with 4 week values 
approximately 25 pg/ml less than control diet values. 
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c. Insulin/Glucagon Ratio, High and Low Sucrose Diets 
Insulin and glucagon ratios were calculated for all patients. 
during the control and fourth week of the study diet periods. The 
two study groups were then compared to their control diet values with 
the data summarized in Table 6. 
I/G ratios increased by 30.2% from control values when patients 
consumed a diet rich in sucrose. This increase reflects the large 
rise in fasting insulin concentration and drop in glucagon concentra-
tion observed in this group. A decrease in I/G ratio was observed with 
the low sucrose diet group. This result reflects the smaller decrease 
in insulin concentration and little change in glucagon concentration 
observed in patients on sucrose~restricted diets. 
F. Lipoprotein Levels During Study Diets 
Blood was drawn twice weekly for lipoprotein electrophoresis dur-
ing the control and study diet periods. Each group of patient results 
were averaged with mean values per week of study represented in Figure 
27. All results were compared to control values and significance was 
determined as changes from control levels. 
a. Effect of High and Low Sucrose Dietary Consumption on 
Lipoprotein Levels 
Figure 27 shows circulating lipoprotein changes from control 
values while consuming sucrose enriched or sucrose depleted diets. All 
lipoprotein concentrations were expressed as percentage of total lipo-
protein present. Patients who consumed low sucrose diets demonstrated 
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Figure 26: Fasting serum glucagon values expressed as changes from con-
trol period value. Each point represents the mean and S.E.M. 
of all patients per group per time period studied. Signifi-
cance is expressed as the difference from the control period 
value for each group. The control period value is the 
average of the last 3 measurements during that period before 
patients were switched to a high or low sucrose diet. 
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TABLE 6 
TABLE OF THE RATIO OF INSULIN OVER GLUCAGON 
Change in 1/G ratio 0/o Change 
Experimental Situation due to diet in 1/G 
From To 
Control Period to 
f 39.2 °/o High Sucrose Diet Period 5.1 ± 1.2 7.1 ±1.0 
r------------------- ------------------ --------
Control Period to 
Period 
6.4 ±1.3 5.5±0.4 J. 14.1 °/o 
Low Sucrose Diet 
Insulin to glucagon ratios were calculated from control diet period and 
week 4 of the study diet period values. The percent change expressed 
is that from the control value. The values are the means and S.E.M. of 
all patients from each group for the time period designated. 
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nonsignificant changes in 8, pre 8 or a lipoprotein percentages from 
control levels. The only lipoprotein fractions showing any change 
were pre 8 lipoproteins which dropped slightly, possibly reflecting 
the decreased fasting triglyceride concentration observed in low suc-
rose study group patients (Figure 17). An insignificant increase was 
also noted for a lipoprotein which probably reflects the increase in 
HDL-cholesterol observed with consumption of low sucrose diets (Figure 
19). 
High sucrose study group patients showed highly significant 
changes from control values in all three lipoprotein fractions. The 
8 lipoprotein fraction showed a significant decrease of approximately 
10% from control values (p <0.01). This percentage was maintained 
from the second week of the study diet to the end. This drop in fast-
ing 8 lipoprotein levels most probably represents the decrease in fast-
ing cholesterol observed while consuming high sucrose diets (Figure 21). 
Pre s lipoprotein levels increased significantly, 10% over control 
levels while consuming high sucrose diets (p< 0.01). This increase 
is probably due to the fasting triglyceride increase observed in high 
sucrose patients (Figure 17). Finally, a decrease in a lipoprotein per-
centage was observed after the first week (p = 0.05) on high sucrose 
diets with a rise back to control values by week three. This slight 
decrease could be a reflection of the decrease in HDL-cholesterol ob-
served with increased sucrose consumption (Figure 19). Not surpris-
ingly, when diets with different sucrose content are consumed lipo-
protein pattern changes seem to reflect, in general, blood lipid alter-
ations. 
G. Triglyceride Turnover 
A commonly used method to estimate triglyceride production is 
based on the two assumptions that the decline in radioactivity of 
plasma VLDL triglycerides after pulse injection of a precursor into 
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this pool is essentially monoexponential and the calculated rate con-
stant obtained provides a valid measurement of the turnover rate of 
plasma triglycerides (419). Radioactive labeling of the triglyceride 
precursor glycerol is generally preferred to free fatty acid labeling 
because less recycling of glycerol occurs after pulse injection and 
a greater monoexponentiality in the decay curve is attained. This 
period is presumed to reflect less glycerol returning to the liver 
from hepatic triglyceride catabqlism (recycling). Figures 28 and 29 
represent single patient decay curves where linear regression analysis 
was used to derive patient•s turnover results. Figures 30 and 31 are 
graphs depicting the fractional turnover rates (K values) of the patient 
population plotted against triglyceride concentration. Table 7 demon-
strates changes in total turnover rate relative to the respective study 
diet. Figures 32 and 33 illustrate total turnover rates plotted against 
triglyceride concentration. 
a. Typical Patient Curve 
Figure 28 illustrates the plasma radioactivity plotted semilog-
arithmically against time for one study patient. Two turnovers were 
performed, the first at the end of the control diet period and the 
second after two weeks on either the high or low sucrose study diet. 
A decay curve of the methanol fraction containing polar constituents is 
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Figure 28: Triglyceride radioactivity curves after intravenous injec-
tion of tritiated glycerol in one of the patients who parti-
cipated in triglyceride turnover studies. The open squares 
represent the turnover data collected immediately after the 
control diet period was completed. The closed circles re-
present the curve generated after two weeks on the study 
diet. The open triangles represent the counts found in the 
polar methanol wash after Folsch extraction procedures for 
nonpolar lipids were performed from the sample taken during 
the second turnover procedure. This fraction represents free 
glycerol, labeled free fatty acids and all other labeled 
material other than nonpolar lipid. 
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shown, representing free glycerol and glycerol that has been used to 
manufacture free fatty acids. Removal of the labeled triglycerid~ from 
this patient•s plasma pool was monoexponential for approximately 17 
hours. Figure 28 was not uniformly indicative of all the patients 
studied. In some instances, the monoexponential component only occurred 
between 1-12 hours. With these patients, a slower decay with a de-
creased slope was found to occur 12 hours after the test was initiated. 
This slow decay section of the curve could occur from recycling of the 
glycerol, from the plasma compartment, into new triglyceride or it could 
represent another slow synthetic triglyceride pool. In these cases, the 
portion of the curve with the greatest slope was used to calculate frac-
tional turnover rates. A linear regression analysis was performed on 
this section of the curve and this line was extrapolated back to zero 
since this Y intercept value is considered the maximum radioactive 
incorporation of label into the plasma triglyceride pool. The patient 
represented in Figure 29 is given two pulse injections of glycerol, one 
at the end of the control diet and one two weeks after the initiation of 
the study diet. The Y intercept of 12, 115 disintegration in 20 minutes 
is obtained after the first pulse injection and the intercept at 95% 
disintegrations in 20 minutes is obtained after the second injection two 
weeks later. 
b. Calculation of K Value Turnover 
K values for this patient were determined by estimating the decay 
half life (T 1/2) from the most linear part of the decay curve. This 
patient had T 1/2 values of 8.5 hours and 7 hours for the first turnover 
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Figure 29: Representative plots of first and second turnover determina-
tions in a patient demonstrating a biphasic decay. The slow 
decay component was dropped from the curve and linear re-
gression analysis was performed on the rapid decay portion. 
The best fit lines are extrapolated back to the Y intercept, 
the value considered to be the maximum incorporation of 
labeled glycerol into the plasma triglyceride pool. T l/2 
values are calculated directly from these figures by ob-
serving the time in which half of the total counts are lost. 
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and second turnover procedure respectively. The K values are calculated 
from the relationship 
K = 0.693 
T 1/2 
and for this particular patient were 0.081 hr -1 and 0.099 hr -1 for 
the first and second turnover procedures respectively. 
c. Fractional Turnovers as Plotted Against Triglyceride 
Concentration 
The fractional turnover rates (K value) obtained after consumption 
of the control diet from all patients studied were plotted against serum 
triglyceride values obtained during this same time period (Figure 30). 
A significant relationship betwe,en fractional turnover and triglyceride 
concentration was found with a coefficient of correlation of 0.812 and 
a significance of {p <0.001). It should be emphasized that as fraction-
al turnover rate (K) decreases, triglyceride concentration increases. 
This inverse relationship was seen in all patients studied. 
d. Plasma Total Turnover for Triglyceride Removal 
Total plasma VLDL triglyceride turnover rates were calculated 
from the fractional turnover rate and the plasma VLDL triglyceride 
concentration using the following equation: 
triglyceride turnover= plasma triglycerides {mg/dl) X 
plasma volume (dl/kg) X _1 fractional turnover rate (hr ) 
The relative plasma volume for this population was considered to 
be 0.45 dl/kg {57). This assumption has been validated by Adams and 
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Figure 30: Fractional turnover rates, obtained from decay curves gen-
erated after the control diet period was completed, were 
plotted against triglyceride values in 19 patients. These 
control fractional turnovers were used to construct a line 
which was considered to be representative of the patient 
population studied. This control line was used to assess 
changes in the relationship between fractional turnover 
and triglyceride concentration due to diet. 
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Kissebah (59). Changes in total triglyceride turnover when patients are 
switched from the control diet to the study diet (high and low sucrose) 
are illustrated in Table 7. The values listed in the 11 from 11 column are 
control diet total turnovers calculated from the patients who were 
randomized to either high or low sucrose diets. The 8.0 mg/kg/hr repre-
sents the mean of the control total turnover values from 10 patients 
before they were switched to a high sucrose diet. The total turnover 
value of 9.8 mg/kg/hr represents the mean value of total triglyceride 
turnover before nine other patients were switched from the control diet 
to the low sucrose study diet. When patients consumed high sucrose 
diets after control diets, their ~ean total turnover values in-
creased significantly from a mean value of 8.0 mg/kg/hr to 10.8 
mg/kg/hr (P< 0.01). Low sucrose study patients showed the opposite 
effect with a decrease in total turnover values from 9.8 mg/kg/hr to 
9.2 mg/kg/hr (not significant p=0.2). 
e. Plasma Total Turnover Rates Versus Triglyceride Concentration 
Figure 31 and Figure 32 demonstrate the relationship between 
total triglyceride turnover, which represents total body pool trigly-
ceride turnover and triglyceride concentration. It has been suggest-
ed that the hyperbolic curve relating triglyceride concentration to 
triglyceride turnover is analogous to the relationship between sub-
strate concentration and reaction velocity described by the Michaelis 
Menton equation (418). Figure 31 illustrates the patients who were 
TABLE 7 
TURNOVER RATES FROM 
CONTROL PERIOD TO STUDY PERIOD 
TOTAL TURNOVER 
GROUP VALUES SIGNIFICANCE 
mg/kg-hr 
From To 
l 
High Sucrose Diet S.Q + O.SjiO.S+I.O p <0.01 
i 
I 
Low Sucrose Diet 9.8 ±1.2 19.2-1-0.9 NS j 
Changes in total turnover values from control dietary period 
to study diet. The significance was determined by paired t 
analysis which compared control values with study diet turn-
over values for each individual patient. 
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studied while consuming the control diet. Their control total turn-
over values were plotted against their triglyceride concentration 
during the same period. The results indicate that higher plasma tri-
glyceride concentrations are generally associated with increases in 
triglyceride turnover (r = 0.851, P< 0.001). It can also be seen that 
triglyceride concentration and turnover rates are not linearly related 
throughout the entire range of triglyceride concentration. As total 
turnover rates exceed 12 mg/kg/hr the triglyceride concentrations in-
crease much more rapidly. 
The shape of the curve suggests that the removal rate for plasma 
triglycerides follow the kinetics of a saturable enzyme system. The 
Vmax calculated from this curve is approximately 12.5 mg/kg/hr for this 
patient population. In normal adult populations the Vmax for the 
enzyme system was found to be 30 mg/kg/hr (402). Therefore, this 
patient population demonstrates depressed total turnover rates rela-
tive to normal population studies. The comparison of data from HSD 
and LSD to the normal line represents the metabolic changes in the 
triglyceride removal system that occur when patients are switched 
from the control diet to either study diet. The patients who consumed 
the high sucrose diet demonstrated no change or a slight increase from 
control values. Patients consuming the low sucrose diet showed little 
change from control values when their points where plotted against the 
line generated during the control diet (Figure 32). 
Finally, Figures 33 and 34 demonstrate the change from control 
values that occur in total turnovers when the study diets were con-
sumed. These results were obtained after body weight correction fac-
22 
20 
18 
16 
'-
14 
,s:; 
I l2 01 
.X. 
...... 10 
01 
E 8 
6 
4 
2 
174 
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Figure 31: The relationship between plasma triglyceride total turnover 
and plasma triglyceride concentration in 19 patients after 
the two week control dietary period was completed. The 
line generated represents this patient population consum-
ing a diet of average sucrose content. Vmax was determined 
by the point at which the system demonstrated zero order 
kinetics and was found to be 12.5 mg/kg/hr. 
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tors were determined. Total turnover rates (TO) are increased when 
body weight factors are included. One observation predominates, 
patients who consumed the high sucrose diet demonstrated a slight in-
crease in turnover rate with large TG increases (Figure 33). The 
small TO/ TG ratio may suggest a removal defect predominates in the 
grossly lipemic individual (TG >200). The low sucrose study group 
predominantly showed the opposite effect whenever the changes in turn-
over rate exceeded 3 mg/kg/hr possibly suggesting synthesis stimulates 
remova 1 (Figure 34). 
H. Triglyceride Turnover Kinetic Evaluation of System 
a. Linear Transform of Michaelis Menton System 
Even though an approximation of Vmax is obtained by plotting 
total turnover versus triglyceride concentration (Figure 31). Vmax 
and Km values can be calculated more accurately from a linear trans-
formation of the Michaelis-Menton equation. By this process a plot of 
[S /V] versus [S] is produced (Figure 35). Data reduction in the for-
mat of triglyceride concentration/turnover ( S/V) versus triglyceride 
concentration ([S]) was performed separately for patients consuming 
high sucrose, low sucrose, and control diets. The control group data 
is generated from all patients who consumed the control diet (n=19) 
before being switched to either the high sucrose (n=10) or the low suc-
rose diet (n=9). The three lines generated intercept theY axis at 
approximately the same point. The X intercept of the line generated 
from patients consuming the control diet was found not to be statisti-
cally different from the X intercept of the lines obtained after con-
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Figure 32: The relationship between plasma triglyceride total turnover 
and plasma triglyceride concentration in 10 patients con-
suming high sucrose diets (black circles) and 9 patients 
consuming low sucrose diets (open circles). The line and 
Vmax shown are from Figure 31. The points demonstrate the 
changes that occurred in this relationship due to dietary 
manipulation. 
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Figure 33: Plot of total turnover vs. triglyceride concentration in 
patients who consumed the high sucrose diet. Each line 
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represents one patient whose control and study diet values 
are compared. Most lipemic patients demonstrated large in-
creases in triglyceride concentration with small increases 
in total turnover with the exception of one patient who 
demonstrated the opposite relationship in this overall 
effect (*). These results suggest a possible removal de-
feet. The area designated by the box represents the normal 
patient response area (54). 
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Figure 34: Plot of total turnover vs. triglyceride concentration in 
selected patients who consumed the low sucrose diet. Each 
line represents one patient whose control and study diet 
values are compared. Note the opposite trend in results 
as compared to Figure 33. 
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sumption of the study diets (high and low sucrose). Since the X inter-
cept represents the triglyceride concentration at 1/2 Vmax (Km), this 
suggests the Km for the patients consuming high or low sucrose diets 
remained unchanged from control Km values. Linear regression analysis 
for all groups demonstrated a highly significant correlation of r=0.745, 
p<O.OOl for the control group, r=0.890, p<0.001 for the high sucrose 
group and r=O. 929 with a p < 0. 001 for the 1 ow sucrose study group. 
Figures 36 and 37 represent the results obtained from each group 
after consumption of the control diet compared with the results of the 
same study group after consumption of the study diet (high or low 
sucrose). In these plots, Vmax equals 1/slope and Km equals the X 
intercept or the product of the vertical y intercept and Vmax. The 
slope of the control line in Figure 36 is 0.052 ± 1.5x10-2. There-
fore, the Vmax for the high sucrose group consuming the control diet 
is 19.3 ± 5.76 mg/kg/hr. Though this Vmax value is higher than con-
trol group Vmax from Figure 31 it still reflects a lower than normal 
Vmax for the enzyme system. The higher Vmax calculated above re-
flects a more accurate measurement of Vmax done by this linear method 
of analysis. The Km obtained for the HSD obtained group consuming the 
control diet is approximately 260.7 ± 101.3 mg which is the product of 
the vertical intercept of the line (13.48 ± 3.36) times the Vmax (19.3 
± 5.76 mg/kg/hr). 
Consumption of a sucrose enriched diet after the control diet 
altered [S] and S/V values so that linear regression analysis produced 
-
3 d . 1 a new line with a slope of 0.039 ± 6.5 x 10 an a vert1ca y inter-
cept of 13.17 ± 2.13. The Vmax calculated for the triglyceride trans-
60 r control =0.745 (o --) 
50 
40 
p<O.OOI 
rHSD =0.890 {ll-·-·) 
p < 0.001 
(o---) 
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Figure 35: 
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[S] 
The relationship between [S] and S/V, where [S] is the serum 
triglyceride concentration (mg/dl) and Vis the triglyceride 
turnover rate in mg/kg/hr, produces a linear transform of 
the turnover system. The solid line with open circles repre-
sents all 19 patients whose turnovers were performed 
immediately after the control dietary period had ended. The 
line with the open triangles and line dot configuration was 
generated from the 10 patients who consumed high sucrose and 
the open square dashed line represents the 9 patients who 
consumed the low sucrose diet. Both high and low sucrose 
diet turnover studies were performed after a two week inter-
val in which individuals consumed the appropriate study diet. 
The control turnovers were done in the same patients after a 
two week interval while patients consumed the control diet of 
120 gms of sucrose per day. 
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port system was determined to be 25.6 ± 4.3 mg/kg/hr and the Km 
(calculated as above) was 337.6 ± 78.4 mg. Though slightly higher than 
control values these differences were found to be not statistically 
significant using two tailed t analysis. 
Figure 37 shows the comparison of the triglyceride transport data 
obtained from the low sucrose study group after control and sucrose re-
stricted diets were consumed. The line generated from the turnover data 
after consumption of the control diet had a slope of 5.5 x 10-2 ± 1.54 
x 10-2 with a y intercept of 9.36 ± 4.16. The Vmax obtained from the 
reciprocal of the slope was found to be 18.2 ± 5.1 and the Km for this 
group was determined to be 170.2 ± 89 mg. 
Consumption of the sucros~ depleted diet after the control diet 
produced a new line with a slope of 0.041 ± 7.3 x 10-3 and a y inter-
cept of 13.71 ± 1.8. The Vmax was 24.3 ± 4.3 and the Km of this 
group was determined to be 332.8 ± 73.4. Again no significant dif-
ference in Km and Vmax values could be obtained when the kinetic 
values from the control and low sucrose period were compared. 
The results above indicate that the Vmax for both study groups 
remained relatively unchanged from the Vmax obtained during the control 
period. Both groups demonstrated no change in Km values from the con-
trol group when two tailed t analysis was used. The lack of change in 
Km values when the high sucrose diet was consumed demonstrates an un-
responsiveness of the removal system to increased triglyceride which is 
released into the plasma pool after synthesis in the liver. 
I. Polyacrylamide Gel Electrophoresis and Isoelectric Focusing of 
VLDL Apoproteins 
a. Pattern of apo VLDL on SDS Polyacrylamide Gels 
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Polyacrylamide gel electrophoresis in sodium dodecyl sulfate was 
performed on samples which were obtained from each patient during both 
control and study diet periods. These assays were performed to assess 
the changes in apoprotein composition which occurred from dietary 
changes during the study. A typical pattern from several of the 
patients samples is shown in Figure 38. These patients have a large 
CIII 1 band which is always prevalent in hyperlipemic individuals. The 
CII band is observed as a thin, sharp band which migrates to a position 
above the CIII 1 band. The E banQ is seen as a large diffuse band 
which migrates a short distance into the gel. The B apoprotein, be-
cause of its large size and molecular weight, does not penetrate into 
the gel ·but remains as a large band between the interface of the 
stacking gel and separating gel. The CIII 2 band migrates furthest 
and is observed as a band occupying a position slightly below the 
large CIII 1 band. A typical densitometric pattern usually observed 
from these VLDL samples is diagrammed in Figure 39. Reading this 
pattern from left to right corresponds to the bottom and the top of 
the gel respectively. Again the typical apoprotein pattern of a 
hyperlipemic individual is observed. All apoprotein fractions from 
the VLDL sample are expressed as the percent of total soluble ape-
protein present. 
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Figure 36: Plot of triglyceride concentration/turnover ([S]/V) versus 
triglyceride concentration ([S]) done separately for the 
group of patients who were randomized to high sucrose diets 
after control sucrose diets were consumed. Ten patients were 
studied in this group. r value for control equals 0.685 
with a p< 0.01. The r value for the line generated after 
high sucrose consumption equals 0.890 with a p < 0.001. 
60 
50 
40 
[S] 30 
-v-
20 
10 
Control vs. LSD 
•--- Control 
o- Low Sucrose 
Figure 37: Plot of triglyceride concentration/turnover ([S]/V} versus 
triglyceride concentration ([S]} done separately for the 
group of patients who were randomized to low sucrose diets 
after control sucrose diets were consumed. Nine patients 
were studied in the group. The r value for the control 
equals 0.651 with a p <0.01 and the r value for the line 
generated after the low sucrose diet was consumed equals 
0.929 with a p < 0.001. 
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Figure 38: SDS polyacrylamide gel electrophoresis of VLDL apoprotein 
derived from ten of the patients who participated in the 
study. Ten percent polyacrylamide separating gel with 2.5% 
stacking gels were used. Two hundred ug of protein was 
added to each gel and electrophoresed for approximately 8 
hours at 2.5 rnA per tube. Gels were stained with a solu-
tion containing 1 ~ Amido Schwarz in acetic acid. 
b. Soluble Apoprotein Percentages Observed in This Patient 
Population 
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Data from 20 study patients listing the composition of the ape-
protein fractions present at the time of entry into the study is seen 
in Table 8. The mean values of these fractions can be compared with a 
table of apoprotein fractions from normal individuals in Table 9. It 
should be observed that the greatest differences between the two groups 
of patients is that hyperlipemic individuals demonstrate a large in-
crease in the apo CIII1 fraction and a noticeable decrease in the apo 
E component relative to the normal patient population. 
c. Isoelectric Focusing Patterns Observed for Apo VLDL 
Isoelectric focusing in 7.5% polyacrylamide gels through a pH 
gradient of 4-8 was performed on all samples obtained for VLDL ape-
protein determination. The major advantage of isoelectric focusing 
on apoprotein samples is the separation of isoprotein subunits of the 
apo E fractions. Figure 40 is a print of isoelectric patterns from 
several of the patients who were incorporated into the study. The apo 
E fraction can be divided into 3 isoprotein subunits. The E1 isopro-
tein band migrates roughly to the midpoint of the gel and has an iso-
electric point of approximately 5.31. The band is diffuse and is com-
posed of several minor subfractions. Apo EII migrates to approximately 
the same position in the gel, but is found slightly above apo E1. Its 
isoelectric pH is 5.39. Apo EIII, the heaviest staining band, migrates 
the shortest distance into the gel with an isoelectric point of 5.44. 
The densitometric pattern of one of these gels is shown in Figure 41. 
Apo C proteins are the most acidic and migrate to an isoelectric point 
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Figure 39: Typical densitometric scan of SDS polyacrylamide gel electro-
phoresis of VLDL apoprotein derived from hypertriglyceridemic 
patient. A Gelman, Model #ACD-18 was used to produce the scan 
represented. 
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TABLE 8 
SOLUBLE APOPROTEINS AS PERCENT OF 
TOTAL SOLUBLE APOPROTEIN 
APO E APO CII APO CIII 
21.5 16.3 51.0 
19.4 20.6 37.2 
29.8 20.7 31.9 
10.1 13.4 55.3 
13.6 27.7 27.6 
25.7 18.2 44.7 
22.2 28.1 25.3 
30.7 22.0 29.4 
20.3 12.0 41.6 
23.3 17.3 37.5 
25.3 14:4 47.5 
20.9 15.8 45.0 
24.4 21.4 23.3 
22.6 27.3 21.6 
23.0 18.8 32.7 
36.3 19.8 31.3 
23.4 8.5 45.3 
16.8 8.7 48.2 
28.6 15.3 25.9 
37.8 17.9 18.5 
23.8 18.2 36.0 
f,5 1.2 2.4 
APO CII 12 
11.3 
22.4 
17.5 
21.2 
28.2 
11.4 
20.3 
17.9 
26.0 
22.0 
12.8 
17.9 
28.9 
28.5 
25.4 
12.6 
9.5 
26.3 
30.2 
25.5 
20.8 
1.5 
Table of soluble apoproteins represented as percent of total 
soluble apoprotein present in 20 of the patients who parti-
188 
cipated in the study. Values were obtained at time of patient 
incorporation into the study. 
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TABLE 9 
Table 2. Distribution of Cholesterol in Lipoproteins 
No. R .. auve distribution, A.baofute distribution, • 
In % of total (and SEM) mg/L serum (and SEM) 
Group group U9 VLDL IDL LDL HDL VLDL IDL LDL HDL 
Control 17 12/5 6 (1) 1 (0.3) 65 (2) 27 (2) 130(20) 30 (10) 1350 (90) 570 (50) 
Diabetic 25 10/15 10(3) 4(1) 64 (2) 22 (2)" 250 (120) 90 (30) 1550 (100) 530 (50) 
Normolipidemic 15 7/8 7 (1) 4(7) 63 (2) 26 (1) 140 (20) 80 (10) 1310 (70) 580 (40) 
f VLDL 6C 2/4 16 (4)" 4(1) 60 (3) 20 (8) 480 (120)" 110 (40) 0 1760 (260) 590 (200) 
t LDL 7C 2/5 13 (3) 3 (1) 71 (4)" 13 (2) 0 410 (100) 100 (20)" 2210 (110)d 400 (60)• 
• Recovery of cholesterol in the ultracentrifugal fractions was 78-91% of the serum value; the absolute distribution as based on the relative distribution 1n the 
ultracentritugal tractions, corrected to 100% recovery (disregarding chylormcrons). 
tt Differs from control value, p <0.02. 
c See Table 1. 
dQiffers from control value, p <0.001. 
Table 3. Apoprotein Composition of Soluble VLDL Protein, in Percent (±SEM) 
Group (no.) (1)• Cl E en 
Control (12) 5.2 (0.8) 10.6 (1.7) 32.4 (3.1) 11.4 ( 1.1) 
Diabetic (27) 3.7 (0.7) 11.0 (1.4) 28.1 (2.1) 14.3 (0.8)c 
Normolipidemic 3.8 (0.9) 13.1 (1.8) 28.6 (2.9) 13.4 (1.1) 
(14) 
f VLDL (6)d 3.6 (1) 8.7 (2.2) 24.7 (3.8) 15.2 (1.9) 
f LDL (7) 1 3.6 (0.7) 6.5 (1.2) 31.5 (3.8) 16.5 (1.2) 8 
• Band 1 on the electrophOretic qel. near the ongin; ldentity not determined. 
0 Includes AI, All, and one Wlidentified band mov•ng between All and CU. 
Clll1 
18.2 (1.9) 
24.4 (1.9)C 
21.9 (5.8) 
29.2 (4.5)• 
23.4(2.1) 
c Analysis of variance: difference between diabetics and controls significant at p <0.025. 
em• Minor components 111 
15.8 (1.5) 6.1 (1.8) 
17.9.(0.9\ <JC 
17.5 (1.5) 
18.6 (0.9) 
18.4 (1.2) 
CII/CIII, 
0.65 (0.04) 
0.66 (0.2) 
0.68 (0.06) 
0.56 (0.06\ 8 
0.71 (0.04) 
d Includes ttvee subrects with 1ncrease 10 VLOL (phenotype IV) and three subjects with increase in both VLOL and LOL (phenotype 118). Thera was no difference 
observed between these two subgroups. 
• Within analySIS of variance. differs from control with p <O.OS. 
1 Phenotype IIA. 
Distribution of cholesterol in lipoproteins and apoprotein com-
position in percent of soluble VLDL protein in percent from a 
normal control, diabetic, and normolipemic population as reported 
from reference #63. The apoprotein percent composition from these 
three groups should be used for comparison with the VLDL apoprotein 
composition of the hyperlipemic patients participating in the sue-
rose study. 
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of approximately 4.3. The most basic protein observed is apo c1 which 
has an isoelectric point between pH 6.0 and 6.5. The isoelectric 
gradient which was generated during each electrophoresis is seen in 
Figure 41. The pH range was between 3.5 and 8.0. 
d. Changes Observed in Apo VLDL as a Result of Different Sucrose 
Diets 
The composition of apoprotein subunits in VLDL lipoproteins were 
compared between control diet and study diet periods in all patients who 
participated in the study. Samples were obtained three times weekly 
during both the control and study diet periods. The different VLDL 
apoprotein concentrations found i~ patients consuming the high or low 
sucrose diets as compared to the control diet are illustrated in Figure 
42. All apoprotein concentrations are represented as the percent (%) 
of total peptide present. This includes total apo E and all apo C pro-
teins, but the apo B protein, because of its size, does not penetrate 
the gel and is considered an insoluble apoprotein. Total apo E does 
not change significantly in these hyperlipemic patients from the con-
trol dietary period to either the high or low sucrose dietary period 
(Figure 42). Apo CII also remained stable throughout the study with 
no significant changes observed between control and study diet periods. 
Significant changes were observed in the apo CIII1 and apo 
CIII 2 protein fractions of the VLDL lipoprotein during the study. The 
apo CIII 1 fraction increased significantly in patients consuming the 
high sucrose diet, from a control value of 34% to almost 47% of total 
soluble peptide present. This increase was statistically significant 
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Fiaure 40: Isoelectrically focused gels of VLDL apoproteins derived from 
9 of the patients who participated in the study. 7.5% poly-
acrylamide separating gels were used and samples were 
electrophoresed and stained as described in Materials and 
~1ethods. 
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Figure 41: Typical densitometric scan of an isoelectrically focused gel 
containing apo VLDL derived from a hypertriglyceridemic 
patient. Gelman Model #ACD-18 was used for scanning and peak 
integration of samples. 
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(p<0.05 using paired t analysis). The apo CIII1 fraction decreased 
from the control period values in patients consuming the low sucrose 
diets. However, this decrease was not significant. In general, the 
apo CIII2 fraction changed in an opposite fashion relative to changes 
observed for the apo CIII 1 fraction with consumption of both study 
diets. Specifically, the apo CIII 2 fraction decreased slightly from 
the control diet concentrations with consumption of the high sucrose 
diet (nonsignificant, p <0.02). However, apo CIII2 fraction increased 
significantly when patients consumed the low sucrose diet, from a con-
trol value of approximately 20% of the total apoprotein to a study diet 
value of 28% of total apoprotein {p=0.05). 
In summary, nonsignificant ~hanges were observed in total apo E 
and apo CII concentrations from control values when patients consumed 
either high or low sucrose diets. Apo CIII 1 and CIII2 showed the 
most significant changes observed. Apo CIII 1 increased significantly 
from control values when patients consumed a diet rich in sucrose. In 
contrast, apo CIII 2 increased significantly from control values when 
low sucrose diets were consumed. 
Data generated from the isoelectric focusing measurements indi-
cated relevant changes that occurred in the concentration of the apo E 
isoprotein subfractions with consumption of different sucrose study 
diets. Figure 43 graphically demonstrates changes in these subfractions 
-from control diet values when diets rich in sucrose or low in sucrose 
were consumed. Minor changes from control values were realized in apo 
El and apo E2 isoprotein concentrations when either high sucrose or 
low sucrose diets were consumed (nonsignificant p > 0.30). The apo EIII 
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Figure 42: Effect of different sucrose content diets on apoprotein com-
position of VLDL. Group II high sucrose n = 17. Group III 
low sucrose n = 13. Group I control n = 30. Results 
represent soluble peptide in the apoprotein as percent of 
total soluble peptide present. Values represent mean ± 
S.E.M. of all patients per group. 
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isoprotein subspecies showed a significant increase from control values 
when patients consumed high sucrose diets (p <0.05). Patients consuming 
sucrose restricted diets had relatively unaltered apo EIII levels from 
control period values. 
e. Correlations Between Apoprotein Subfractions and Triglyceride 
Concentrations 
The importance of alterations in apoprotein content of the VLDL is 
demonstrated in Figures 44 through 48. These illustrate the relation-
ship between apoprotein content and triglyceride concentration observed 
in study patients. All of the correlation studies performed were done 
during the last week of the study diet for both high and low sucrose 
groups. Figure 44 illustrates the relationship between the percen-
tage of apo CIII 1 observed and the triglyceride concentration 
measured in all patients consuming high sucrose diets. The correla-
tion was significant (r=0.723 and P< 0.001). Figure 45 also demon-
strates this same relationship in all patients who consumed low sucrose 
diets. The correlation was again highly significant (r=0.823, 
p< 0.001). From Figures 44 and 45, it is observed that as apo CIII 1 
protein percentages increased, triglyceride concentration also in-
creased. Patients who had apo CIII 1 concentration composing 50% or 
more of their soluble apoproteins present had triglyceride concentra-
tions sometimes as high as 400 to 600 mg/dl. Thus, in these patients, 
apo CIII 1 levels correlate directly to triglyceride concentration. 
The relationship between apo CII/CIII 1 ratios and triglyceride 
concentration is illustrated in Figures 46 and 47. In both groups of 
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Figure 43: Changes in each apo E isoprotein subunit as a result of 
dietary manipulation. Values from all patients in a parti-
cular study group while consuming the control diet are com-
pared to values from these same patients while consuming 
either high or low sucrose content diets. C represents the 
control diet and S represents the period of either high or 
low sucrose intake. 
197 
patients the ratio of apo CII/CIII 1 had an effect on triglyceride con-
centrations. As the apo CII/CIII 1 ratio increased, triglyceride co~­
centrations decreased. A significant correlation was observed in apo 
CII/CIII 1 ratios and triglyceride concentrations in patients who con-
sumed high sucrose diets (r=0.682, a p< 0.001). Patients who consumed 
the sucrose restricted diet also demonstrated a strongly significant 
correlation between apo CII/CIII 1 ratios and triglyceride concentra-
tions (r=-0.871 and a p<0.001). 
Finally, the relationship between apo CIII 2/CIII 1 and trigly-
ceride concentration in the high sucrose patient population is observed 
in Figure 48. The low sucrose population demonstrated a similar re-
lationship. It should be observe,d that the negative correlation be-
tween apo CIII2/CIII 1 and triglyceride concentrations was signifi-
cant (r = -0.60 and a p = 0.05). When triglyceride concentrations 
were elevated apo CIII 2/CIII 1 ratios were depressed. Patients with 
apo CIII 2/CIII 1 ratios of 0.25 or less had triglyceride concentra-
tions of 350 mg/dl or more. Similarly, those patients with ratios 
of 1.25 or greater had triglyceride concentration of 150 mg/dl or 
less. 
In summary, the above results show that apoprotein concentra-
tions, especially apo CII, CIII 1 and CIII 2 had significant effects 
on triglyceride levels in this population of patients . As apo CIII 1 
increased, triglyceride concentration also increased. Apo CII/CIII 1 
ratios and triglyceride concentrations were inversely related. With 
more apo CII present relative to apo CIII 1, lower plasma triglyceride 
concentrations were observed in the study group. In addition, a similar 
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Figure 44: The effect of apo CIII 1 in VLDL on plasma triglyceride con-
centration in 17 patients on the high sucrose diet. A sig-
nificant positive correlation was found (r=0.723, p<0.001). 
These values were generated from patients during the final 
week of the high sucrose diet. 
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Figure 45: The effect of apo CIII 1 in VLDL on plasma triglyceride con-
centration in 13 patients on the low sucrose diet. A sig-
nificant positive correlation is observed (r=0.823, 
p < 0.001). These values are taken from patients in the final 
week of the study after being randomized to the low sucrose 
diet. 
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relationship was observed between apo CIII 2/CIII 1 ratios and trigly-
ceride concentrations in this patient population. With more apo C~II 2 
present relative to apo CIII1, triglyceride concentrations found in 
individual patients were decreased. 
J. Abnormal VLDL Found in Several Patients Participating in the 
Sucrose Study 
a. Observations of VLDL Lipoprotein Electrophoresis 
A particularly interesting observation was found in 4 patients 
who consumed sucrose enriched diets. While the lipoprotein electro-
phoresis measurements were done during both control and study diet 
periods, it was noticed that thes~ patients demonstrated a variable 
hyperlipemic electrophoretic pattern. This pattern could be classi-
fied as type IV while they were consuming the control diet, but 
changed to a type III hyperlipemic pattern when they consumed the 
high content sucrose diets. A sequential electrophoretic pattern from 
one of these patients is illustrated in Figure 49. The relatively 
large pre Sband associated with type IV hyperlipemic individuals 
gradually disappears during the study diet and is incorporated into 
the S band. This pattern is characteristic of an individual with type 
III hyperlipemia having the broad band pattern. 
b. Isoelectric Focusing on Abnormal VLDL Lipoproteins 
Since the possibility existed that these patients could have a 
VLDL different in composition from the rest of the high sucrose patient 
population, their apoprotein electrophoresis results were compared to 
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Figure 46: The apo CII/CIII 1 ratio and its effect on plasma trigly-
ceride concentration in 17 patients who consumed high sue-
rose diets. A significant negative correlation was ob-
tained (r= -0.6817, P<0.001). These values were obtained 
after patients had consumed the high sucrose study diet 
for a 4 week period. 
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Figure 47: The apo CII/CIII1 ratio and its effect on plasma trigly-
ceride concentration in 13 patients who consumed the low 
sucrose diet. A significant negative correlation was 
obtained (r= -0.871 and a p <0.001). These values were 
obtained after patients had consumed the low sucrose 
study diet for a period of 4 weeks. 
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Figure 48: The apo CIII 2/CIII 1 ratio and its effect on plasma tri-
glyceride concentration in patients who consumed the high 
.. 
sucrose diet. A significant negative correlation was ob-
tained (r= -0.600 with a p = 0.05). These values were 
obtained after patients had consumed the high sucrose 
study diet for a period of 4 weeks. Eleven patients were 
used to obtain the results shown. Similar results were 
obtained from patients who consumed the low sucrose study 
diet for the 4 week period. 
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that from the remaining high sucrose patient population. No appreci-
able differences could be found in the SDS PAGE patterns from the 
designated abnormal VLDL subgroup and the rest of the patient popula-
tion. Comparison of the patterns obtained from isoelectric focusing 
procedures on abnormal VLDL and the VLDL from other patients consum-
ing high sucrose diets illustrated an interesting difference. A 
typical isoelectrically focused gel containing the VLDL from a hyper-
lipemic individual consuming the high sucrose diet is shown in Figure 
50. Particular attention must be paid to the apo E isoprotein pattern 
of this patient. The typical apo E pattern with the most acidic apo 
E1 being a diffuse band, and two thick apo Ell and apo EIII bands is 
observed. Figure 50 also repres~nts the isoelectrically focused VLDL 
from the 4 patients in question. Again observe the apo E isoprotein 
pattern. The diffuse apo E1 band is present and the apo Ell band is 
directly above. However, no apo EIII band can be observed in these 
patients. Several repeat electrophoreses were performed on these 
patients with the same apo E isoprotein pattern observed. It is 
possible that the loss of this particular apo E isoprotein band could 
be responsible for the differing pattern observed in these 4 patients 
during lipoprotein electrophoresis. 
K. The Effect of Variable Sucrose Content Diets on Platelet 
Aggregation 
a. Effects of Sucrose Content on Total Platelet Aggregation 
The possibility that variable sucrose content diets could also 
affect platelet aggregation was studied in all the patients who parti-
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High Sucrose Diet 
Control Period ----+Study Diet Period 
Fiaure 49: Typical lipoprotein electrophoretic pattern obtained from 
VLDL abnormal individual during the control and study diet 
period. Observe how the pre- B band seems to migrate a 1 ong 
with the B band after high sucrose dietary consumption. 
This pattern was found in 4 individuals who consumed the 
high sucrose diet. 
, 
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cipated in the project. Platelet aggregation measurements were done 
once a week during both control and study diet periods. The aggrega-
tions done during the control period were compared to those done dur-
ing either high or low sucrose consumption. In this way, changes in 
platelet aggregation due specifically to diet could be ascertained. 
Figure 51 shows the effect of high sucrose dietary consumption on 
platelet aggregation. Data from 4 representative patients from the 
high sucrose study group are shown. All results are represented as 
percent light transmittance through the mixing cuvette, where more light 
is transmitted when more platelets have aggregated. In all patients 
consuming the high sucrose diet illustrated in Figure 51, an increase 
in aggregation occurred over th~ control aggregation values. In some 
cases the increase was as high as 55 units on the percent transmission 
scale. In other cases, the increase observed was slight, consisting 
of only 10% units. However, in all cases, an increase in platelet 
aggregation was realized. Figure 52 illustrates the effect of low 
sucrose diets on platelet aggregation using data from 3 representative 
patients. All the patients shown in Figure 52 demonstrated a slight 
decrease in aggregation while consuming the low sucrose study diet as 
compared to the control diet. However, relatively little change from 
control diet values was observed in many of the patients who consumed 
the low sucrose diet and these patterns far outnumbered patient data 
demonstrating a slight decrease. 
The overall effect of sucrose content in diets on platelet aggre-
gation is shown in Figure 53. The figure represents measurements done 
on 30 patients, 17 consuming high sucrose diets and 13 consuming low 
207 
N 
Fi gure 50: Isoelectrically focused samples of VLDL from patients who 
consumed the high sucrose diet and demonstrated a shift in 
their lipoprotein pattern from type IV to type III. This 
VLDL designated VLDL abnormal (VLDL abn) was found in only 
4 of the patients studied. Observe the apo E isoprotein 
pattern as compared to the normal. No apo EIII band exists 
in the VLDL of these 4 patients. These samples were ob-
tained at the end of the high sucrose dietary period. Gel 
preparation and focusing procedure done as described in 
Materials and Methods. 
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Fig ure 51: Platelet aggregation curves from 4 patients who consumed the 
high sucrose diet after consumption of the control diet. 
Each patient is designated by number. The dark line repre-
sents that patient•s total aggregation at the end of the 
control period. The light line represents that patient•s 
aggregation at the end of the high sucrose study diet. 
Aggregation results are represented as % light trans-
mitted through the measuring cuvette. 
209 
sucrose diets. Each group is an average of the platelet aggregations 
obtained while consuming the study diet as compared to that groups• 
average aggregation while consuming the control diet. A slight, but 
insignificant decrease in total aggregation was observed from control 
aggregation values in the patient group consuming the low sucrose diet. 
However, in patients consuming the high sucrose diet, a significant in-
crease in average aggregation was observed over the control platelet 
aggregations. The patients who consumed high sucrose diets had mean 
control aggregation values of approximately 50% which increased to 65% 
light transmitted after high sucrose consumption. This 15% increase 
in light transmission was significant (p <0.05). 
b. Platelet Sensitivity Studies 
Platelet sensitivity studies were also done in both study groups 
by varying the concentration of the aggregating agent, epinephrine. 
Seven patients from each group had 30 cc of blood drawn. Appropriate 
plasma dilutions with platelet rich and platelet poor plasma were made 
to obtain enough samples to perform 20 aggregations per study. The 
platelet sensitivity assays were performed during both control and 
study diet periods. Each patient's platelet sensitivity results during 
the study diet were compared to the results obtained when the same 
patient consumed the control diet. The concentration of aggregating 
agent at which the second phase platelet response disappeared was con-
sidered to be the lowest concentration of aggregating agents at which 
the platelets could adequately respond. 
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Time in Minutes 
Fi gu re 52: Platelet aggregation curves from 3 patients who consumed low 
sucrose diets after consumption of the control diet. Each 
patient is designated by number. The dark line represents 
that patient 1 S total aggregation at the end of the control 
period. The light line represents that patient 1 s aggrega-
tion at the end of the sucrose dietary period. Aggregation 
is measured in % light transmittance through the measuring 
cuvette. 
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Figure 53: The effects of dietary sucrose on platelet aggregation in 30 
patients: 17 consuming high sucrose and 13 consuming low 
sucrose diets. Each group consuming either study diet is 
compared with itself after consumption of the control sucrose 
diet. C represents the mean SEM aggregations of all patients 
from the study group after consumption of the control diet. 
HSD and LSD represent the mean SEM aggregations after con-
sumption of the high and low sucrose diet respectively. 
Significance (*) is at the p< 0.05 level. 
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The platelets of patients consuming the low sucrose diet showed 
little change in sensitivity when compared to the control diet values. 
However, the patients who were placed in the high sucrose regimen after 
the control period demonstrated an increased sensitivity to the aggre-
gating agent as compared to the control diet. Table 9 illustrates the 
effect of sucrose enriched diets on platelet sensitivity. Platelets of 
all patients consuming sucrose-enriched diets were more sensitive to the 
aggregating agent. In some cases, concentrations of epinephrine as low 
as 0.25 and 0.1 uM elicited the second phase response. The concentra-
tion of aggregating agent that elicits the second phase response in a 
normal population is between 2.5 and 5 uM. 
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TABLE 10 
PlATELET SENSITIVITY WITH VARYING CoNCENTRATICl'lS OF EPINEPHRINE C VS,S 
_so_ 10 _5_ ..1..5_ _lj)_ 0.5 0.25 0.1 ..EL 
c 51 31 51 22 NS 
Ls 75 70 69 62 ff) 16 NS 
c 66 68 63 9l 20 NS 
2.s 57 53 58 51 49 28 15 NS 
c 70 68 69 63 66 23 NS 
3.s 71 74 67 75 64 63 14 NS 
c 22 23 NS 
4.s 58 54 54 40 24 NS 
5.c 55 56 49 42 NS 
s 66 56 40 41 32 NS 
c 71 69 70 67 28 NS 
6.s 63 66 66 61 72 63 65 24 
c 56 56 53 52 42 25 NS 
7.s 70 72 69 61 62 61 19 NS 
Platelet sensitivity in 7 patients who consumed the high sucrose 
study diet after consumption of the control sucrose diet. C 
represents the sensitivity results at the end of the control 
diet period. S represents the sensitivity results at the end of 
the study diet period. Results are expressed as the % light 
transmittance through the cuvette after 5 minutes of incubation 
with aggregating agent. The effect of the aggregating agent is 
considered non-significant (NS) if no second phase response is 
initiated after addition of aggregating agent. 
6. DISCUSSION AND SIGNIFICANCE 
This study sought to ascertain the metabolic consequences of high 
carbohydrate diets in diabetics with hypertriglyceridemia. This was 
initially prompted by the observations of Anderson et al. (10) as to 
the effect of carbohydrate restriction and high carbohydrate diets in 
men with chemical diabetes. The clinical relevance of this question 
was underscored in 1979 when the American Diabetes Association (ADA) 
released its new dietary guidelines for diabetics. The ADA recommended 
allowances for carbohydrate intake be increased to 50 or 60% of the 
total calories consumed in contrast to 40% as recommended only a few 
years earlier (6}. Reduction of dietary fat was the main objective of 
these proposed changes since excess fat was presumed to be the patho-
genic factor in accelerated arteriosclerosis observed in diabetics. 
In a recent editorial, Reaven states that 11 although it is common-
ly considered to be a temporary phenomenon, the transient nature of 
carbohydrate induced increases in triglyceride levels is not supported 
by a great deal of experimental data 11 (102). Reaven succinctly re-
viewed the incidence of favorable and unfavorable effects of high car-
bohydrate diets and concluded that most of the reported studies dealt 
with normal well controlled diabetics and treated type I or type II 
diabetics on high fiber diets (102). He felt the need of a study with 
"diets .•• similar in all but proportion of carbohydrate and con-
sisting of food stuffs that patients will be able to tolerate chroni-
cally". He particularly expressed concern for the effect of high carbo-
hydrate diets on hypertriglyceridemic, non-insulin dependent diabetics. 
The need to know the advantages, if any, of a truly sucrose 
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restricted diet in the treatment of the 85% of diabetics having type 
II (non-insulin dependent) diabetes, a form of the disease in whic~ a 
third of the patient population is hypertriglyceridemic, is of great 
importance. It is also important to ascertain critical levels of 
dietary sucrose at which glycemic control and triglyceride metabolism 
may become altered in these patients. 
Our experimental protocol specifically focused on sucrose in-
gestion in the above group. Sucrose is the least studied component 
in diabetes, yet is the largest chemically homogenous component in the 
regular diet (11). Sucrose intake amounts to 40 to 60% of dietary 
carbohydrate in the non-diabetic population of industrialized countries 
(11). Since a great proportion ;Of processed foods have variable but 
large proportions of added sucrose not reported or quantitated (137), 
the increased consumption of processed carbohydrate containing food-
stuffs by the diabetic population predisposes these patients to in-
creased sucrose ingestion. 
As discussed in the literature review, most reports dealing with 
the effects of sucrose on a given population used artificial diets, 
either composed of liquid nutrients or extremely high in carbohydrate 
proportion. Albrink and Newman (38) found that high and low fiber 
diets also affected insulin and glucose responses to a meal rich in 
carbohydrate. In this study, the diets were composed of natural 
nutrients which closely mimic the intake pattern and fiber content of 
a normal outpatient diet. 
Initial experiments were concerned with the specific effects of 
sucrose enriched or sucrose restricted diets on relevant blood chemistry 
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parameters of the diabetic patient. The effects of different sucrose 
content diets on levels of serum glucose, urinary glucose, trigly~ 
ceride, cholesterol, HDL-cholesterol, and patterns of lipoprotein 
electrophoresis are summarized in Table 11. Specific effects of 
dietary sucrose content are represented since each patient's results, 
while consuming either low or high sucrose diets, are compared to the 
results obtained when the same patient ingested the control sucrose 
diet. Basically (and intentionally), sucrose content is the only para-
meter of the diet that changes significantly. 
Surprisingly, alteration of dietary sucrose levels had essential-
ly no effect on serum or urine glucose levels (Figures 13 and 15). 
These results are in contrast to the findings of Reiser (40), Cohen 
(26), and Akgun (31) who state that increased sucrose ingestion causes 
a rise in blood serum glucose levels in normals and diabetics. Reiser 
(40) found that high sucrose diets caused an increase in mean glucose 
levels compared to low sucrose intake in non-diabetic subjects. Cohen 
(26) administered high and low sucrose diets with subsequent testing of 
glucose tolerance. He found impaired glucose tolerance after high 
sucrose consumption and suggested that because sucrose consisted of one 
half glucose, its ability to stimulate insulin release was also halved. 
Akgun (31) also found plasma glucose levels were lower when sorbitol or 
fructose was ingested, but when sucrose content in the diet was in-
creased, plasma glucose levels rose. He could not find any link be-
tween plasma glucose levels and insulin response. 
The results of the other studies discussed above are question-
able, since in many cases other dietary factors which could effect 
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TABLE 11 
HIGH SUCROSE DIET LOW SUCROSE DIET 
:Triglyceride AM + p < 0. 001 No Change 
P~1 NS + p ( 0. 001 + 
HDL-Cho1esterol AM - NS + p ~ 0. 005 
PM No Change No Change 
Cho 1 estero 1 AM p=O.OS No Change 
PM - p=0.05 - NS 
Serum G1 ucose AM - p ( 0. 02 - NS 
PM 
-
NS - NS 
Urine No Change p c::O.Ol No Change -p=O.OS 
Glucose Low Spiller High Spiller Low Spiller High Spiller 
a Lipo 
-
NS + NS 
a Lipo - p < 0. 01 No Change 
. Pre a 1 i po + p ( 0. 01 - NS 
Summary of the effects of different sucrose diets on blood and 
urine chemistries in the patient population, (+) designates an 
increase in values, (-) designates a decrease. NS signifies no 
significant change observed. Significant changes demonstrated 
by p value. AM values signify the fasting state, PM values 
represent the postprandial state. 
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plasma glucose concentrations were ignored. The studies of both Akgun 
(31) and Reiser (40) utilized sucrose diets which were artificial ~nd 
not consistent with normal dietary intake patterns. In both studies, 
sucrose solutions were given and no dietary fiber content considera-
tions were made. Dietary fiber has been clearly documented as having 
favorable effects on postprandial glucose concentrations in normal and 
non-insulin dependent diabetic subjects (460, 461). When sugar and 
pectin were incorporated into a large breakfast, postprandial glucose 
levels were significantly reduced as compared to the same individual 
eating fiber free meals containing similar nutrients. When patients 
with mild diabetes were given a water soluble fiber along with an 
oral glucose tolerance test solu~ion, postprandial glucose concentra-
tions were significantly lower compared to similar test solutions 
without fiber. Other investigators (15) have confirmed the short 
term beneficial effects of fiber supplements on glucose and meal 
tolerance tests. Others have demonstrated long term improvement in 
glucose tolerance or metabolism with fiber supplemented diets (462, 
463). The extent to which plant fiber induces carbohydrate malab-
sorption has not been quantitated. The total absorption of simple 
sugars ingested with soluble fibers does not appear to be diminished, 
but the hydrolysis and absorption of complex carbohydrates may be de-
creased. With high fiber diets, fasting and average blood glucose con-
centrations were significantly lower and urine glucose excretion was 
also significantly impaired (464). Glucose metabolism was also im-
proved with the high fiber diet, despite lower endogenous insulin con-
centrations. When patients were subsequently placed on a low fiber 
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diet, the improvement observed with the high fiber diet was reversed 
and average glucose concentration was similar to values observed on 
the initial low fiber diet. 
Plant fibers influence glucose metabolism and insulin require-
ments by altering intestinal absorption of carbohydrate and by in-
directly affecting hormone secretion probably by influencing insulin 
sensitivity and glucose metabolism in various tissues (464). The 
effect of plant fiber on the rate of carbohydrate absorption has been 
examined in greater extent than other possible mechanisms that would 
affect glucose metabolism. However it seems unlikely that it would 
account solely for the observed effects. Many plant fibers and fiber 
rich foods appear to delay gastri~ emptying thus providing carbohydrate 
to the intestines for digestion and absorption more slowly than after a 
low fiber meal. The gelatinous globules presumably formed in the small 
intestine by water soluble fibers may retard starch and sugar hydrolysis 
by separating carbohydrate to the distal jejunum where carbohydrate is 
less efficiently absorbed due to lower concentrations of disacchari-
dases. In addition, fiber may inhibit digestive enzyme activities and 
slow the digestion and absorption of carbohydrate, proteins and fats. 
Since our study diets contained high concentrations of sucrose and 
relatively standard amounts of natural fiber, the effect of sucrose con-
tent in a diet of normal composition was adequately measured. Thus, the 
differences in our results, as compared to other investigators most 
probably reflect the structural components of the diet and are much more 
representative of the specific effect of sucrose intake on a diabetic 
population consuming disaccharide in a non-hospital, home situation. 
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Restricting sucrose intake in diabetic patients is based on the 
premise that sucrose might cause rapid oscillations of blood gluco~e, 
result in glucosuria and cause interference with metabolic control (2). 
Our studies demonstrate no such oscillation. The fact that urine 24 
hour glucose concentrations decrease when isocaloric carbohydrate diets, 
which have high sucrose content, are given is extremely interesting. 
Diets which are isocalorically similar should affect urinary glucose 
output in a similar fashion. It can only be concluded from our study 
that sucrose enriched diets have no effect on causing an increase in 
urinary glucose output. The decreased excretion of glucose must mean 
that the carbohydrate moiety is metabolized and is not excreted by the 
patient. The decrease in gluco$uria on the low sucrose diet is ex-
pected since the total carbohydrate intake of these patients was slight-
ly less and the refined sucrose intake was minimal (the majority of 
carbohydrate being starch). The observation that the control group also 
demonstrated a slight decrease in 24 hour glucosuria suggests that hos-
pitalization could also lower glucose excretion. Though this could be a 
factor, we feel that it could not alone lead to the significant re-
duction in 24 hour urine glucose excretion observed in patients consum-
ing the study diets. The lack of any significant increase in serum 
glucose concentration or urinary glucose output while consuming the high 
sucrose diet points to the possibility that the increased proportion of 
calories as sucrose, may be utilized metabolically to produce trigly-
ceride. Examination of the data obtained on fasting triglyceride con-
centrations indicates large increases in circulating triglyceride 
levels after high sucrose intake and relatively little change in these 
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levels following low sucrose intake (Figure 17). These results are 
substantiated by other reports which stress the effect of sucrose ~on­
tent in the diet on circulating blood lipid. Nikkila {465), MacDonald 
{30, 34) and Kuo (23) studied normal and non-diabetic subjects finding 
that increased dietary sucrose intake significantly alters the metabo-
lism of triglyceride in human subjects. Studies by Sunt (466), Cohen 
(28), and Chlouverakis (142) have demonstrated that sucrose appeared 
to be responsible for the increased levels of circulating lipids ob-
served in some diabetic patients. These studies suggest that the 
absence of fat in the diet was being met by the synthesis of lipid due 
to carbohydrate induction. Further evidence to support this possibility 
was seen in the altered fatty acjd pattern observed in patients on a 
high sucrose regimen in which the observed increase in oleic acid is 
consistent with the conversion of carbohydrate to fat (23). 
The effect of sucrose induced carbohydrate hyperlipemia was 
challenged by Albrink and Newman (38) who ascertained the effects of 
high and low fiber diets on plasma lipid levels. They gave two high 
carbohydrate diets, one with high fiber, the other with low fiber and 
suggested that carbohydrate induced hyperlipemia does not occur if the 
carbohydrate diet is rich in dietary fiber. Our results refute these 
findings. We demonstrated a significant sucrose induced hypertrigly-
ceridemic effect even though our diets had standard fiber contents. 
Mann et al. (33) were able to reduce serum triglyceride levels an 
average of 22% in non-diabetics through voluntary sucrose restriction. 
Though we were able to reduce sucrose intake to 3 g/day, much lower than 
possible in the self-selected diets of Mann, we observed no reduction in 
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triglyceride levels with restricted sucrose intake. Fasting trigly-
ceride levels remained virtually the same as those observed when the 
120 g/day sucrose control diet was given. Postprandial triglyceride 
concentrations significantly increased from control diet values when 
patients consumed the low sucrose diet, probably reflecting the slight-
ly higher lipid content of the low sucrose diet (Figure 18). Again, no 
effect on fasting triglyceride levels were observed, either as a result 
of sucrose restriction or altered postprandial lipid values. With this 
in mind, the introduction of sucrose into the diabetic diet at levels of 
less than 120 gm/day might be safe. This might allow easier compliance 
with the moderate fat restriction now recommended for the population at 
large which is even more compell)ng for the diabetic patient. 
The changes in triglyceride concentration were not paralleled by a 
rise in serum cholesterol levels in patients on either study diet 
(Figure 21). Both fasting and non-fasting cholesterol levels decreased 
relative to control diet values with consumption of the high sucrose 
diet. This indicates that high carbohydrate ingestion does not increase 
cholesterol levels, a principal advantage in diabetic patients when car-
bohydrate intake is increased (6). The observation that high carbohy-
drate, high sucrose diets calorically similar to the control, resulted 
in a lowering of cholesterol levels indicates that the sucrose content 
of the diet has no effect on cholesterol levels in the blood. This is 
further illustrated by the fact that although sucrose content was re-
duced to an extremely low level, no improvement in serum cholesterol 
concentration was realized. Again, a dietary regime in which small 
amounts of sucrose are included could be beneficial because the 
, 
' 
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increased palatability would lead to greater dietary compliance. 
Though HDL-cholesterol concentrations are often insensitive ~o 
diet (467), levels increased significantly while patients consumed the 
low sucrose diet. HDL-cholesterol levels showed no change, or in some 
cases, a slight decrease in patients on high sucrose diets (Figure 19). 
This inverse relationship between HDL-cholesterol and plasma trigly-
ceride concentration has been extensively documented (453-455). Blum 
et al. (457) showed that dietary substitution of carbohydrate for fat 
is accompanied by an increase in VLDL, a decrease in HDL and a reduc-
tion in the ratio of HDL2 to HOL3. The negative association with 
total triglyceride concentration is stronger for HDL2 than HDL3. 
There also appears to be a sex related difference in the inverse rela-
tionships between HDL-cholesterol and VLDL triglyceride though this 
difference was not tested in this study (456). In both study groups, 
HDL-cholesterol levels may be lowered since these individuals were 
diabetic. The HDL-cholesterol results obtained after low sucrose in-
take represent a small metabolic benefit. It must be pointed out that 
high sucrose diets did not result in any significant deterioration of 
HDL-cholesterol plasma levels (Figure 19). 
The recognition of HDL-cholesterol as a negative risk factor for 
the development of premature cardiovascular disease is well known (454, 
455). Two general mechanisms have been proposed by which HDL is a 
primary deterrent for the development of cardiovascular disease. The 
first mechanism involves the proposed role of HDL in cholesterol trans-
port in which HDL facilitates removal of cholesterol from peripheral 
cells to the liver for ultimate removal by the body. The second mecha-
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nism involves the competitive inhibition of LDL binding to peripheral 
cells by HDL. Decreased plasma levels of HDL, in both cases, cou~d 
be postulated to cause an increased cholesterol build up in the body. 
The ingestion of low sucrose diets did result in a significant in-
crease in serum HDL cholesterol levels, the only benefit obtained by 
sucrose restriction. However, in contrast to Blum (457) who demon-
strated a decrease in HDL-cholesterol following increased carbohydrate 
intake, this study shows that ingestion of high sucrose diets caused 
minimal reductions in HDL-cholesterol levels. 
Lipoprotein concentrations changed predictably in conjunction 
with the changes in the lipid concentrations discussed above (Figure 
27). The greatest change occurred in the S and pre-S lipoprotein con-
centrations during consumption of the high sucrose diet. A large 
increase in pre-s lipoprotein concentration with reciprocal decrease 
in lipoprotein concentration was observed. Since little significant 
change was observed in these fasting parameters while low sucrose diets 
were consumed, sand pre-s lipoprotein levels also changed little in 
this study group. 
The dramatic rise in fasting serum triglyceride concentration and 
the decrease in urinary glucose output with consumption of the high 
sucrose diet indicates that retained carbohydrate might be used to pro-
duce triglyceride in the liver de novo. Increased triglyceride synthe-
sis may be due to a metabolic condition peculiar to the diabetic. 
Normal patients, in many instances, did not demonstrate the extreme 
fluctuation in triglyceride concentration seen in the type II diabetics 
in this study (24, 29, 31, 23). 
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If indeed the metabolism of sucrose is different in diabetics, 
then differences might be reflected in the concentration of hormones 
required to metabolize the disaccharide. Insulin and glucagon re-
sults obtained from patients consuming the different study diets con-
firm this speculation. In general, the observed changes in hormone 
concentrations in these patients when high and low sucrose diets were 
administered were quite different. Relatively high fasting insulins 
were observed in all patients upon admission to the study. This was 
generally expected since many type II diabetics may demonstrate insulin 
resistance and thus elevated fasting insulin concentrations (446). When 
high sucrose diets were administered, fasting and non-fasting insulins 
increased dramatically. This effect of hyperinsulinemia with increased 
sucrose ingestion has also been observed in other reports (33, 34, 39, 
40, 46). Low sucrose diets however, resulted in relatively little 
change in fasting and non-fasting levels. 
Insulin increments, the difference between fasting and non-fasting 
insulins, clearly increased when high sucrose diets were consumed, as 
seen in Figure 25. This significant increase in non-fasting insulins 
over the control diet clearly demonstrates that dietary sucrose content 
affects insulin secretion in these hyperlipemic diabetics. As an addi-
tional consequence, Beck-Nielsen and Pederson (39) demonstrated that 
high sucrose feeding can result in a 36% decrease in specific cell bind-
ing fractions for insulin. A decrease in insulin binding is associated 
with reciprocal increases in plasma insulin concentration. This situa-
tion may contribute, along with increased insulin secretion, to the 
hyperinsulinemic status of these patients. 
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Another mechanism by which this hyperinsulinemia could occur is 
explained by adaptive changes in the intestine in response to in-
creased sucrose intake. Sucrase activity was greater in humans who 
consumed isocaloric diets containing sucrose as compared to glucose 
(41). The concept of specific dietary regulation of jejunal sucrase 
activity has been investigated by Rosenweig and Herman (136). Reiser 
demonstrated that a high sucrose diet caused a large secretion of GIP 
as compared to isocaloric diets which were composed of starch (44). 
He also found the disaccharidase enzyme and GIP secreting cells were 
in close approximation on the brush border of the intestinal wall. 
Since disaccharidase activity has been shown to occur in proximal 
areas of the small intestine, the sucrose absorbed in this part of the 
small intestine has been found to be an important secretogogue for GIP 
(138). GIP is known to be an important stimulator of insulin release 
(48, 139). The more rapid absorption of glucose after a sucrose load 
in these adapted individuals may lead to an enhanced secretion of GIP. 
Overall, the effect of disaccharide in producing hyperinsulinism is 
probably the result of increased insulin resistance due to loss of peri-
pheral binding sites and of increased insulin secretion due to greater 
stimulation of GIP hormone. 
In this study, hyperinsulinism develops at precisely the same time 
as the development of hypertriglyceridemia. These results directly con-
tradict the findings of Hayford and Danney (36) who found negative 
correlations between triglyceride and insulin levels. However, our re-
sults are in agreement with the findings of Olefsky and Eaton (37, 46) 
who demonstrated a positive effect of insulin upon the production of 
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hypertriglyceridemia. Evidence that insulin promotes VLDL-triglycer-
ide secretion was shown by Salans (447). Using perfused liver slices, 
Letarte and Fraser (448) demonstrated that insulin promotes the in-
corporation of 14 glucose into fatty acid moieties of hepatic lipid 
and increases their subsequent release. Further support for the con-
cept of increased dietary sucrose causing a hyperlipemic response, 
through increased triglyceride synthesis, was demonstrated by Michaelis 
(140) who found lipogenic enzymes in the rat liver were induced to a 
greater extent when animals were fed sucrose than when consuming equi-
valent amounts of glucose. Bruchdorfer (141) found increases in 
hepatic fatty acid synthetase enzymes after high sucrose diets. Olefsky 
(37) believed, as the results of; our own study indicated, that hyper-
insulinemia acts upon the liver to accelerate hepatic triglyceride syn-
thesis and secretion resulting in elevated triglyceride levels. 
The changes observed in circulating glucagon levels in response 
to different sucrose content diets probably occur due to the insulin 
response previously discussed. This assumption is reasonable since the 
cells of the pancreas belong to a family of cells which are sensitive 
to insulin concentration (451). Unger (42) has postulated that reduc-
tion in sensitivity of the cells to chronic elevations of insulin re-
sulted in decreased suppressibility of glucagon release. Our studies 
do not confirm this postulate since the circulating levels of glucagon 
decreased with increasing insulin concentration. 
Other reports have supported the concept of increased triglyceride 
synthesis causing hypertriglyceridemia in response to dietary carbohy-
drate type and load (50-52). Because a removal defect of triglyceride 
228 
from the plasma could also be responsible for this patterned lipemic 
response, the possibility of the existence of a defect in removal was 
determined by in vivo techniques utilizing radiolabeled glycerol. Two 
possibilities could exist to increase plasma triglyceride levels, syn-
thesis could saturate the removal mechanism, or alterations could occur 
in the removal of triglyceride from the plasma caused by a defect in 
the lipase enzymes or the substrates on which the enzymes act. 
Results of this study agree with those of Nikkila and Kekki (57) 
who found the enzyme system (lipoprotein lipase) followed Michaelis 
Menton kinetics and could be saturated. We found that patients who 
consumed the high sucrose diet showed no statistically significant 
change in Km when compared to t~ose values obtained while consuming 
the control diet. These results do not agree with those of Adam's and 
Kissebah (59) who demonstrated an increased Km but a decreased Vmax in 
their patients who consumed high carbohydrate diets. However, it must 
be emphasized that the Vmax values obtained from our patient population 
on both high and low sucrose diets appeared to be still lower than those 
obtained from normal patient populations (59). Patients who consumed 
the low sucrose diet showed no change in Km or Vmax from the control 
values and it must be assumed that sucrose restriction offered no 
improvement in peripheral triglyceride removal efficiency. 
The apparent inability of these patients to activate their tri-
glyceride removal mechanisms, by lowering Km, after sucrose induced 
triglyceride production is intriguing. This possible faulty removal 
mechanism, not observed in normal patients (402) could be an additional 
causative factor in the hyperlipemic response observed after high 
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sucrose intake. The inability to activate the triglyceride removal 
system, when high sucrose diets are consumed, could be related to a 
change in VLDL apoprotein cofactors first identified by Bar-On {64). 
Endogenous lipoproteins are presumed to be the natural substrates for 
the lipoprotein lipase enzymes. The results obtained in this study 
could be a reflection of two possible mechanisms: the VLDL isolated 
from the different groups may not be identical or the lipoprotein 
lipase system may contain two different enzymes which have different 
characteristics. 
Experiments performed to substantiate sucrose induced changes 
in the apoprotein constituents of the VLDL demonstrated that high 
sucrose diets resulted in an inorease in apo CIII 1 protein, an in-
hibitor of lipoprotein lipase (218) (Figure 42). Furthermore, apo 
CIII1 levels were significantly correlated with triglyceride concen-
tration in this study (Figure 44). Apo CIII 2 levels were found to de-
crease in these same patients. Apo CII was slightly decreased or re-
mained the same. 
Overall, the ratio of apo CII/apo CIII1 decreased and signifi-
cant correlations between this ratio and triglyceride concentrations 
were observed (Figure 46). These results corroborate the findings of 
Gabor and Spain (63), and Lambert (68) and Catapano (69) who believed 
the relative amounts of apo CII as compared to apo CIII1 enhanced the 
interaction between lipoprotein lipase and triglyceride within the cell 
surface monolayer. These results also substantiate the postulate put 
forth by Alaupovic (154) who proposed that the type of apoprotein found 
in VLDL reflected the nutritional and metabolic status of the indivi-
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dual. 
We did not observe an increase in apo CII levels during the _high 
carbohydrate sucrose intake as suggested by Falko (67). The initially 
low apo CII concentration observed in these patients may be best ex-
plained by the depressed HDL-cholesterol levels found in all patients 
who entered the study. Havel (271) demonstrated that chylomicron and 
VLDL metabolism involve net transfers of apo CII protein from HDL to 
VLDL and back to HDL. The nascent VLDL that is released from the liver 
is stabilized by apo CII from circulating HDL. While the transfer of 
apo CII back to HDL is proportional to triglyceride hydrolysis (275), 
insufficient levels of HDL, and a decreased capacity to supply VLDL 
with apo CII, will prevent norm~l triglyceride hydrolysis resulting in 
increased triglyceride concentration. 
Speculation on the effect of apo CIII1 and CIII2 on VLDL 
metabolism was suggested by Shelburne and Windler (281, 282). These 
investigators observed that apo CIII 1 not only inhibited lipoprotein 
lipase but also demonstrated a pronounced inhibitory effect on hepatic 
uptake of VLDL. Bar-On and Roheim (64) noted that apo CIII 1 and apo 
CIII 2 were different only in sialic acid content. It is possible that 
this glycoprotein is similar to other sialated glycoproteins which 
demonstrate correlation between sialic acid levels and hepatic receptor 
affinity (283). Apo CIII1 may provide a mechanism for denying lipo-
proteins hepatic access until appropriate peripheral metabolism has 
occurred. If apo CIII1 were not present, ineffectual recycling of the 
lipoprotein by the liver would occur. The uptake of remnant VLDL will 
be decreased if apo CIII1 is not removed in the periphery and could 
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result in hyperlipemia. In contrast, apo CIII 2 does not inhibit lipo-
protein lipase but can diminish the effect of apo CIII1 by binding.to 
the same active site but still allowing the lipase to be activated by 
apo CII (269, 270). It has been observed that the sialic acid content 
of these two proteins is determined by their residency time in the 
Golgi apparatus of hepatic cells (217). The fact that apo CIII 1 has 
less sialic acid residues indicates the amount of time spent in the 
Golgi is less than that for apo CIII 2. 
Increased insulin found in patients who consumed the HSD stimu-
lates triglyceride production. Since hepatic triglyceride synthesis is 
increased, VLDL production is increased as well. The residency time of 
total apo CIII in the Golgi app~ratus is decreased resulting in an in-
creased proportion of apo CIII 1 in these patients. Since apo CII is 
also depressed, because of lower circulating HDL levels, the decreased 
ratio of CII/CIII1 apoprotein does not stimulate increased lipoprotein 
lipase activity even in the presence of increased circulating trigly-
ceride levels. Finally, since the triglyceride and apo CIII1 are not 
removed as rapidly as normal, the VLDL circulates for an extended period 
of time. The observations above could account for the decreased uptake 
of a portion of partially hydrolyzed lipoproteins which contain rela-
tively high levels of apo CIII1. Patients who consumed the low 
sucrose diet exhibited little change in the triglyceride removal Km 
values from control to study diet. In these patients apo CIII 2 levels 
increased while apo CIII 1 levels decreased or remained the same. 
Thus, inhibition of lipoprotein lipase can not be postulated as above. 
In fact, these results would point to an increased removal of VLDL by 
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plasma lipase. However, studies from several laboratories suggest 
that human plasma lipoprotein lipase activity is a combination of 
several lipases which have different properties (266, 458). It has 
been found that insulin levels could play a role in specific lipase 
activity (266). Certain lipoprotein lipase enzymes appear to be more 
susceptible to insulin concentrations than others. Since the low suc-
rose study group had slightly lower or unchanged insulin levels, it could 
be possible that one set of enzymes remains inactive because of lower 
insulin concentrations resulting in no change in Km observed in this 
patient population. Also, Persson (61) demonstrated that patients who 
had normal or increased cholesterol levels with steady triglyceride 
levels would have normal lipoly~ic activity. Cholesterol levels re-
mained stable or increased slightly in the LSD study patients. A 
possibility exists that the kinetic data generated by low sucrose diet 
individuals reflects a two enzyme system. One enzyme is inhibited, 
resulting in an increased Km, while the other is stimulated, to clear 
triglyceride more rapidly, resulting in a decreased Km. This compensa-
tory mechanism allows for little observable change to occur in both 
plasma triglyceride levels and Km values in these patients. 
The data on the effect of sucrose enriched diets on apo E levels 
were partially corroborated by Mahley (226) who demonstrated that 
dietary changes could elicit an increase in apo E concentration. His 
diets contained high amounts of cholesterol however, and to date, the 
specific effect of sucrose on apo E is unreported. This study demon-
strated no significant change in total apo E, but a significant in-
crease in one of the isoprotein subunits, apo EIII, was observed in 
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high sucrose diet patients (Figure 43). Low sucrose diets demonstrated 
no effect on isoprotein composition of apo E. Increase in the apo_ EIII 
subunit would seem plausible since Schneider (321) has demonstrated 
that apo EIII is one of the main protein cofactors needed for proper 
hepatic uptake of remnant VLDL. Studies by Havel and others have 
demonstrated that patients with type III hyperlipoproteinemias, charac-
terized by a dysfunctioning apo EIII protein, generally were observed 
to have decreased hepatic uptake of intermediate density lipoprotein 
(223, 227-228). The increase in apo EIII observed in our patients may 
be a mechanism used by the individual to produce accelerated clearance 
of these remnant VLDL lipoproteins and aid in triglyceride clearance 
from the plasma. 
Other experimental data corroborating the above mechanism was 
obtained from four patients whose response to high sucrose consumption 
differed from the others. Their hyperlipoproteinemic pattern shifted 
from type IV to type III (Figure 49). These patients demonstrated a 
complete absence of the apo EIII isoprotein subunits (Figure 50). The 
remnant VLDL have prolonged circulating half-lives due to decreased 
apo EIII and are devoid of most apo C proteins due to the action of 
lipoprotein lipase. Therefore, the remnant VLDL of these patients 
have more s character since there is more apo B as total apoprotein. 
Since the charge of this lipoprotein now resembles that of the 
lipoprotein, electrophoretic migration is similar or identical to the 
broad s pattern. Loss of apo EIII inhibits the uptake of these rem-
nants by the liver and increases their circulating half-lives. Since 
these remnants still contain nominal amounts of triglyceride, this 
mechanism increases the hyperlipemic response observed in these 
patients. 
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The above assumptions cannot be made to explain the change in 
the lipoprotein pattern when high sucrose diets are consumed by this 
patient subgroup. However, it could be possible that a small amount 
of apo EIII is produced by these patients. In these study patients, 
increased synthesis of triglyceride by the liver stimulates VLDL pro-
duction to such an extent that apo EIII synthesis lags behind and the 
VLDL produced either have extremely low concentrations of the apo EIII 
protein or are totally lacking in the structural component. 
Therefore, in general, the results of this series of experiments 
demonstrate that sucrose causes; increased synthesis of triglyceride, but 
also alters the apoprotein content of nascent VLDL released by the 
liver, and possibly functions to decrease removal of peripheral VLDL by 
lipoprotein lipase. 
Another line of approach to study the effect of sucrose consump-
tion on type II diabetics is to investigate platelet adhesiveness and 
platelet aggregation. Increased platelet aggregation has been ob-
served in diabetics (89-92). Since hyperlipemia has also been demon-
strated to increase platelet function (97), a natural relationship 
exists between the effects of sucrose on circulating lipids and plate-
let aggregation. Renaud (387) was the first to demonstrate the effect 
of dietary-induced hyperlipemia on platelet aggregation. His results, 
and the results of this study, demonstrate that increased hyperlipemia 
causes increased platelet aggregation (Figure 53). Szanto et al. (101) 
found that increased insulin levels correlate well with increased 
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platelet adhesiveness. Our studies confirm these findings as well. 
The low sucrose study patients, who demonstrated insignificant altera-
tions in insulin concentration, also had unaltered platelet responses 
to diet. But patients consuming high sucrose diets had increased 
insulin levels, platelet sensitivity and platelet aggregation. 
Farbiszewski et al. (389) also observed a distinct effect of lipopro-
teins on platelet aggregation. In our study, patients who consumed 
high sucrose diets had increased circulating VLDL and increased plate-
let responses to aggregating agents. It is possible that lipoproteins 
interact with platelets in the circulation altering platelet membrane 
components. Bolton (98) found the 8 lipoprotein interacts with certain 
receptor sites on the platelet Sijrface resulting in altered platelet 
mobility. Since VLDL contain similar apoprotein constituents, extended 
circulating half lives of these lipoproteins, due to decreased clear-
ance, might allow the platelets to incorporate these lipoproteins or 
their components into their membranes. 
A mechanism for the increased platelet sensitivity observed in 
these patients, other than changes in membrane fluidity, was reported 
by Sinha (398). This investigation demonstrated that increased lipid 
incorporation into the platelet membrane is associated with decreases 
in the activity of membrane bound adenyl cyclase and depressed cAMP 
levels. Insulin, a known inhibitor of cAMP production, is elevated 
in the patient who consumed high sucrose diets. Since cAMP is a potent 
inhibitor of platelet aggregation, a decrease in cAMP levels induced 
by both increased lipid incorporation and increased insulin concentra-
tions could cause increased platelet aggregation in these hyperlipemic 
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patients. Thus, the impact of the high sucrose diet through either 
mechanism results in the development of increased platelet aggregation 
and responsiveness of platelets to aggregating agents. 
The deleterious effects of sucrose seem to occur only when ex-
tremely high levels of the disaccharide are ingested. Our results show 
that even when sucrose intake is reduced to a point which would be 
impossible to obtain in an outpatient dietary regime, lipid production, 
blood glucose, urinary glucose output, VLDL composition and platelet 
aggregation are altered minimally or unchanged when compared to a diet 
consisting of 120 g/day sucrose intake. Fasting triglyceride levels in-
creased only with the highest sucrose levels, demonstrating that ex-
quisite sensitivity of hypertriElyceridemics to another normally used 
nutrient, alcohol (52) does not seem to apply for the more ubiquitous 
disaccharide. But the general conclusion is one that we share with 
Frank Nutall that 11 Actually, there is little scientific basis for the 
complete exclusion of refined sugars from a diabetic persons diet 11 (51). 
A. Conclusion and Future Directions 
This study was designed to ascertain the effects of sucrose con-
sumption in a diabetic population which is predisposed to hyperlipemia. 
This was a relevant problem since many studies, as alluded to pre-
viously, presented conflicting results concerning the effect of sucrose 
on blood lipid levels, glucoregulatory hormones and lipid transport 
mechanisms. Diabetic dietary therapy has shown a pronounced shift 
toward increased carbohydrate consumption. Therefore, the ingestion 
of refined sugars, especially sucrose, which remains unquantitated and 
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hidden in certain foodstuffs, has possibly increased. Also dietary 
acceptance is an important factor in any chronic therapy. The pal~ta­
bility that small amounts of sucrose adds to a diet lends an increased 
likelihood of compliance with the dietary regime and ultimately, im-
proved blood glucose control. Thus, it is mandatory to know the effects 
of graded amounts of sucrose in natural mixed diets and the chemical 
response of these type II diabetics to such diets. 
Ideally, an experimental search for a cause of hyperlipemia would 
be to investigate whether the suspected factor actually produces the 
disease. But, none of the ordinary laboratory animals can be made to 
develop the hyperlipemic state as seen in man, and of course, it is out 
of the question that one should pttempt to do so in humans. The alter-
native is short term experiments in man in which attempts to reproduce 
some of the characteristics of hyperlipemia are made. The experiments 
designed here enabled us to answer a number of questions concerning the 
effects of sucrose as an etiological factor in diabetic control and the 
development of hypertriglyceridemia. The primary goal was to see 
whether sucrose produced, not simply an increase in triglyceride con-
centration, but as many other potential abnormalities associated with 
poor diabetic control. 
This study demonstrated that under controlled conditions, no 
special sensitivity to variation in sucrose restriction can be ob-
served. Essentially, no effect of widely variable sucrose levels on 
blood glucose and glucosuria was identified. In addition, no 
deleterious changes in the levels of serum HDL-cholesterol or choles-
terol were seen when diets rich in sucrose were ingested. Furthermore, 
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no improvements to normal levels could be detected when sucrose re-
stricted diets were given to this patient population. On the other 
hand, high sucrose consumption had a most significant effect resulting 
in a great increase in fasting triglyceride levels. The changes in 
the plasma lipoprotein constituents reflect, predictably, changes that 
occurred in the lipid constituent of the plasma. 
Glucoregulatory hormones showed a pronounced increase in circu-
lating levels of fasting insulin with significantly larger insulin in-
crements and a reduction in fasting glucagon levels with consumption 
of high sucrose diets. This suggests that the hypertriglyceridemia 
associated with increased sucrose intake is due to increased trigly-
ceride synthesis. Kinetic studies of the plasma triglyceride pool 
demonstrated that sucrose rich diets had no effect on the affinity of 
the removal system for plasma triglyceride. Thus the lack of any 
stimulated increase in peripheral triglyceride removal, while consum-
ing (HSD) could be a contributing factor to the hyperlipemic response. 
Again, complete sucrose restriction and complex starch replacement 
offered little improvement in fasting insulin concentration and plasma 
triglyceride removal mechanisms over those obtained by intermediate 
(control) sucrose levels. 
Studies of the very low-density lipoprotein (VLDL), the main 
carrier of triglyceride in the fasted state, and the apoproteins that 
comprise them were carried out in order to identify whether the pro-
portions of dietary sucrose affect these transport proteins. It was 
found that high sucrose consumption alters the apoprotein content of 
the VLDL. The apo CII/CIII ratio decreased which could have resulted 
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in decreased stimulation of the lipoprotein lipase system and an 
altered removal of VLDL from the plasma pool. The increase in apo 
CIII may be a reflection of either a decreased residency time in the 
hepatocyte Golgi apparatus of VLDL apoprotein components or an in-
creased plasma residency time of the VLDL in the peripheral pool. The 
former is a reflection of a possible increased liver VLDL secretion 
due to increased triglyceride synthesis. The latter is a result of an 
elongated plasma pool half life as demonstrated by the extremely low K 
values observed in these patients. 
We have also demonstrated that elevated sucrose intake associated 
with hyperlipemia results in increased platelet aggregation and sensi-
tivity of platelets to aggregating agents, never before reported in the 
literature. 
The minimal effects of a daily consumption of sucrose in quanti-
ties of less than 100 gm per day suggests that its cautious introduc-
tion in mixed meals might allow easier compliance with the moderate fat 
restriction now recommended for the diabetic population at large. 
Furthermore, by contributing to palatability, dietary sugar will ease 
the life of many diabetics perhaps contributing to better adherence to 
diet as part of the whole health care program in diabetic treatment. 
In view of this, we strongly recommend that sucrose intake from all 
sources be monitored in a valid manner. The implementation of this 
study would entail a radical new outlook in dietary therapy for the 
diabetic. Perhaps, it is reasonable to suggest that sucrose content 
of packaged, frozen, and canned foods be determined and that a 
campaign be launched to inform the susceptible population. 
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